





































































adapted	 reference	 strains.	 Therefore,	 minimally	 adapted	 clinical	 strains	 were	
grown	in	two	cell	culture	systems:	immortalised	and	primary.	Plaque	phenotype,	
growth	kinetics	and	inflammatory	response	triggered	were	evaluated	and	it	was	





identified	 and	 evaluated	 as	 a	 potential	 candidate	 for	 subsequent	 phylogenetic	




Finally	 a	 robust	 in	 vitro	 model	 for	 the	 evaluation	 of	 potential	 therapeutic	
candidates	for	HPIV3,	based	on	a	panel	of	minimally	passaged	clinical	strains	as	
well	as	a	culture-adapted	reference	strain,	was	set	up.		This	model	was	applied	to	
three	 potential	 inhibitors	 of	 HPIV3:	 ribavirin,	 favipiravir	 and	 zanamivir.	 The	
results	showed	that	clinical	strains	were	at	 least	as	susceptible	to	ribavirin	and	
favipiravir	as	the	laboratory	reference	strain	and	significantly	more	susceptible	






outcome	 of	 work	 done	 in	 collaboration	 except	 as	 declared	 in	 the	 Preface	 and	
specified	in	the	text.	
It	 is	 not	 substantially	 the	 same	 as	 any	 that	 I	 have	 submitted,	 or,	 is	 being	
concurrently	 submitted	 for	 a	 degree	 or	 diploma	 or	 other	 qualification	 at	 the	
University	of	Cambridge	or	any	other	University	or	similar	institution	except	as	
declared	 in	 the	 Preface	 and	 specified	 in	 the	 text.	 I	 further	 state	 that	 no	

























































































































































































































































































































































































































































































Human	 parainfluenza	 viruses	 (HPIVs)	 were	 originally	 isolated	 from	 three	
children	with	 lower	 respiratory	 tract	 infections	 in	 the	 1950s	 (Vainionpää	 and	
Hyypiä,	 1994;	 Henrickson,	 2003).	 The	 viruses	 were	 found	 to	 be	 distinct	 from	
influenza	 despite	 similarities	 in	 pathology	 and	 were	 subsequently	 classified	
together	 with	 other	 non-segmented	 negative	 sense	 RNA	 viruses	 in	 the	 order	
Mononegavirales	 (Pfaller,	 Cattaneo	 and	 Schnell,	 2015),	 as	 shown	 in	 Figure	 1-1.	
Viruses	belonging	to	this	order	share	a	number	of	similarities	and	encompass	a	
diverse	 range	 of	 clinically	 and	 economically	 relevant	 pathogens	 as	 well	 as	 a	
diverse	range	of	hosts	including	humans,	animals,	birds	and	plants	(King,	2012)	.	
Within	 the	 scope	 of	 clinically	 relevant	 human	 disease,	 this	 order	 contains	
families	 such	 as	 Filoviridae,	 that	 includes	 Ebola	 and	 Marburg	 viruses;	
Rhabdoviridae,	that	includes	lyssaviruses;	and	Bornaviridae	that	cause	a	diverse	
range	 of	 CNS	 infections	 in	 animals	 with	 potential	 cross-infections	 in	 humans.	








was	 generated	 using	 MEGA	 (Tamura	 et	 al.,	 2013)	 based	 on	 full	 genome	
sequences.	 Branch	 lengths	 are	 scaled	 to	 substitutions/site.	 Abbreviations	 and	
accession	 numbers:	 Borna	 -	 AJ311524.1;	 Nyamanini	 -	 NC_012703.1;	 Lyssa	 -	
MF187880.1;	 Rabies	 -	 AF499686.2;	 Vesiculovirus	 -	 JX569193.2;	 Marburg	 -	
DQ217792.1;	 Ebola	 -	 AF086833.2;	 Midway	 -	 NC_012702.1;	 HMPV	 –	 human	
metapneumovirus	 (MG431250.1);	 RSV	 –	 respiratory	 syncytial	 virus	
(KM360090.1);	MuV	–	mumps	virus	(AF345290.1);	PIV5	–	parainfluenza	virus	5	
(NC_006430.1);	 NDV	 –	 Newcastle	 disease	 virus	 (AF375823.1);	 MeV	 –	 measles	
virus	 (AF266290.1);	ASPV	–	Atlantic	salmon	parainfluenza	virus	 (EF646380.1);	
BPIV	 –	 bovine	 parainfluenza	 virus	 (D84095.1);	 Fer-de-lance	 -	 NC_005084.2;	
Hendra	 -	 NC_001906.3;	 Nipah	 -	 NC_002728.1;	 Sendai	 -	 M30202.1;	 HPIV1-4	 –	
human	 parainfluenza	 virus	 1-4	 (KX570602.1;	 KM190939.1;	 NC_001796.2;	
KF483663.1)	
	
HPIVs	 from	 the	 Paramyxovirinae	 can	 be	 subdivided	 into	 four	 types	 based	 on	
antigenic	 and	 phylogenetic	 characteristics	 and	 these	 all	 belong	 to	 the	 family	



















































respiratory	 infections	 in	humans,	namely	 respiratory	 syncytial	virus	 (RSV)	and	
human	 metapneumovirus	 (HMPV).	 The	 Paramyxovirinae	 comprise	 five	 main	
genera	 that	 encompass	 a	 range	 of	 clinically	 relevant	 viruses.	 These	 include	
morbillivurses	 (measles	 (MeV)),	 rubulaviruses	 (mumps	 (MuV),	 HPIV2	 and	 4),	
henipaviruses	 (Nipah	 and	 Hendra	 viruses)	 and	 respiroviruses	 (HPIV1	 and	 3).	







more	 additional	 proteins	 from	 the	 polycistronic	 phosphoprotein	 (P)	 gene	 and	
the	second	is	the	neuraminidase	activity	(or	lack	thereof)	of	the	main	attachment	








(Fields,	 Knipe	 and	 Howley,	 2013).	 They	 consist	 of	 a	 nucleocapsid	 helical	
structure	 that	 contains	 the	 viral	 RNA,	 fully	 encapsidated	 by	 the	 nucleocapsid	
protein	 (NP).	 The	 components	 that	 form	 the	 active	 viral	 polymerase	 complex,	
namely	the	large	polymerase	(L)	and	the	phosphoprotein	(P)	are	associated	with	
the	nucleocapsid	complex.	The	core	is	surrounded	by	a	lipid	envelope,	lined	with	






a	 core	 that	 consists	 of	 the	 RNA	 genome	 enclosed	 fully	 by	 the	 nucleocapsid	
protein	(NP),	with	the	large	polymerase	(L)	and	phosphoprotein	(P)	bound	to	the	

















factor/immune	 control	 (yellow),	matrix	 (red),	 glycoprotein	 (blue),	 polymerase	
(green)	 structure	 in	 members	 of	 this	 order.	 The	 size	 of	 the	 genomes	 and	
individual	 components	 is	 scaled	 to	 their	 respective	 lengths.	 Adapted	 from	




3′ 	-	 nucleocapsid	 protein	 (NP),	 phosphoprotein	 (P)	 -	 which	 also	 codes	 for	
accessory	 proteins	 C/D	 and	 V,	 matrix	 (M)	 protein,	 fusion	 (F)	 protein,	
haemagglutinin	 neuraminidase	 (HN)	 protein,	 large	 polymerase	 (L)-5′	(Galinski	
and	Wechsler,	 1991;	 Vainionpää	 and	 Hyypiä,	 1994;	 Fields,	 Knipe	 and	 Howley,	
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ends	 with	 another	 highly	 conserved	 segment	 termed	 “gene	 end”,	 these	 are	
approximately	 10-13	 nucleotides	 in	 length.	 Genes	 are	 separated	 by	 short	 non-





The	 lifecycle	 of	 HPIV3	 is	 summarised	 in	 Figure	 1-4.	 The	 infection	 is	 initiated	
when	 the	 HN	 protein	 binds	 to	 the	 cell	 surface	 receptor	 (Elango	 et	 al.,	 1986;	
Suzuki	et	al.,	2001).	It	then	triggers	the	F	receptor	to	undergo	a	conformational	
change	 causing	 the	 virus	 to	 fuse	 with	 the	 host	 cell	 (Porotto	 et	 al.,	 2011).	 The	
RNA-nucleocapsid	core	is	then	released.	 	L	and	P	form	the	polymerase	complex	
and	P	 chaperones	 the	 complex	 to	 the	helical	nucleocapsid	 (Chattopadhyay	and	
Banerjee,	2009;	Dochow	et	al.,	2012).		The	polymerase	engages	the	RNA	near	the	
3′	end	 of	 the	 genome	 and	 proceeds	 along	 it	 with	 individual	 N	 subunits	 being	
displaced	 and	 then	 replaced	 as	 it	 passes	 by.	 	 Transcription	 begins	 when	 the	
polymerase	complex	encounters	the	start	signal	and	continues	until	the	gene	end	
segment	 is	 encountered	 (Noton	 and	 Fearns,	 2015).	 Viral	mRNA	molecules	 are	
then	 modified	 to	 mimic	 host	 messenger	 RNAs,	 acquiring	 a	 5’	 methylated	 cap	
structure	 and	 a	 polyadenylated	 3’	 tail	 (Vainionpää	 and	 Hyypiä,	 1994;	
Henrickson,	 2003;	 Fields,	 Knipe	 and	Howley,	 2013).	 It	 has	 been	 shown	 that	 in	
RSV,	cap	methylation	 is	essential	 for	 further	elongation	of	 the	 transcript.	 If	 cap	
methylation	 fails	 the	 polymerase	 complex	 aborts	 transcription	 (Barik,	 1993).		
The	polymerase	then	continues	to	scan	the	non-coding	intergenic	region	until	it	









cell	 fusion	 (2).	 The	 viral	 core	 is	 released	 into	 the	 cytoplasm	 (3).	 Viral	 L	 and	 P	
form	 the	 polymerase	 complex,	 which	 binds	 to	 the	 RNA	 encased	 in	 the	
nucleocapsid	 (4)	 and	 transcription	 (5)	 begins.	 Viral	 mRNAs	 are	 capped,	
polyadenylated	and	then	translated	into	viral	proteins	(6).		Genes	at	the	3′	end	of	
the	 viral	 RNA	 are	 transcribed	 more	 frequently,	 eventually	 leading	 to	 a	










































to	 them	 in	 complex	with	 P,	 as	 described	 above	 (Chattopadhyay	 and	 Banerjee,	
2009).	 	 It	 is	widely	 believed	 that	 this	 immediate	 encapsidation	 plays	 a	 crucial	
role	 in	 pushing	 the	 polymerase	 into	 the	 state	 where	 it	 disregards	 intergenic	
regions	and	proceeds	with	RNA	replication	(Fields,	Knipe	and	Howley,	2013).		It	
has	 been	 postulated	 that	 an	 excess	 of	 NP	 and	 P	 proteins	 is	 required	 for	 the	
polymerase	 to	 initiate	 at	 the	 very	 first	 base	 of	 the	 template	 at	 the	 3′ end.	 	 As	
these	 are	 not	 present	 upon	 viral	 entry,	 the	 polymerase	 initiates	 at	 the	 start	
region	of	the	first	gene	and	commits	to	transcription.	As	the	concentration	of	NP	
and	P	rises	during	infection,	the	polymerase	gains	the	capacity	to	initiate	at	the	
3′ end.	 	However	 if	 the	concentration	of	 these	 two	proteins	 is	not	sufficient	 for	
immediate	 encapsidation	of	 the	new	anti-genomic	RNA,	 the	polymerase	 aborts	
elongation	and	returns	to	transcription.	As	the	concentration	of	NP	and	P	rises,	
and	 nascent	 RNA	 is	 encapsidated,	 the	 polymerase	 is	 pushed	 into	 a	
hyperprocessive	state	and	commits	to	elongation	(Noton	and	Fearns,	2015).		The	
new	 nucleocapsids	 are	 then	 guided	 towards	 the	 cellular	 membrane	 by	 the	 M	
protein,	 that	 is	 itself	 associated	 both	 with	 the	 lipid	 bilayer	 as	 well	 as	 the	
cytoplasmic	tails	of	the	glycoproteins	(Stone	and	Takimoto,	2013;	Bracken	et	al.,	
2016),	 the	 new	 viral	 particles	 bud	 from	 the	 cell	 surface	 and	 the	 connection	 is	





The	 HPIV3	 nucleocapsid	 protein	 is	 515	 aa	 long	 (Figure	 1-3B).	 It	 fully	
encapsidates	 the	 viral	 RNA	 and	 forms	 a	 helical	 nucleocapsid	 structure	 that	 is	
required	 for	 virus	 assembly,	 packaging	 and	 release	 of	 new	 viral	 particles.	 The	
symmetry	inherent	in	this	process	forms	the	basis	of	the	“rule	of	six”	where	the	
length	of	the	genome	must	be	a	multiple	of	six	for	Paramyxovirinae	(Henrickson,	
2003;	 Fields,	 Knipe	 and	Howley,	 2013).	 Additionally	NP	 serves	 the	 function	 of	
protecting	 the	 RNA	 from	 the	 host	 innate	 immune	 response	 and	 subsequent	
degradation	 (Heggeness	 et	 al.,	 1980).	 	 It	 also	 provides	 a	 template	 for	 the	
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polymerase	 complex	 during	 viral	 transcription	 and	 replication	 (Figure	 1-4).		
Each	nucleocapsid	protein	has	an	N-terminal	and	a	C-terminal	core	domain	that	




importance	 of	 NP	 in	 virus	 assembly	 has	 been	 shown	 in	 the	 virus-like	 particle	
(VLP)	formation	experiments	in	NDV	and	Sendai	virus.	In	the	latter,	it	has	been	
shown	 that	 the	 interaction	 of	 NP	 with	 the	 F	 protein	 on	 the	 host	 cellular	





The	 phosphoprotein	 (P)	 is	 604	 aa	 long	 (Figure	 1-3B).	 It	 is	 a	 key	 player	 in	 the	
formation	 of	 the	 transcription	 and	 replication	 complex	 of	 the	 virus.	 P	 has	 the	
capacity	to	bind	both	NP	and	L.	By	binding	NP	it	prevents	the	polymerisation	of	
this	protein	as	well	as	the	encapsidation	of	non-viral	RNA	by	chaperoning	NP	to	







to	 protrude	 outwards,	 thus	 allowing	 it	 to	 bind	 to	 the	 nucleocapsid	 complex	
(Noton	 and	Fearns,	 2015).	 Recently	 an	 additional	 immunomodulatory	 role	 has	
been	 attributed	 to	 P.	 It	 was	 found	 to	 interact	 with	 synaptosomal	 associated	
protein	 29	 (SNAP29)	 and	 prevent	 it	 from	 binding	 to	 syntaxin	 17,	 thereby	
inhibiting	the	fusion	of	autophagosomes	and	lysosomes	during	autophagy	(Ding	
et	 al.,	 2014).	 	 The	 authors	 have	 hypothesised	 that	 this	 mechanism	 serves	 to	
enhance	extracellular	viral	yields	by	sequestering	virions	via	a	co-localisation	of	
the	M	protein	with	 the	 autophagosome.	 This,	 in	 turn,	 facilitates	 the	 binding	 of	
	 25	
newly	 formed	 virus	 particles	 to	 the	membrane	 and	 ultimately	 the	 release	 and	
budding	 of	 virions.	 A	 similar	 subversion	 of	 this	 pathway	 is	 seen	 in	 other	 viral	






protein	 is	 expressed	 in	 the	 Sendai	 virus,	 a	 well-established	 model	 for	
respirovirus	infection	(Kato	et	al.,	1997),	HPIV3	does	not	express	the	full	length	
V	protein	(Fields,	Knipe	and	Howley,	2013).	Instead	a	D	protein	is	produced	by	
addition	of	 five	G	residues	(Haller	et	al.,	2000).	 It	has	been	 linked	to	 interferon	
beta	(IFNβ)	interference	and	its	deletion	has	been	shown	to	restrict	viral	growth,	
but	the	full	extent	of	its	role	remains	unclear	(Roth	et	al.,	2013).		
The	 C	 protein	 of	 HPIV3	 is	 199	 aa	 long	 and	 has	 been	 found	 to	 be	 essential	 for	




Banerjee,	 2004).	 The	 C	 protein	 has	 also	 been	 shown	 to	 interact	 directly	 with	
growth	 factor	 receptor-bound	 protein	 2	 (GRB2)	 and	 activate	 the	 MAPK/ERK	





The	 matrix	 protein	 is	 353	 aa	 long	 (Figure	 1-3B).	 The	 main	 functions	 of	 this	





the	nucleocapsid	 complex	 to	 the	 same	 site.	 	Most	 studies	 on	 the	 structure	 and	
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function	of	paramyxovirus	M	proteins	have	been	carried	out	in	Sendai	and	NDV	
viruses.	 These	 have	 included	 studying	 gene	 deletions	 (Bracken	 et	 al.,	 2016),	






greater	 homology	 between	 C-terminal	 domains	 of	 paramyxoviruses	 than	
between	the	N-terminal	domains,	which	suggests	that	the	N-terminal	domain	is	
involved	 with	 more	 virus-specific	 interactions	 (El	 Najjar	 et	 al.,	 2014).	 Recent	
work	has	also	demonstrated	that	the	matrix	protein	of	HPIV3	initiates	mitophagy	
by	binding	 to	mitochondrial	Tu	 translation	elongation	 factor	 (TUFM),	 and	 thus	




The	 fusion	 protein	 of	 HPIV3	 is	 539	 aa	 long	 (Figure	 1-3B)	 and	 as	 the	 name	
suggests	mediates	fusion	between	the	virus	and	the	host	cell	(Figure	1-4).	It	is	a	
class	 one	 viral	 fusion	 protein	 with	 a	 structure	 and	 function	 shared	 by	 many	
viruses	 (Palgen	 et	 al.,	 2015).	 In	 short,	 a	 class	 one	 viral	 fusion	 protein	 is	
synthesised	as	a	precursor	(designated	F0		in	HPIV3)	and	cleaved	en	route	to	the	
cell	 surface	 by	 a	 protease	 in	 the	 late	 compartments	 of	 the	 secretory	 pathway;	
into	 an	 N	 terminal	 element	 (F2	 in	 HPIV3)	 which	 contains	 a	 receptor	 binding	





prior	 to	 cell	 binding	 (Porotto,	 Salah,	 et	 al.,	 2012).	 Cleavage	 site	 variants	 have	
been	 shown	 to	 affect	 the	 fusogenicity	 of	 HPIV3	 (Palmer	 et	 al.,	 2012).	 During	










The	 HN	 genome	 of	 HPIV3	 encodes	 a	 second	 surface	 viral	 glycoprotein,	




of	 this	 interaction	 determines	 the	 tropism	 of	 HPIV3.	 It	 has	 previously	 been	
shown	 that	 both	 HPIV1	 and	 3	 bind	 to	 sialic	 acids	 at	 the	 terminal	 branching	
polylactosamine	 structures	 (Suzuki	 et	 al.,	 2001).	 HPIV1	 has	 the	 ability	 to	
recognise	 α2,6-linked	 sialic	 acids,	 that	 are	 predominantly	 expressed	 in	 the	
human	 trachea,	 whereas	 HPIV3	 may	 require	 a	 specific	 accessory	 glycochain	
(Fukushima	 et	 al.,	 2014).	 	 The	 latter	 may	 be	 key	 to	 different	 pathologies	
exhibited	 by	 respiroviruses	 in	 clinical	 settings.	 	 This	 is	 reflected	 by	 the	 in	vivo	
pathology	 of	 both	 viruses	 where	 HPIV1	 predominantly	 infects	 the	 upper	
respiratory	 tract,	 whereas	 HPIV3	 is	 associated	 with	 lower	 respiratory	 tract	
infections	and	pneumonia	(Suzuki	et	al.,	2001;	Henrickson,	2003;	Fukushima	et	
al.,	2014).		
After	binding	 to	 the	 cell	 surface	 the	HN	engages	 the	F	protein	and	 triggers	 the	
conformational	change	that	will	 lead	to	 fusion	with	the	host	cell	 (Porotto	et	al.,	
2011).	The	timing	of	 the	 triggering	of	 the	F	protein	 is	essential	 for	viral	 fitness	
both	 in	 vivo	 and	 in	 vitro	 (Prince,	 Ottolini	 and	Moscona,	 2001).	 The	 interaction	
with	F	is	confined	to	the	second	binding	site	of	HN	and	it	has	been	shown	that	HN	
and	F	 associate	 even	before	 receptor	 engagement	 via	 the	 primary	 binding	 site	





Howley,	 2013).	 A	 number	 of	 previous	 studies	 have	 shown	 that	 the	 balance	
between	 receptor	 binding	 and	 the	 neuraminidase	 function	 of	 the	 HN	
glycoprotein	 is	 essential	 to	 the	 virus	 cycle	 (Huberman,	 Peluso	 and	 Moscona,	
1995;	Moscona,	 1997;	Porotto,	 Salah,	et	al.,	 2012).	This	has	been	 linked	 to	 cell	
culture	 adaptation	 where	 a	 more	 fusogenic	 phenotype	 with	 reduced	
neuraminidase	 activity	 is	 observed	 (Palmer	 et	 al.,	 2012).	 A	 functioning	
neuraminidase	 also	 mediates	 viral	 interference	 (Horga	 et	 al.,	 2000):	 by	





The	 L	 protein	 of	 HPIV3	 is	 a	 large	 RNA-dependent	 RNA-polymerase	 (RdRp)	 of	
2233	 amino	 acids	 long	 (Figure	 1-3B).	 In	 the	 absence	 of	 P	 protein,	 HPIV3	 L	 is	
unstable	 and	 prone	 to	 degradation	 or	 the	 formation	 of	 non-functional	 dimers	
(Chattopadhyay	and	Banerjee,	2009;	Cox	and	Plemper,	2015).	The	complex	that	
it	 forms	with	 the	 phosphoprotein	 carries	 out	 a	 number	 of	 functions	 including	
mRNA	 synthesis,	 5 ′ capping	 and	 methylation	 of	 nascent	 RNAs	 and	
3′ polyadenylation	(Henrickson,	2003;	Fields,	Knipe	and	Howley,	2013;	Cox	and	
Plemper,	 2015;	 Noton	 and	 Fearns,	 2015)	 (Figure	 1-4).	 Six	 highly	 conserved	
regions	 have	 been	 identified	 in	 the	 L	 proteins	 of	 other	 members	 of	
Mononegavirales	 (Cox	and	Plemper,	 2015;	Pfaller,	 Cattaneo	and	Schnell,	 2015).	
So	 far,	 conserved	 region	 III	 (GDNQ	 sequence)	 has	 been	 identified	 as	 the	
polymerase	active	site,	VI	(GXGXG)	 is	 involved	 in	cap	methylation	and	region	V	





Human	 parainfluenza	 viruses	 (HPIV)	 are	 members	 of	 the	 Paramyxoviridae,	 a	
family	 in	 the	 order	 of	 Mononegavirales.	 There	 are	 four	 subtypes	 (1.1.1		




et	 al.,	 2017).	 The	 epidemiological	 pattern	 of	 HPIV	 in	 England	 and	 Wales	 has	
remained	similar	over	the	last	30	years,	with	HPIV3	being	the	dominant	serotype	
(68.3%	of	circulating	strains),	with	peaks	occurring	annually	between	March	and	
June	 (Zhao	et	al.,	 2017)	 (Figure	1-5).	There	 is	 little	 variation	 from	 this	pattern	







HPIV	 is	 an	 important	 respiratory	 pathogen	 with	 a	 broad	 spectrum	 of	
presentation	 and	 a	 significant	 impact	 both	 in	 the	 paediatric	 and	 the	
immunocompromised	cohorts.	 In	 the	 former	 it	 is	responsible	 for	up	to	6.8%	of	
all	 paediatric	 admissions	 for	 respiratory	presentations	 (Weinberg	et	al.,	 2009).	
In	 the	 immunocompromised	 population,	 the	 reported	 incidence	 of	 infection	
varies	between	5	 and	12%	with	 lower	 respiratory	 tract	 infections	 (LRTIs)	 and	
mortality	of	up	to	75%	being	reported	(Seo	et	al.,	2014;	Shah	et	al.,	2016).		Most	
primary	 infections	 occur	 below	 the	 age	 of	 five	 and	 immunity	 to	 HPIV3	 is	
incomplete,	 potentially	 because	 of	 various	 immune	 evasion	 strategies	 (See	
Section	 1.5.4)	 (Spriggs	 et	 al.,	 1987;	 Murphy	 et	 al.,	 1988;	 Henrickson,	 2003;	
Schomacker	et	al.,	2012)	and	re-infections	occur	throughout	life.		
	
HPIV infections in different age groups are shown in
Figure 2, showing that overall, the most commonly
affected age group was children aged <1 year followed
by 1- to 4-year-olds. The differences in prop rtions
between the age groups were gradually becoming
much smaller over the study period. The proportions
from infants aged <1 year have shown a significant
long-term decreasi g trend (P < 0·001), while the pro-
portions for other age groups show a slow but statis-
tically significant long-term increasing trend: 1–4
years (P< 0·01), 5–14 years (P< 0·001), 15–44 years
(P < 0·01), 45–64 years (P < 0·001) and 565 years
(P < 0·001). The group with the lowest proportion
infected was the 5–14 years age group in recent years.
Fig. 1. Weekly numbers of human parainfluenza virus (HPIV) detection by serotype in England and Wales, 1998–2013
(LabBase System).
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Transmission	 of	HPIV3	 is	 through	 respiratory	droplets	 and	 fomites,	where	 the	
virus	 can	 remain	 viable	 for	 up	 to	 10	 hours	 given	 the	 right	 conditions	 of	
temperature	and	humidity	(Brady,	Evans	and	Cuartas,	1990).	Extensive	studies	
conducted	 with	 respiratory	 syncytial	 virus	 (RSV),	 a	 closely	 related	
paramyxovirus,	 have	 also	 identified	 gloves	 and	 hospital	 gowns	 as	 potential	
sources	 of	 nosocomial	 transmission	 (Chow	 and	 Mermel,	 2017).	 Transmission	
within	 the	 immunocompromised	 cohort	 is	 exacerbated	 by	 prolonged	
asymptomatic	shedding	(Zambon	et	al.,	1998;	Jalal	et	al.,	2007),	although	in	the	
paediatric	cohort	the	evidence	for	this	is	conflicting	(Piralla	et	al.,	2009;	Aliyu	et	
al.,	 2015).	 Paediatric	 outbreaks	 are	 further	 complicated	 by	 complex	 shared	




Overall	 there	 is	 a	 broad	 spectrum	 of	 pathology	 and	 severity	 that	 is	 associated	
with	 HPIV3	 infection	 (Herzog	 et	 al.,	 1989;	 Cilla	 et	 al.,	 2008;	 Park	 et	 al.,	 2009;	








2015).	 In	 severely	 immunosuppressed	 individuals	 there	 have	 been	 reports	 of	
giant-cell	pneumonia	(Butnor	and	Sporn,	2003),	transplant	rejection	(Herzog	et	
al.,	1989;	Vilchez	et	al.,	2003)	and	systemic	viraemia	with	spread	to	other	organs	
including	 CNS	 involvement	 with	 fatal	 outcomes	 (Madden,	 Burchette	 and	 Hale,	
2004).	 The	 impact	 in	 the	 adult	 post-haematology	 transplant	 cohort	 has	 been	
widely	 reported	 (Zambon	 et	 al.,	 1998;	 Cortez	 et	 al.,	 2001;	 Jalal	 et	 al.,	 2007;	
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Maziarz	 et	al.,	 2010)	with	 conflicting	 reports	 on	 outcome,	 depending	 on	 other	
organisms	isolated	as	well	as	the	immunosuppression	status	of	the	patient.		
A	 number	 of	 small	 studies	 have	 evaluated	 the	 impact	 of	 respiratory	 viruses	
including	 HPIV3	 in	 the	 paediatric	 oncology	 cohort	 (Bowden,	 MD,	 1997;	
Christensen,	Nielsen	and	Hasle,	2005;	Piralla	et	al.,	2009;	Lindblom	et	al.,	2010;	
Ustun	 et	al.,	 2012;	 Berrueco	 et	al.,	 2013;	 Benites	 et	al.,	 2014;	 Söderman	 et	al.,	
2016;	Torres	et	al.,	 2016;	 Santolaya	et	al.,	 2017).	 In	 each	 case,	 outbreaks	were	
identified	 retrospectively	 and	 prospective	 identification	 of	 a	 point	 source	 was	
not	 possible	 (Piralla	 et	 al.,	 2009;	 Berrueco	 et	 al.,	 2013).	 There	 is	 limited	
consensus	on	prevalence,	severity	of	infection	and	clinical	outcome	data.	HPIV3	
has	 been	 reported	 as	 a	 causative	 pathogen	 in	 1-18%	 of	 respiratory	 viral	
infections	 in	 paediatric	 oncology	 patients,	 and	 as	 such	 has	 been	 conflictingly	
described	as	both	a	common	as	well	as	a	relatively	rare	pathogen	(Christensen,	
Nielsen	and	Hasle,	2005;	Lindblom	et	al.,	2010;	Ustun	et	al.,	2012;	Benites	et	al.,	




studies	could	be	attributed	 to	confounding	 factors	such	as	 immunosuppression	
status,	 a	 separate	 study	 found	 that	 there	 were	 no	 additional	 risk	 factors	 in	
developing	HPIV3	complications	 in	haematopoietic	stem	cell	 transplant	 (HSCT)	
patients	 (Ustun	 et	 al.,	 2012;	 Torres	 et	 al.,	 2016;	 Santolaya	 et	 al.,	 2017).		
Additionally,	 the	 prevalence	 of	 co-infections	 with	 more	 than	 one	 respiratory	
virus	 in	 this	 cohort	 has	 been	 quoted	 to	 be	 between	 2	 and	 26%	with	 both	 no	
clinical	impact	(Lindblom	et	al.,	2010;	Torres	et	al.,	2016)	and	increased	severity	
of	 infection	reported	(Cilla	et	al.,	2008;	Ustun	et	al.,	2012).	 	The	above	suggests	







Currently	 there	 is	 no	 licensed	 vaccine	 for	 HPIV3,	 although	 due	 to	 its	
epidemiological	 impact,	 a	 number	 of	 candidates	 have	 been	 evaluated	 over	 the	
years	 (Murphy	 et	 al.,	 1988;	 Schmidt	 et	 al.,	 2012).	 	 A	 cold	 adapted	 attenuated	
vaccine	candidate	 cp45	 (cold	passage	45)	 (Belshe	and	Hissom,	1982)	has	been	














Currently	 there	are	no	 licensed	 treatments	 for	HPIV3.	Ribavirin	 is	a	nucleoside	
analogue	 with	 broad	 anti-viral	 activity	 in	 vitro	 with	 a	 number	 of	 proposed	
mechanisms	of	action	including	GTP	depletion	via	IMP	dehydrogenase	inhibition,	
inhibition	 of	 viral	 polymerase	 and	 inhibition	 of	RNA	 capping	 (Crotty,	 Cameron	
and	 Andino,	 2002;	 Leyssen	 et	 al.,	 2005).	 It	 has	 been	 successfully	 used	 for	
treatment	 of	 hepatitis	 C	 and	 is	 licensed	 for	 treatment	 of	 respiratory	 syncytial	
virus	 (RSV),	 another	 member	 of	 the	 Paramyxoviridae,	 in	 young	 children.	
Although	 ribavirin	 has	 two	 Food	 and	 Drug	 Administration	 (FDA)	 black	 box	
warnings	 including	 teratogenicity	 and	 haemolytic	 anaymia,	 it	 is	 generally	well	
tolerated	 with	 bronchospasm	 (aerosolized)	 (Falsey,	 2012)	 and	 reversible	




originally	 seen	as	a	promising	 therapeutic	 candidate	 for	 treatment	of	HPIV3	 in	
haematopoietic	stem	cell	transplant	(HSCT)	patients	with	mixed	outcomes	being	
reported	 in	 small,	 uncontrolled	 studies	 and	 case	 reports	 (Lewis	 et	 al.,	 1996;	
Chakrabarti	et	al.,	2000).	However	a	number	of	recent	more	systematic	studies	
and	meta	analyses	have	shown	that	ribavirin	had	little	or	no	effect	on	morbidity	
and	mortality	 in	 patients	with	 proven	 lower	 respiratory	 tract	 infection	 (LRTI)	
caused	 by	 HPIV3	 (Seo	 et	 al.,	 2014).	 High-dose	 intravenous	 gammaglobulin	
similarly	had	no	effect	(Falsey,	2012;	Shah	et	al.,	2016)	.	Although	the	efficacy	of	
ribavirin	 has	 been	 shown	 in	vitro	 for	 tissue	 culture	 adapted	 strains,	 its	 lack	 of	
therapeutic	efficacy	 in	patients	necessitates	another	evaluation	of	 its	 inhibitory	




activity	 in	 vitro	 (Furuta	 et	 al.,	 2013).	 	 First	 marketed	 in	 2003,	 it	 is	 licensed	
against	influenza	in	Japan.		Favipiravir	is	a	selective	and	potent	inhibitor	of	RNA	
dependent	 RNA	 polymerases	 and	 has	 been	 shown	 to	 be	 virucidal	 by	 inducing	
catastrophic	 viral	 mutagenesis	 (Furuta	 et	 al.,	 2013;	 Arias,	 Thorne	 and	
Goodfellow,	 2014;	 Vanderlinden	 et	 al.,	 2016).	 	 	 In	 vitro	 it	 has	 demonstrated	
activity	against	a	broad	range	of	RNA	viruses,	 including	positive	 stranded	RNA	
viruses	such	as	norovirus,	Flaviviridae	and	negative	stranded	RNA	viruses	such	
as	 Filoviridae	 (including	 Ebola)	 and	 Paramyxoviridae	 (Jochmans	 et	 al.,	 2016;	
Sissoko	 et	 al.,	 2016;	 Vanderlinden	 et	 al.,	 2016).	 	 Among	 the	 latter,	 the	
effectiveness	 of	 favipiravir	 has	 been	 demonstrated	 in	 vitro	 on	 culture	 adapted	
strains	 of	 human	 metapneumovirus	 (HMPV),	 RSV,	 HPIV	 and	 measles	 virus	
(Jochmans	et	al.,	2016).	 	So	 far	 this	antiviral	has	not	been	assayed	against	wild	
type	clinical	strains	of	HPIV3.		
1.3.4.2.3 Zanamivir	
Zanamivir	 is	 a	 neuraminidase	 inhibitor	 and	 is	 licensed	 for	 the	 treatment	 of	
influenza	 under	 the	 trademark	 name	 of	 relenza.	 It	 inhibits	 influenza	 by	
preventing	the	release	of	new	viral	particles	from	the	infected	cell.	Although	its	
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impact	 on	 the	 clinical	 outcome	 of	 influenza	 infection	 has	 recently	 been	
questioned	 (Jefferson	 et	 al.,	 2014),	 its	 low	 toxicity	 profile	 and	 mechanism	 of	
action	 would	 nonetheless	 make	 it	 a	 potential	 candidate	 for	 the	 treatment	 of	
HPIV3.		HPIV3	relies	on	a	joint	haemagglutinin-neuraminidase	(HN)	protein	both	




the	 influenza	 neuraminidase	 to	 suggest	 a	 potential	 high	 affinity	 for	 zanamivir	
(Lawrence	et	al.,	2004).	The	role	of	this	protein	in	both	viral	binding	and	fusion	
with	 the	 target	 cell,	 as	well	 as	 in	 the	 release	of	 the	nascent	 virus	 from	 the	 cell	
surface,	 indicates	 the	 potential	 for	 zanamivir	 to	 interfere	 with	 the	 viral	
replication	 cycle	 of	 HPIV3	 at	 two	 points.	 	 In	 vitro	 studies	 on	 tissue	 culture	
adapted	strains	have	generally	concluded	that	zanamivir	has	the	potential	to	act	
as	 a	 binding	 inhibitor	 of	 HPIV3	 albeit	 at	 EC50	 values	 approaching	 milimolar	
concentrations,	 making	 this	 an	 unfeasible	 in	 vivo	 candidate	 (Greengard	 et	 al.,	






drug	 delivery	 (Shanmugam	 et	al.,	 2013)	 and	 synergy	 (Bailly	 et	al.,	 2016).	 In	 a	
recent	 study,	 the	 anti-parasitic	 drug	 suramin	 was	 discovered	 to	 be	 a	 non-
competitive	 inhibitor	 of	 HPIV3	 HN	 protein,	 synergistic	 with	 the	 action	 of	
zanamivir.	 However	 the	 concetrations	 required	 were	 still	 prohibitively	 high	
(Bailly	et	al.,	2016).		Equally	it	has	been	reported	that	low	dose	ribavirin	has	the	
capacity	to	potentiate	favipiravir	 in	treatment	of	Ebola	in	a	small	animal	model	
(Westover	 et	 al.,	 2016).	 Although	 the	 pathologies	 of	 these	 diseases	 are	 vastly	




Other	 novel	 therapeutics	 for	 HPIV3	 have	 been	 proposed,	 based	 both	 on	 the	
structure	of	 the	virus	as	well	as	on	 the	mechanisms	of	 infection	and	pathology	
(Hayden,	 2009,	 2013).	 	 Among	 the	 most	 promising	 drugs	 is	 a	 new	 sialidase	
fusion	protein	 inhibitor	DAS181	(Ansun	BioPharma,	2017).	This	drug	has	been	
identified	 as	 a	 potential	 therapeutic	 candidate	 for	 viruses	 that	 are	 reliant	 on	 a	
sialic	 acid	 receptor	 for	 cell	 entry	 including	 influenza,	 reovirus,	 rotavirus,	
adenovirus	 and	 parainfluenza	 viruses	 (Triana-Baltzer	 et	 al.,	 2009;	 Stencel-
Baerenwald	 et	 al.,	 2014).	 	 As	 an	 inhibitor	 of	 HPIV3	 it	 has	 been	 shown	 to	 be	
effective	both	in	human	airway	epithelial	(HAE)	cells	and	a	small	animal	model	
(Moscona	et	al.,	 2010),	 as	well	 as	 in	 a	number	of	 clinical	 cases	 (Chalkias	et	al.,	
2014;	Waghmare	et	al.,	 2015;	 Salvatore	et	al.,	 2016).	 Phase	 I	 trial	 results	 have	
been	 encouraging,	 although	 some	 potential	 adverse	 side	 effects	 have	 been	
reported	in	patients	with	underlying	atopy	(Zenilman	et	al.,	2015;	Colombo	et	al.,	
2016).		
Newer	 approaches	 have	 centered	 around	 structure	 guided	 synthesis	 of	 novel	
compounds	 (Alymova	et	al.,	 2004,	2005;	Tindal	et	al.,	 2007)	 .	These	have	been	
tested	both	in	vivo	and	in	vitro	with	a	particular	focus	on	finding	a	more	efficient	
inhibitor	for	the	HN	of	HPIV3	(Moscona,	2005).	 	Other	potential	targets	include	





To	 date	 most	 of	 the	 experimental	 work	 on	 HPIV3	 has	 been	 conducted	 using	
significantly	 laboratory	 adapted	 strains.	 Two	 strains,	 in	 particular	 have	 been	
widely	used:	JS	strain	and	Washington	strain.	
The	Washington	strain	is	alternatively	identified	as	C243	or	strain	47885.	It	was	
originally	 isolated	 from	 a	 one	 year	 old	 female	 in	 1957	 in	 Washington	 DC	
(Galinski,	Mink	and	Pons,	1988;	Galinski	and	Wechsler,	1991).	It	was	propagated	
in	 LLC-MK2	 cells,	 and	 has	 since	 been	 used	 as	 a	 prototype	 strain	 for	 outbreak	
tracking	 (Zambon	 et	al.,	 1998;	 Jalal	et	al.,	 2007),	 phylogenetic	modeling	 (Goya,	
Mistchenko	 and	 Viegas,	 2016;	 Košutić-Gulija	 et	 al.,	 2017),	 studies	 of	 virus	
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evolution	 (Tsutsui	 et	 al.,	 2017),	 therapeutic	 inhibitor	 development	 and	
evaluation	(Tindal	et	al.,	2007;	Guillon	et	al.,	2014;	Bailly	et	al.,	2016)	and	vaccine	
research	 (Haller	et	al.,	 2000;	 Senchi	et	al.,	 2013)	 among	others.	An	early	 study	










passaged	 14	 times	 in	 African	 Green	 monkey	 kidney	 cells	 (AGKM)	 and	 plaque	
purified	 to	 serve	 as	 a	 vaccine	 candidate	 (Belshe	 and	Hissom,	 1982).	 Therefore	
the	 JS	 strain	 has	 since	 become	 the	 main	 strain	 for	 HPIV3	 vaccine	 research	
(Belshe	et	al.,	1992,	2004),	including	recombinant	vaccines	(Schmidt	et	al.,	2001;	
Greer	et	al.,	 2007)	and	development	of	 reverse	genetics	 systems	 (Durbin	et	al.,	
1997;	Roth,	Li	and	Barnard,	2010;	Beaty	et	al.,	2017)		The	JS	strain	was	found	to	
be	distinct	 from	the	prototype	Washington	strain	(Stokes	et	al.,	1992)	with	 the	




Until	 recently	 the	 isolation	 and	 propagation	 of	 any	 virus	 for	 diagnostic	 or	
experimental	purposes	was	reliant	on	its	ability	to	proliferate	in	cell	culture.	As	
discussed	 above,	 heavily	 culture	 adapted	 strains	 of	 HPIV3	 are	widely	 used	 for	
research.	 HPIV3,	 especially	 in	 its	 adapted	 form	 grows	 readily	 in	 many	
immortalised	culture	systems.	To	name	but	a	few:	LLC-MK2	cells	(Galinski,	Mink	
and	Pons,	1988),	Vero	cells	(Schmidt	et	al.,	2001),	BEK	and	AGKM	cells	(Belshe	
and	 Hissom,	 1982),	 A549	 (Guillon	 et	 al.,	 2014),	 	 MDBK	 cells	 (Coelingh	 and	
Winter,	1990).		Overall	HPIVs	are	known	to	propagate	more	readily	in	epithelial	
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rather	 than	 fibroblast	 cell	 lines	 (Henrickson,	 2003).	 	 These	 viruses	 are	 not	
known	to	be	cytopathic	in	cell	culture,	although	they	are	known	to	become	more	
fusogenic	 and	 destructive	 with	 increased	 adaptation	 to	 a	 particular	 cell	 line	
(Henrickson,	2003;	Palmer	et	al.,	2012;	Palermo	et	al.,	2016).		
1.4.3 Small	animal	models	
The	 use	 of	 small	 animal	 models,	 particularly	 rodents	 is	 widespread	 in	 virus	
research	 (Adachi	and	Miura,	2014).	These	are	particularly	useful	when	a	 small	
animal	equivalent	of	the	virus	exists,	such	as	in	the	case	of	Sendai	virus	(murine)	
and	HPIV1	 (human)	 (Adderson	et	al.,	 2015),	 as	 the	model	 virus	 is	 thus	 able	 to	
replicate	 in	 its	 natural	 host.	 	 However	 no	 such	 model	 is	 available	 for	 HPIV3.	
Animal	models	of	HPIV3	have	included	ferrets	(Mascoli	et	al.,	1976),	guinea	pigs	
(Ye	 et	 al.,	 2010),	 hamsters	 (Rydbeck,	 Love	 and	 Norrby,	 1988)	 and	 cotton	 rats	
(Porter	et	al.,	1991).	The	latter,	in	particular	is	considered	to	be	a	good	model	for	
HPIV3	infection	as	infection	in	cotton	rats	is	thought	to	reproduce	faithfully	the	
effects	 of	 infection	 as	well	 as	 vaccine	 efficacy	 in	 humans	 (Ottolini	 et	al.,	 1996,	
2002;	 Boukhvalova,	 Prince	 and	 Blanco,	 2009).	 However	 these	 are	 complex	 to	
handle	 and	 no	 genetically	 specific	 lineages	 currently	 exist	 (Green,	 Huey	 and	
Niewiesk,	2013).		
1.4.4 Human	airway	epithelial	cells	





(Stewart	 et	 al.,	 2012),	 virology	 (Banach	 et	 al.,	 2009)	 and	 others	 (Balloy	 et	 al.,	
2015).	In	HPIV3	research	it	has	been	used	to	study	inflammatory	responses	and	
growth	kinetics	of	different	parainfluenza	subtypes	(Zhang	et	al.,	2005;	Schaap-
Nutt	 et	 al.,	 2012)	 and	 novel	 therapeutic	 drug	 testing	 (Moscona	 et	 al.,	 2010).	
Additionally	it	is	considered	to	be	a	very	close	approximation	of	the	natural	host	
for	virus	culture	(Palmer	et	al.,	2012;	Palermo	et	al.,	2016).		The	above,	coupled	
with	 the	 current	 trend	 to	 reduce	 the	 use	 of	 animal	 in	 scientific	 research	
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et	 al.,	 1999)	 that	 more	 fusogenic	 variants	 of	 these	 viruses	 trigger	 a	 stronger	
inflammatory	response,	thus	precipitating	a	more	clinically	adverse	infection	but	
equally	contributing	to	faster	clearing	of	the	virus.	Hence,	it	could	be	argued	that	
a	 more	 fusogenic	 phenotype	 would	 constitute	 a	 more	 aggressive,	 but	
paradoxically	less	successful	strain	in	an	immunocompetent	population.		This	is	
consistent	with	what	is	observed	in	a	clinical	scenario.	In	patients	with	an	intact	








in	 which	 HPIV3	 directly	 subverts	 the	 immune	 system	 and	 ensures	 viral	
persistence.	(Fields,	Knipe	and	Howley,	2013).	The	C	protein	of	HPIV3	prevents	
STAT1	phosphorylation	with	the	subsequent	inhibition	of	IFN	α	and	β	signalling	




Clearance	 of	 HPIV3	 is	 impaired	 by	 creation	 of	 infection	 reservoirs:	 HPIV3	 has	
been	 shown	 to	 prevent	 autophagy	 of	 infected	 cells	 (Ding	 et	 al.,	 2014)	 and	 to	
enhance	 the	 survival	 of	monocytes	 by	 triggering	 the	GM-CSF	 autocrine	 loop	 in	
vivo	(Plotnicky-Gilquin	et	al.,	2001).	Additionally	the	C	protein	of	HPIV3	is	known	
to	activate	the	MAPK/EPK	pathway	to	create	a	favourable	environment	for	viral	
replication	 (Caignard	 et	 al.,	 2009).	 Clinically	 this	 leads	 to	 an	 increased	
production	 of	 mucus,	 blocking	 airways	 and	 preventing	 the	 clearance	 of	
pathogens	 (Vareille	 et	 al.,	 2011;	 Schomacker	 et	 al.,	 2012).	 This	 in	 turn,	
predisposes	 to	 secondary	 infections	 and	 adversely	 affects	 clinical	 outcome	
(Alymova	et	al.,	2005;	Yamaya	et	al.,	2010).		
1.5.3 Inflammatory	response	
In	 the	 general	 population,	 HPIV3	 has	 been	 compared	 to	 RSV,	 another	
paromyxovirus,	 with	 a	 well-studied	 immune	 driven	 disease	 enhancement	
mechanism	(Openshaw	and	Tregoning,	2005).	 	 In	RSV	 infections,	 it	 is	often	not	
the	 viraemia	 itself,	 but	 the	 immune	 response	 of	 the	 host	 that	 causes	 the	most	
damage	and	mediates	disease	severity.	This	aspect	has	been	less	well	studied	in	
HPIV3,	 with	 conflicting	 data	 on	 correlation	 of	 chemokine	 production	 and	 the	
severity	of	disease	(Gern	et	al.,	2002).			
Increases	 in	 pro-inflammatory	 chemokines	 such	 as	 RANTES,	 IL-6,	 MIP1	 alpha	
and	beta	as	well	as	IP10	and	IL8	has	been	reported	both	in	in	vitro	(Zhang	et	al.,	
2005;	 Schaap-Nutt	 et	 al.,	 2012;	 Lewandowska-Polak	 et	 al.,	 2015)	 and	 in	 vivo	




in	 patients	 with	 pre-existing	 atopy	 (Ye	 et	 al.,	 2010;	 Johnson	 et	 al.,	 2013;	
Lewandowska-Polak	et	al.,	 2015).	As	mentioned	above,	 it	 has	been	 shown	 that	




against	mild	 infections	 (Spriggs	 et	 al.,	 1987)	 and	 that	maternal	 antibodies	 are	
protective	to	some	extent	in	infants	before	the	age	of	6	months	(Lee	et	al.,	2001).			
However,	 overall	 the	 adaptive	 immune	 response	 against	 HPIV3	 is	 incomplete	
and	 infections	 occur	 throughout	 life	 (Fields,	 Knipe	 and	 Howley,	 2013)	 for	 a	
number	of	reasons.	Activation	of	dendritic	cells	is	essential	for	the	formation	of	a	
long	 -term	 adaptive	 immune	 response	 and	 prevention	 of	 re-infection	with	 the	
same	 virus	 (Howard	 et	 al.,	 2004).	 HPIV3	 infects	 and	 replicates	 readily	 in	





most	 important	 in	 terms	 of	 long-term	 protection	 (Spriggs	 et	 al.,	 1987).	 As	
described	above,	HPIV3	has	a	mechanism	that	down	regulates	the	production	of	
F	proteins	(Lingemann	et	al.,	2015)	thus	further	down-regulating	the	production	




antibodies	 required	 for	 protection	 are	 short	 lived	 (Fields,	 Knipe	 and	 Howley,	
2013).	 There	 is	 currently	 little	 experimental	 evidence	 linking	HPIV3	HN	 and	F	
phenotype	with	variations	 in	 the	adaptive	 immune	response	(Kato	et	al.,	1999;	
Lingemann	et	al.,	2015).	However	it	could	be	argued	that	more	fusogenic	strains	





As	 described	 above,	 HPIV3	 is	 an	 important	 pathogen	 with	 significant	 clinical	
impact.	 Overall,	 to	 date,	 there	 is	 little	 data	 and	 consensus	 on	 the	 interplay	
between	host	and	virus	factors	in	the	pathogenesis	and	disease	severity	caused	
by	 HPIV3	 (Schomacker	 et	 al.,	 2012).	 It	 is	 widely	 accepted	 that	 HPIV3	 has	 a	
particularly	 significant	 impact	 in	 immunocompromised	 patients,	 which	 would	
indicate	 that	 host	 response	 is	 an	 important	 contributor	 to	 the	 pathogenesis	 of	
HPIV3	 infection	 (1.3.3	 Morbidity	 and	 Mortality).	 	 However	 it	 has	 also	 been	
shown	 that	 clinical	 severity	 can	 be	 correlated	 to	 viral	 phenotype	 and	 to	 the	
fusogenicity	 of	 the	 viral	 strain	 in	 particular	 (1.5	 Pathogenesis).	 Despite	 this,	
there	 is	 little	 data	 on	 the	 genetic	 diversity	 of	 circulating	 strains,	 potential	
correlation	with	their	phenotype	and	consequently	clinical	impact.	
As	 immunity	 to	HPIV3	 is	 incomplete,	 regular	 peaks	 in	 cases	 in	 late	 spring	 and	
summer	occur	in	the	community	(Zhao	et	al.,	2017).	This	has	the	potential	to	lead	
to	 outbreaks	 in	 healthcare	 settings	 with	 ensuing	 impacts	 on	 morbidity	 and	
mortality	as	well	as	structural	and	financial	consequences	for	the	health	service,	
such	 as	 ward	 closures	 and	 bed	 shortages.	 Although	 there	 are	 a	 number	 of	
potential	 therapeutic	 candidates	 for	 HPIV3,	 there	 is	 currently	 neither	 licensed	
treatment	 nor	 vaccine	 (see	 Section	 1.3.3).	 While	 much	 research	 has	 been	
conducted	 in	 this	 area,	most	 of	 it	 has	 been	 carried	 out	 on	 significantly	 culture	
adapted	 reference	 strains	 (see	 Section	 1.4.1).	 As	 mentioned	 above,	 there	 is	
sufficient	 evidence	 to	 support	 that	 these	 do	 not	 represent	 a	 true	 reflection	 of	













collected	 between	 2011	 and	 2015	 by	 the	 PHE	 laboratory,	 Addenbrooke’s	
hospital,	 Cambridge.	 This	 laboratory	 covers	 Cambridge	University	Hospitals	 as	
well	 as	 the	 wider	 geographical	 area	 of	 North	 Herfordshire,	 East	 Anglia,	






teams.	 Patient	 demographics	 and	 immunosuppression	 status	 were	 retained	
where	 possible.	 Further	 patient	 information	 including	 patient	 movement,	
symptom	 onset,	 other	 organisms	 isolated	 and	 clinical	 outcome	were	 extracted	
from	EPIC	hospital	systems	(www.epic.com)	where	required.	
All	patients	were	originally	diagnosed	by	routine	respiratory	diagnostic	PCR	on	
upper	 respiratory	 tract	 samples	 (either	 swabs	 or	 naso-pharyngeal	 aspirates).	
The	 multiplex	 PCR	 diagnostic	 panel	 used	 has	 been	 validated	 for	 the	 PHE	
diagnostic	 laboratory	 at	 Addenbrooke’s	 hospital,	 Cambridge	 and	 includes	 the	
following	 common	 respiratory	 viruses:	 influenza	 A	 and	 B,	 RSV,	 enterovirus,	
rhinovirus,	 HMPV,	 adenovirus	 and	 HPIV1-4.	 The	 samples	 were	 identified	 as	




The	 culture	 adapted	 HPIV3	 strain	 (MK9)	 was	 obtained	 from	 Public	 Health	






The	 PLC/PRF5	 human	Alexander	 hepatoma	 cell	 line	was	 obtained	 from	Public	
Health	England	(PHE)	culture	collections.	HPIV3	has	been	cultured	previously	in	
numerous	cell	lines	including,	among	others:	CV-1,	293T,	Hep2,	MDCK	and	Vero	
(Palmer	et	al.,	2012;	 Jochmans	et	al.,	2016).	 In	 this	case	 the	PLC/PRF5	cell	 line	




The	 PLC/PRF5	 cell	 line	was	maintained	 in	 Dulbecco’s	Modified	 Eagle	Medium	
(DMEM)	 high	 glucose	 medium	 supplemented	 with	 10%	 fetal	 bovine	 serum	




nasal	 cells	 sourced	 from	a	 single	 donor:	 46-year-old	 Caucasian	 female	with	 no	




transferred	 into	 media	 upon	 arrival	 and	 were	 maintained	 at	 37°C	 at	 100%	
humidity,	5%	CO2.	The	medium	was	changed	every	2-3	days	as	per	the	protocol	
supplied	by	Epithelix.	Surface	mucus	was	removed	once	a	week	by	washing	the	





Cell	 monolayers	 were	 set	 up	 at	 70%	 confluence	 in	 T25	 flasks	 and	 each	
monolayer	 was	 inoculated	 with	 20	 μl	 clinical	 sample	 in	 200	 μl	 maintenance	
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medium	 (high	 glucose	 DMEM	with	 1%	 fetal	 bovine	 serum	 (FBS)	 and	 2mM	 L-











Growth	of	 clinical	 samples	 in	 immortalised	 cells	was	 carried	out	 in	 two	cycles.	
During	the	 first	cycle	 the	cells	were	 infected	as	described	above	and	viral	yield	




second	 passage.	 	 Additionally	 11	 samples	 were	 chosen	 at	 random	 from	 those	
classified	 as	 negative	 for	 further	 culture	 to	 evaluate	 potential	 yield	 from	
subsequent	passages	even	if	no	growth	was	detected	at	passage	1.	After	second	
passage,	positive	samples	were	stored	and	those	classified	as	either	negative	or	
intermediate	were	 passaged	 one	more	 time,	 afterwards	 positive	 samples	were	
stored	and	all	others	discarded.			
During	 the	 second	 cycle	 all	 samples	 that	 were	 classified	 as	 non-positive	 at	
passage	 one,	 underwent	 a	 second	 passage.	 Samples	 classified	 as	 positive	were	







the	 supernatant	 and	 cells	 were	 collected	 and	 clarified	 by	 centrifugation.	
Subsequently	20	μl	of	the	clarified	supernatant	in	200	μl	of	maintenance	media	







of	 clinical	 sample	 in	 100	 μl	 of	 pre-warmed	 serum	 free	medium	 supplemented	
with	 penicillin	 100	 U/ml,	 streptomycin	 100	 μg/ml,	 gentamicin	 50	 μg/ml,	
ceftazidime	 50	 μg/ml,	 vancomycin	 50	 μg/ml	 and	 fungizone	 (amphotericin	 B)	
5μg/ml	 to	minimize	bacterial	and	 fungal	out	growth,	as	above.	Cells	were	 then	




5%	 CO2	 for	 30	 min.	 Following	 the	 incubation	 the	 sample	 was	 removed	 by	
pipetting	 and	 viral	 titre	 was	 quantified	 by	 qPCR	 protocol	 (see	 below).	 Wells	
where	 growth	 was	 detected	 were	 freeze-thawed	 to	 maximize	 virus	 yield	 and	














in	maintenance	media.	The	plates	were	 incubated	at	33°C	 	+	5%	CO2	for	 seven	
days.	Agarose	plates	were	inverted	and	Avicel	plates	were	kept	immobile	for	the	










3,3'-diaminobenzidine	 (DAB)	 stain	was	 prepared	 using	 a	 previously	 published	
protocol	(Thordal-Christensen	et	al.,	1997).	 In	brief,	stock	solutions	of	1%	DAB	
and	 0.3%	 hydrogen	 peroxide	 were	 prepared,	 aliquoted	 and	 stored.	 When	
required,	250	μl	of	1%	DAB,	250	μl	of	0.3%	hydrogen	peroxide	and	5	ml	of	PBS	
were	mixed	 to	 produce	 a	 working	 stain.	 TrueBlue	 Peroxidase	 Substrate	 (KPL,	
SeraCare,	catalogue	number	5510-0052)	stain	required	no	prior	preparation.		
2.4.2 Immunofocal	plaque	assay		
Monolayers	 at	 80-90%	 confluence	 (1	 x	 106	 cells/well)	 were	 set	 up	 in	 6	 well	
plates	and	 infected	with	serial	dilutions	of	virus	stock	(500	μl/well).	 Infections	
were	 carried	 out	 in	 maintenance	 medium	 (high	 glucose	 DMEM	 supplemented	
with	 1%	 fetal	 bovine	 serum	 (FBS),	 penicillin	 (100	 SI	 units/ml),	 streptomycin	
(100	μg/ml)	and	2	mM	L-glutamine)	at	37°C	for	2	hours.		The	inoculum	was	then	
removed	and	the	monolayers	washed	twice	 in	PBS.	A	1%	agarose	overlay	with	
50%	maintenance	medium	was	 applied	 to	 the	 infected	monolayer.	 The	 plates	






HPIV3	 antibodies	 at	 1:5000	 dilution	 in	 PBS	 containing	 5%	 FBS	 at	 room	
temperature	 for	 1	 hour	 (500	 μl/well).	 The	 antibodies	were	 raised	 against	 the	
following	 epitopes	 NQESNENTDPRTERF	 (amino	 acids	 96-110),	
NRVDQNDKPYVLTNK	 (amino	 acids	 525-539),	 and	 KEWIRRSNQKLDSIG	 (amino	









The	plates	were	 then	 scanned	 on	Epson	Perfection	V330	Photo	 scanner	 at	 the	
following	resolutions:	800	dpi	for	small	plaque	phenotype	and	300	dpi	and	500	
dpi	for	large	and	medium	plaque	phenotype	for	plaque	counting	and	surface	area	
measurements	 respectively.	 The	 plaques	 were	 then	 analysed	 using	 the	 Fiji	
analyse	 particles	 module.	 In	 brief,	 the	 global	 scale	 was	 set	 by	 measuring	 the	
diameter	of	a	well	in	pixels	on	the	image	and	scaling	it	to	the	physical	diameter	of	









thus	 generated	 was	 then	 overlaid	 onto	 the	 original	 image	 using	 the	 “overlay”	
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function	to	confirm	that	all	plaques	were	correctly	identified	and	included	by	the	
analysis.	 Adjustments	 to	 particle	 size	 and	 circularity	 were	 then	 carried	 out	 to	




X,	 GraphPad	 Software,	 La	 Jolla	 California	 USA,	 www.graphpad.com.	 Linear	
regressions	 from	 the	 standard	 curve	 for	 qPCR	 were	 fitted	 using	 the	 linear	
regression	model.	 Dose	 response	 curves	 for	 drug	 inhibition	 assays	were	 fitted	
using	 the	 4	 parameter	 logistic	 (4PL)	 fit.	 Curves	with	R2	>	 0.9	 and	 a	 p<0.05	 for	






Cells	 in	 96	 well	 plates	 were	 either	 mock	 inoculated	 or	 inoculated	 with	 serial	
dilutions	 of	 each	 inhibitor	 (ribavirin,	 favipiravir	 or	 zanamivir)	 starting	 with	 a	
concentration	of	1	mM	in	eight	biological	repeats.	Plates	were	then	incubated	at	
33°C	for	7	days	and	assayed	with	CellTiter-Blue®	Cell	Viability	Assay	(Promega)	
as	per	 the	manufacturer’s	 instructions.	The	dose	of	1mM	was	chosen	 to	 reflect	
the	upper	limit	of	a	potential	physiological	dose	in	a	patient.		
2.5.2 Plaque	reduction	assay		
Cell	 monolayers	 were	 either	 mock	 inoculated	 or	 inoculated	 with	 the	 MK9	
reference	strain	stock	dilutions	required	to	produce	20-100	plaques	in	each	well.	
Inhibitors	 at	 required	 concentrations,	 or	 an	 equivalent	 volume	of	diluent	were	




Cell	 monolayers	 were	 either	 mock	 inoculated	 or	 inoculated	 with	 laboratory	
strain	(MK9)	virus	stock	 in	 triplicate.	The	 inoculum	was	 then	removed	and	the	
monolayers	 were	 washed,	 covered	 with	 maintenance	 medium	 containing	 the	
inhibitors	 at	 required	 concentrations,	 or	 the	 equivalent	 volume	of	 diluent,	 and	






maximum	 effective	 concentration	 (EC50)	 and	 90%	 maximum	 effective	
concentration	 (EC90)	 values,	 as	 interpolated	 from	 the	 dose	 response	 curve	 of	
infectious	particle	reduction	in	the	supernatant	using	reference	strain	MK9,	were	
used.	The	EC50	value	for	zanamivir	was	inferred	from	the	dose	response	curve	of	




the	 required	 viral	 dilutions	 in	 maintenance	 medium,	 with	 or	 without	 the	
indicated	concentrations	of	zanamivir.	The	inoculum	was	then	removed,	the	cells	
were	washed	with	PBS,	 covered	with	agarose	overlay	and	 incubated,	 fixed	and	
immunostained	as	per	protocol	above.		
2.5.5 Pre-incubation	with	zanamivir		
High	 viral	 titres	 (at	 least	 105	 PFU/ml)	 were	 pre-incubated	 with	 different	
concentrations	 of	 zanamivir	 or	 with	 equivalent	 volume	 of	 diluent	 (PBS)	 for	 1	
hour	 at	 37°C.	 	Mock	 controls	with	 virus	 on	 its	 own,	 UV	 inactivated	 virus	with	
zanamivir,	 and	 zanamivir	 on	 its	 own,	 were	 included.	 Post	 incubation,	 the	






to	 EC50	 ZNV	 by	 growth	 inhibition	 (see	 above).	 For	 binding	 inhibition	 two	
concentrations	 of	 the	 inhibitor	 were	 used.	 The	 lower	 concentration	
corresponded	to	the	EC50	interpolated	from	the	dose	response	curve	of	binding	
inhibition	 using	 laboratory	 strain	 MK9	 and	 the	 higher	 was	 the	 maximum	









0.7	 ml	 of	 fresh	 HAE	 culture	 medium	 pre-warmed	 to	 37°C	 and	 the	 cells	 were	
washed	as	described	above.		
	
Figure	 2-1	 Diagram	 of	 transwell	 support	 with	 HAE	 cells.	 HAE	 cells	 were	
grown	in	transwell	supports,	each	resting	in	0.7	ml	of	HAE	culture	medium	at	an	


























to	 a	 new	24	well	 plate,	 containing	 0.7	ml	 of	 pre-warmed	 culture	medium.	The	












the	 basolateral	 surface	 or	 HAE	 cells.	 The	 kit	 contained	 the	 following	 targets:	
Eotaxin/CCL11;	GM-CSF;	GRO-α/CXCL1;	 IFNα;	 IFNγ;	 IL-1β;	 IL-1α;	 IL1-RA;	 IL-2;	
IL-4;	 IL-5;	 IL-6;	 IL-7;	 IL-8/CXCL-8;	 IL-9;	 IL-10;	 IL-12	p70;	 IL-13;	 IL-15;	 IL-17A;	
IL-18;	 IL-21;	 IL-22;	 IL-23;	 IL-27;	 IL-31;	 IP-10/CXCL-10;	 MCP-1/CCL2;	 MIP-1α;	
MIP-1β;	 RANTES;	 SDF1α;	 TNFα;	 TNFβ.	 All	 samples	were	 diluted	 in	 a	 ratio	 1:1	
apart	 from	samples	taken	at	 the	final	 time	point	(72	hours)	where	the	samples	
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were	 diluted	 1:10	 in	 DMEM.	 	 The	 assay	 was	 read	 on	 a	 Luminex	 200	 system	
Luminex	 xPONENT	 for	 LX100/LX200	 version	 3.1;	 the	 doublet	 discrimination	
(DD)	 gate	 was	 set	 at	 5,000-25,000	 with	 a	 timeout	 of	 60	 seconds	 and	 bead	
event/bead	 region	 at	 50-00	 as	 per	 manufacturer’s	 instructions.	 The	 final	
concentrations	 of	 each	 target	 were	 calculated	 based	 on	 the	 standard	 curve	
generated	used	 the	Bio-Plex	Manager	Software	version	6.1	using	 the	standards	





Total	 RNA	 from	 samples	 was	 extracted	 using	 the	 GenElute	 Mammalian	 Total	
RNA	Miniprep	kit	(Sigma)	according	to	the	manufacturer’s	guidelines.	This	was	
amplified	on	the	ViiA7	Real	Time	PCR	system	(Applied	Biosystems)	using	a	qPCR	
protocol	 obtained	 and	modified	 from	 the	 standard	 operating	 procedure	 (SOP)	
for	HPIV3	typing	used	by	the	PHE	diagnostic	laboratory,	Addenbrooke’s	Hospital,	
Cambridge.	 	 The	 primers	 and	 the	 taqman	 probe	 used	 were:	 forward	 5'-
GCTCCTTTYATCTGTATCCTCAGAGATCC-3'	 (nucleotides	 1035-1063,	 accession	
number	 NC_001796.2);	 reverse	 5'-TGATCTTCCCGTCACATACTGTTGCATG-3'	





control	 was	 obtained	 and	 cloned	 by	 TA	 cloning	 using	 the	 PureYield™	 Plasmid	
Midiprep	System	(Promega).	The	sequence	of	the	amplicon	aligned	to	138bp	of	
the	 nucleocapsid	 gene	 of	 HPIV3	 (nucleotides	 1035-1172	 accession	 number	
NC_001796.2).	 	Ten	fold	serial	dilutions	of	the	plasmid	were	subsequently	used	
to	 establish	 a	 standard	 curve.	 Linear	 regression	 of	 the	 standard	 curve	 for	





Total	 RNA	 from	 samples	 was	 extracted	 using	 the	 GenElute	 Mammalian	 Total	
RNA	 Miniprep	 kit	 (Sigma)	 according	 to	 the	 manufacturer’s	 guidelines.	 Full	
genome	 amplification	 was	 achieved	 using	 a	 set	 of	 twelve	 primers	 producing	
twelve	overlapping	amplicons	(Figure	2-2).	All	primer	pairs,	apart	 from	pairs	4	
and	 8,	 were	 generated	 in	 a	 pilot	 project	 conducted	 prior	 to	 this	 PhD	 by	 Dr	
Kyriaki	Ranellou.	Primers	4F	and	8R	were	generated	as	part	of	this	project.	The	
kit	 used	was	 Superscript	 III	 One-step	 RT-PCR	 System	with	 Platinum	Taq	High	




amplification	 the	products	were	 ran	on	a	1%	agarose	gel	 for	 confirmation	and	







designed	 (A)	 and	 used	 to	 generate	 overlapping	 amplicons	 covering	 the	 entire	
HPIV3	genome	as	shown	in	(B)	
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genscript	 sequencing	 primer	 design	 tool	 (http://www.genscript.com).	 These	
were	used	for	Sanger	sequencing	together	with	the	amplification	primers,	aiming	
for	 overlapping	 amplicons	 <	 700bp	 each.	 The	 sequence	was	 then	 aligned	 to	 a	









The	 amplicons	 generated	 had	 their	 concentrations	 determined	 on	 a	 nanodrop	
spectrophotometer	 (Thermo	 Scientific),	 were	 combined	 in	 equimolar	
concentrations	and	sequenced	on	the	Illumina	platform.	Paired	short	reads	were	
then	 processed	 with	 Trimgalore	 to	 remove	 the	 Illumina	 paired	 end	 library	
adapters	 (Nextera	 (https://support.illumina.com/))	 as	 well	 as	 short	 and	 low	
quality	reads	to	retain	those	with	length	>20bp	and	Phred	scores	>20.		Terminal	
primer	 sequences	 were	 subsequently	 removed	 with	 Cutadapt	 (Martin,	 2011).	
Alignment	was	 performed	with	 Bowtie2	 (Langmead	 and	 Salzberg,	 2012),	with	
the	alignment	score	“–-score-min”	of	-0.6,		using	the	Sanger	sequences	obtained	
above	 as	 reference	 (strain	 153	 was	 used	 as	 a	 reference	 sequence	 for	 clinical	
strains)	and	the	consensus	was	extracted	with	Samtools	(Li	et	al.,	2009).		The	“–-
score-min”	 of	 -0.6	 meant	 that	 for	 a	 sequence	 length	 of	 150bp	 (approximate	
maximum	length	of	sequence	obtained),	a	mismatch	of	15	bases	was	permitted.	
This	 provided	 the	 optimum	 tradeoff	 between	 a	 high	 quality	 alignment	 and	
allowance	for	genome	variability,	which	has	shown	only	5%	overall	divergence	
between	recent	clinical	strains	and	the	prototype	Washington	strain	(MK9)	(Mao	
et	al.,	2012)	and	previously	been	shown	not	 to	exceed	10%	at	any	point	 in	 the	
HPIV3	 genome	 (Palermo	 et	al.,	 2016).	 The	 results	were	 then	 compared	 to	 the	
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sequences	obtained	using	 Sanger	 sequencing	of	 the	 laboratory	 strain	MK9	and	
sequence	153	as	well	as	the	consensus	sequences	obtained	using	the	previously	
published	de	novo	Ebola	pipeline	using	QUASR	for	quality	control	and	Spades	3.5	
for	 assembly	 (Arias	 et	al.,	 2016).	 In	 each	 case	 the	 sequences	were	 identical	 to	






Total	 RNA	 from	 samples	 was	 extracted	 using	 the	 GenElute	 Mammalian	 Total	




Table	2-1	Primers	used	 for	amplification	of	HPIV3	 fragment	 for	outbreak	
tracing.	The	primers	used	 for	nested	PCR	amplification	of	HPIV3	 fragment	 for	





RT-PCR	System	with	Platinum	Taq	High	Fidelity	 from	 Invitrogen.	 	 The	 reverse	
transcription	(RT)	step	was	performed	at	50°C	for	30	min.	This	was	followed	by	
a	2min	denaturation	step	at	94°C,	and	35	cycles	of	denaturation	(94°C	for	15	s),	
annealing	 (55°C	 for	 30	 s)	 and	 extension	 (68°C	 3	 min	 30	 s).	 After	 the	 final	
extension	step	(68°C	 for	5	min)	 the	reaction	was	held	at	4°C.	The	second	cycle	
was	 performed	 with	 Taq	 DNA	 polymerase	 (Invitrogen)	 with	 the	 same	 cycling	






















confirmation	 and	 cleaned	 following	 the	 Epoch	 Life	 Science	 Quick	 Protocol	 for	
EcoSpin	All-in-one	Mini	Spin	Columns.	Rhinovirus	genotyping	was	attempted	for	










for	 Mac,	 GraphPad	 Software,	 La	 Jolla	 California	 USA,	 www.graphpad.com.	 All	
samples	were	 link-anonymised	 for	 laboratory	work	 and	 patient	 demographics	
and	 immunosuppression	 status	were	 retained	where	 possible.	 Further	 patient	




All	 HPIV3	 full	 genome	 sequences	 available	 on	 NCBI	 were	 downloaded	 and	
genomes	 originating	 from	 the	 same	 source	 and	 found	 to	 contain	 minimal	
variance	were	removed	for	clarity	and	to	minimize	bias.	Sequences	 in	Genbank	
that	 originated	 from	 strains	 that	were	 repeatedly	 passaged	 in	 culture	 or	were	
deliberately	modified,	such	as	strain	47885,	C243,	14702	and	strain	JS,	were	also	
removed,	leaving	36	diverse	full	genome	sequences.	These,	together	with	the	20	
sequences	 obtained	 in	 this	 project	 were	 aligned	 in	 UGENE	 using	 the	 Muscle	
algorithm	 (Okonechnikov,	 Golosova	 and	 Fursov,	 2012).	 Subalignments	 were	
extracted	using	UGENE.	The	most	suitable	substitution	model	was	selected	using	
the	 JModelTest	 2.0	 Software	 (Darriba	 et	 al.,	 2012).	 Position	 by	 position	 rates,	
distance	 matrices	 and	 maximum	 likelihood	 trees	 were	 generated	 using	
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Molecular	Evolutions	Genetics	Analysis	 (MEGA)	 software	version	7	 (Tamura	et	
al.,	 2007).	 1000	 bootstrap	 iterations	 were	 used	 for	 maximum	 likelihood	 tree	
confidence	 estimates.	 Clusters	 were	 visualized	 using	 Automatic	 Barcode	 Gap	
Discovery	 (ABGD)	 (Puillandre	 et	 al.,	 2012).	 	 A	 Bayesian	 Markov	 Chain	 Monte	
Carlo	 (MCMC)	 inference	 model	 was	 selected	 using	 marginal	 likelihood	
estimation	 using	 path	 sampling	 (PS)	 and	 stepping	 stone	 sampling	 (SS)	 with	
BEAST	 v1.8.4	 with	 a	 chain	 length	 of	 one	 million	 and	 one	 hundred	 path	 steps	








admissions	was	 collected	 between	 08/05/2017	 and	 31/08/2017.	 	 In	 order	 to	
visualize	the	respective	locations	of	patients,	a	timeline	incorporating	admission	
dates,	 symptom	 onset	 and	 first	 confirmed	 HPIV3	 positive	 sample	 was	
constructed	in	GraphPad	Prism	version	6.00	for	Mac,	GraphPad	Software,	La	Jolla	
California	 USA,	 www.graphpad.com.	 Data	 was	 then	 organized	 in	 an	 SQL	
database.	For	the	purposes	of	the	model,	the	susceptibility	period	was	defined	as	
1-7	 days	 prior	 to	 symptom	 onset	 and	 the	 infectious	 period	 as	 4	 days	 prior	 to	
symptom	 onset.	 The	 patient	was	 then	 considered	 infectious	 for	 the	 remaining	
duration	of	the	outbreak	due	to	the	prolonged	asymptomatic	shedding	exhibited	




patients	 included	 the	 paediatric	 oncology	 ward	 involved	 in	 the	 outbreak,	 the	
paediatric	day	unit	(PDU)	and	the	paediatric	intensive	care	unit	(PICU).	Patients	
were	 in	 isolation	at	various	 times	during	 their	stay	and	 freely	ambulant	on	 the	
wards	 during	 others.	 The	 data	 was	 subsequently	 visualized	 in	 KNIME	 3.3.2	
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FoodChain-Lab	 (Weiser	 et	 al.,	 2016).	 SQL	 database	 analysis	 and	 KNIME	 3.3.2	







There	 is	 a	 broad	 spectrum	 of	 pathology	 and	 severity	 that	 is	 associated	 with	
HPIV3	infection	(Herzog	et	al.,	1989;	Cilla	et	al.,	2008;	Park	et	al.,	2009;	Maeng	et	
al.,	2012;	Shah	et	al.,	2016),	from	coryzal	symptoms	in	otherwise	healthy	adults	
to	 bronchiolitis	 to	 lower	 respiratory	 tract	 infection	 (LRTI)	 in	 the	 paediatric	
population	 and	 life-threatening	 pneumonia	 	 in	 the	 immunocompromised.	 The	
above	notwithstanding,	most	studies	have	used	well	established	and	significantly	




HPIV3	 positive	 clinical	 samples	 were	 collected	 from	 the	 PHE	 diagnostic	
laboratory,	 Cambridge	 University	 Hospitals	 and	 stocks	 of	 minimally	 passaged	
clinical	strains	of	diverse	provenance	were	grown	in	tissue	culture.		To	this	end	
protocols	for	viral	growth	and	detection	were	optimized,	using	diagnostic	assays	
as	 starting	 points.	 Additionally,	 an	 immunofocal	 plaque	 assay	 was	 set	 up	 and	
different	overlays,	antibodies	and	stains	were	trialled	in	order	to	create	a	robust	
infectivity-based	assay	to	assess	HPIV3	plaque	phenotype.	Finally,	twelve	sets	of	
primers	were	 optimized	 and	 an	NGS	pipeline	was	 validated	 for	whole	 genome	
amplification	of	HPIV3.	
The	genotypes	and	phenotypes	of	22	clinical	strains	of	diverse	dates	of	collection	












The	 number	 of	 samples	 that	 tested	 positive	 for	HPIV3	was	 extracted	 from	 the	





The	number	of	 samples	 that	 tested	positive	 for	HPIV3	on	 the	 respiratory	virus	








Figure	 3-1	 Total	 samples	 tested	 positive	 for	 HPIV3	 by	 PHE	 diagnostic	
laboratory,	 Cambridge	 University	 Hospitals	 (CUH),	 during	 2011-2017.	




originating	 from	 CUH	 and	 from	 the	 general	 geographical	 area	 covered	 by	 the	

















A. Total number of HPIV3 paediatric and adult cases diagnosed by PHE 















C. HPIV3 cases on the paediatric oncology ward between 01/11 and 08/17












B. HPIV3 cases within Cambridge University Hospitals (CUH), compared to total 
number of cases diagnosed (panel A) between 01/11 and 08/17







The	diagnostic	 criteria	 for	HPIV	 in	 tissue	 culture,	 as	 stated	 in	 the	original	SOP,	
suggested	 that	 the	 presence	 of	 syncytia	 should	 be	 used	 as	 a	marker	 for	 HPIV	
infection	 (Vainionpää	and	Hyypiä,	1994).	Therefore	 the	 cytopathic	effect	 (CPE)	
demonstrated	 by	 both	 the	 MK9	 lab-adapted	 strain	 and	 a	 number	 of	 clinical	




a	 tissue	 culture	 adapted	 strain	 of	 HPIV3	 (Henrickson,	 2003).	 However	 clinical	
isolates	 lack	 this	 adaptation	 and	 may	 also	 contain	 other	 pathogens	 and	
contaminants	 that	 could	 affect	 the	 cell	monolayer.	 For	 instance,	 clinical	 isolate	
















A	 PCR	 amplicon	 from	 an	 HPIV3	 positive	 sample	 obtained	 from	 the	 PHE	
Microbiology	and	Virology	diagnostic	laboratory	was	cloned	by	TA	cloning	into	a	
plasmid	and	subsequently	used	to	establish	a	standard	curve	using	serial	10	fold	
dilutions	 of	 the	 plasmid.	 The	 full	 protocol	 and	 sequences	 are	 detailed	 in	
Materials	and	Methods.		Sequences	for	primers	and	the	taqman	probe,	as	well	as	
the	 cycling	 conditions	 were	 taken	 from	 the	 diagnostic	 typing	 SOP	 for	 human	
parainfluenza	 viruses	 (see	 Materials	 and	 Methods	 for	 details).	 As	 part	 of	 the	
optimization	 of	 the	 protocol	 two	 conditions	 were	 trialed	 with	 primer	
A. Uninfected monolayer B. MK9
C. Clinical isolate 581 D. Clinical isolate 572
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concentrations	 of	 100μM	 and	 500μM	 respectively,	 the	 linear	 regressions	were	
calculated	using	GraphPad	and	can	be	 seen	 in	Figure	3-3.	As	 the	RT	qPCR	was	







Figure	 3-3	 PCR	 optimization.	RT	qPCR	standards	were	 cloned	by	TA	cloning	
into	a	plasmid	from	a	positive	control	obtained	from	the	PHE	Microbiology	and	











Cell	 monolayers	 were	 prepared	 and	 inoculated	 as	 described	 in	 Materials	 and	
Methods.	After	 incubation	the	 inoculum	was	removed,	cells	were	washed	twice	




















in	PBS	and	covered	with	overlay.	2	overlays	were	 trialed:	Avicel	 (2.5%	 in	H20)	










using	 two	 different	 overlays	 Avicel	 (A)	 and	 agarose	 (B)	 using	 the	 HPIV3	
reference	 strain	 MK9.	 Cell	 monolayers	 were	 prepared	 and	 inoculated	 as	
described	 in	 Materials	 and	 Methods.	 Plaque	 assays	 were	 visualized	 using	 the	
immunostaining	 method	 as	 follows:	 cells	 were	 first	 incubated	 with	 primary	
antibody	(ThermoFisher	scientific,	goat,	anti	HPIV	3	and	2)	diluted	1:1000	in	PBS	
with	5%	serum,	then	washed	three	times	in	PBS	and	incubated	with	secondary	









seen	 in	 Figure	 3-6.	 The	 contrast	 obtained	with	 TrueBlue	 Peroxidase	 Substrate	




However	 the	 immunostaining	method	was	 reliant	on	a	 commercially	produced	
antibody	of	considerable	cost	that	was	raised	against	an	unspecified	target.	Given	
the	potential	 issues	with	 the	 impact	of	sequence	variation	on	the	ability	of	 this	
antibody	 to	detect	 clinical	 isolates	we	developed	our	own	anti-HPIV3	antibody	
against	 highly	 conserved	 regions	 of	 the	 F	 protein.	 To	 this	 end	 a	 consensus	
sequence	of	the	F	proteins	of	HPIV3	was	extracted	using	UGENE	(Okonechnikov,	
Golosova	 and	 Fursov,	 2012)	 from	 an	 alignment	 of	 full	 protein	 sequences	
extracted	 from	 the	 Genbank	 (AAB21447.1,	 ABZ85672.1,	 BAA00012.1,	
NP_067151.1,	BAS30451.1,	ACJ70089.1,	BAS30450.1)	Translation	of	 the	F	gene	
of	 the	consensus	sequence	was	also	used	as	an	HPIV3	reference	 (see	Materials	





protein	 alignments	 were	 submitted	 to	 a	 commercial	 supplier	 and	 3	 well-
conserved	epitopes	in	the	fusion	protein	of	HPIV3	were	identified.	The	accession	
numbers	of	sequences	used	are	listed	and	the	alignments	for	the	three	epitopes	





each	 case	 produced	 high	 contrast	 plaques	 using	 the	 MK9	 laboratory	 strain	 of	













final	 optimised	 immunostaining	 protocol,	 the	 results	 of	 which	 can	 be	 seen	 in	
Figure	3-6C.		
	




subsequently	 fixed	 and	 immunostained.	 Plaques	 were	 incubated	 with	 either	 a	
commercial	anti-HPIV3	antibody	 (A	and	B)	or	a	cocktail	of	3	 rabbit	anti-HPIV3	
fusion	protein	antibodies	(C)	as	the	primary	antibody.	As	the	in-house	antibody	
was	 not	 HRP	 conjugates,	 the	 plates	 in	 (C)	 were	 additionally	 incubated	 with	 a	






Interferon	 deficient	 cell	 lines	 have	 been	 generated	 previously	 in	 order	 to	
increase	viral	titres	obtained	in	bovine,	porcine	and	human	cells	of	recombinant	
RSV,	 Bunyamwera	 and	 simian	 virus	 5	 (Young	 et	 al.,	 2003),	 porcine	 sapovirus	




interfere	with	 the	 interferon	pathway,	which	 forms	part	 of	 the	 innate	 immune	
response	of	the	cell	to	infection.	 	BVDV	NPro	polypeptide	targets	the	interferon	
regulatory	 factor	 3	 (IRF3),	 a	 transcription	 factor	 essential	 for	 interferon	







protein	 of	 parainfluenza	 virus	 5	 (PIV5)	 blocks	 interferon	 signalling	 in	 human	




the	 IFN	 response	 of	 the	wild	 type	 cell	 line.	 To	 this	 effect	 PLC/PRF5	 cells	were	
transduced	 with	 lentiviral	 vectors	 expressing	 BVDV	 NPro,	 PIV5	 protein	 or	 an	
empty	 vector.	 Subsequently	 the	 cell	 lines	 were	 evaluated	 by	 measuring	 the	
HPIV3	viral	yield	by	qPCR	and	plaque	titration,	as	well	as	evaluating	the	plaque	
phenotype	of	strain	MK9.	No	differences	in	viral	yield	by	qPCR	(Figure	3-7A)	or	
plaque	 titration	 	 (approximately	 4.7x105	 PFU/ml,	 data	 not	 shown)	 or	 plaque	





Figure	 3-7	 HPIV3	 laboratory	 strain	 infection	 of	 the	 wild	 type	 cell	 line	
PLC/PRF5	and	the	cell	lines	transduced	with	empty	vector,	BVDV,	NPro	and	
PIV5V.	Cell	monolayers	were	prepared	and	virus	was	inoculated	as	described	in	
Materials	 and	 Methods.	 A	 supernatant	 sample	 of	 50µl	 was	 taken	 on	 day	 four			
(D4)	of	incubation	and	viral	copy	number	was	determined	by	one	step	RT-qPCR	
as	 described	 in	 Materials	 and	 Methods.	 Each	 point	 represents	 3	 biological	
repeats	 +/-SEM	 (A).	 Plaque	 phenotype	 (B)	 was	 observed	 at	 7	 days	 post	
inoculation;	 infection	 was	 carried	 out	 as	 described	 in	 Materials	 and	 Methods	
with	 agarose	 overlay	 and	 immunofocal	 staining	 with	 a	 commercial	 HPIV3	
primary	 antibody	 followed	 by	 DAB	 staining,	 as	 described	 in	 Section	 3.3.1.3	
Immunofocal	plaque	assay.	
As	no	dramatic	changes	 in	viral	 titre	 in	the	transformed	cells	was	detected,	 the	
ability	of	the	cells	to	respond	to	a	mimic	of	viral	RNA	was	observed.		Poly	I:C	is	a	
synthetic	 analog	of	double	 stranded	RNA	 (ds	RNA).	Both	natural	 and	 synthetic	
dsRNAs	are	known	to	induce	type	I	IFNs,	especially	IFNβ.	Poly	I:C	is	recognized	


















































interferon	 regulatory	 factor	 3	 (IRF3)	 and	 NF-κB	 protein	 through	 the	 adapter	







in	 turn	 activates	 TIR-domain-containing	 adapter-inducing	 interferon-β	 (TRIF),	
which	 in	 turn	 stimulates	 the	 transcription	 factor	 interferon	 regulatory	 factor	3	
(IRF3)	and	the	NF-B	protein.	These	two	pathways	stimulate	the	transcription	
of	the	IFNβ	genes,	which	eventually	leads	to	the	release	of	the	interferon	by	the	
















were	 cultured	 to	 80-90%	 confluence,	 transfected	 with	 10µg	 of	 poly	 I:C	 by	
Lipofectamine	 2000	 transfection	 according	 to	 the	 manufacturer’s	 instructions	
and	 incubated	 for	6	hours.	 	Total	RNA	was	extracted	as	described	 in	Materials	
and	Methods	and	50	ng	was	subsequently	reverse	 transcribed.	Primers	against	
interferon	 β	 (IGUC0772	 CAGAAGGAGGACGCCGCATTGAC	 and	 IGUC0773	
CCAGGCACAGTGACTGTACTCC)	 and	 β	 actin	 (control) (IGUC0784	
TTCTACAATGAGCTGCGTGTG	 and	 IGUC0785	GGGGTGTTGAAGGTCTCAAA)	were	
used.	The	results	were	calculated	using	the	ΛΛ	Ct	method	(Applied	Biosystems)	
and	 the	 fold	 change	 in	 gene	 expression	described	 relative	 to	 the	mock	 treated	
control.	
	
The	A549	cell	 line,	used	here	as	a	positive	control,	 showed	a	 robust	 interferon	
response,	which	demonstrates	 that	 the	 stimulation	was	performed	 adequately.	
However	neither	the	wild	type	cell	line	nor	the	empty	vector	transduced	cell	line	
showed	 any	 significant	 signs	 of	 interferon	 β	 gene	 induction	 following	 poly	 I:C	
transfection.	 This	 implies	 that	 the	 interferon	 response	 may	 be	 already	
attenuated	 in	 the	 parental	 cell	 line.	 	 A	 subsequent	 detailed	 literature	 search	
indicated	 that	 the	PLC/PRF5	 is	 the	Alexander	hepatoma	cell	 line,	 that	 contains	
the	 integrated	DNA	of	hepatitis	B	 (HBV)	which	 is	 known	 to	 subvert	 the	 innate	
immune	 system	 (Daemer	 et	 al.,	 1980)	 possibly	 due	 to	 the	 homology	 between	
hepatitis	B	virus	DNA	and	sequences	regulating	the	interferon	pathway	(Onji	et	
















































human	 hepatocytes	 (Suslov	 et	 al.,	 2018),	 has	 recently	 been	 published,	 it	 is	 at	
odds	with	other	recent	work	(Lebossé	et	al.,	2017)	that	supports	the	mechanism	
described	 above.	 Overall,	 it	 seems	 that	 interaction	 between	 chronic	 HBV	
infection	and	the	interferon	pathway	is	yet	to	be	fully	elucidated,	but	it	is		likely	





PHL,	 Standard	 Operating	 Procedure-Virus	 Culture	 Section	 Methods	 Reference	
No:	 VIRSOP/005c,	 issued	 20/01/12	 by	 GM	 Sutehall)	 used	 in	 PHE	 laboratory	
Addenbrooke’s	Cambridge	was	used	as	a	 starting	point	 for	 the	development	of	
the	 growth	 and	 infection	 protocol	 for	 HPIV3	 clinical	 samples.	 An	 overnight	
incubation	with	the	virus	inoculum	in	an	unspecified	volume	on	a	roller	and	then	
a	 subsequent	 incubation	 for	 up	 to	 two	 weeks	 at	 33°C,	 was	 specified	 for	
diagnostic	 purposes.	 As	 this	 was	 considered	 to	 be	 both	 technically	 and	
temporally	 impractical	 three	 different	 conditions	 were	 trialed	 using	 different	
volumes	 of	 inoculum	 and	 incubation	 times	 as	 detailed	 in	 Figure	 3-10B.	 Three	
infection	 protocols	were	 established	 taking	 into	 account	 the	 need	 to	 allow	 for	
maximum	virus	binding	and	replication	while	at	 the	same	 time	minimizing	 the	
likelihood	of	contamination,	which	was	particularly	 important	given	the	nature	
of	 the	 inoculum.	 Strain	 MK9	 and	 clinical	 isolate	 600	 were	 chosen	 as	
representative	 samples	 and	 growth	 was	 examined	 using	 the	 three	 conditions	
over	a	period	of	5	days.	Samples	were	removed	from	the	culture	every	24	hours	
and	 the	 levels	of	viral	genome	present	 in	 the	sample	were	determined	by	one-
step	RT-qPCR	as	described	above.	The	results	obtained	are	illustrated	in	Figure	
3-10.	 As	 can	 be	 seen,	 all	 three	 protocols	 demonstrated	 robust	 levels	 of	 virus	
replication,	with	 peak	 viral	 titres	 obtained	 by	 day	 4.	 Based	 on	 these	 results,	 it	






(A)	 and	 clinical	 isolate	 600	 (B)	 were	 inoculated	 or	 mock	 inoculated	 and	
incubated	 according	 to	 the	 three	 infection	 protocols	 trialed	 (C).	 Supernatant	
samples	 of	 50	 µl	 were	 collected	 every	 day	 from	 day	 one	 to	 day	 five.	 Day	 0	
samples	(protocols	I	and	III)	were	collected	immediately	after	the	inoculum	was	
removed,	the	cells	were	washed	and	covered	with	maintenance	medium.	Day	1	




amplicon	 as	 described	 in	 Materials	 and	 Methods.	 Each	 point	 represents	 3	
biological	repeats	+/-	SEM.	













































A. HPIV3 lab-adapted strain (MK9)
B. Clinical isolate 600
C. Infection protocols specifications
Protocol	I Protocol	II Protocol	III
Clinical	sample	(μl) 20μl 20μl 20μl
Maintenance	
medium	(μl) 200μl 200μl 800μl
On rocker at 37°C
for	24	hours

















Figure	 3-11	 Summary	 of	 growth	 success	 rate	 in	 cell	 culture.	 395	 samples	
were	 originally	 inoculated	 onto	 PLC/PRF5	 cells,	 as	 described	 in	 the	 text.	 The	
growth	was	carried	out	in	two	separate	cycles:	over	3	passages	(P1,	P2	and	P3)	
for	cycle	1	and	2	passages	for	cycle	2.	The	number	of	samples	(n)	used	in	each	
step	 is	 indicated,	 as	 well	 as	 the	 number	 of	 samples	 that	 were	 classed	 as	
successful/positive	 (+)	 and	 rejected	 (-)	 at	 each	 stage.	 The	 detailed	 protocol	
criteria	 involved	 in	each	cycle	as	well	 the	outcomes	are	 summarized	 in	Figure	
3-12.	
























The	 results	 according	 to	 protocols	 specific	 to	 each	 cycle	 are	 shown	 in	 Figure	
3-12.	 Only	 43/395	 samples	 were	 successfully	 grown	 at	 passage	 1	 as	 seen	 in	
Figure	3-12.	Two	further	samples	were	excluded	due	to	co-infection	with	other	








and	 anti-fungal	 concentrations	 in	 maintenance	 media	 (see	 Materials	 and	







Figure	 3-12	Growth	 of	HPIV3	 clinical	 strains	 in	 cell	 culture	 (according	 to	




copies/ml	 “+”),	 intermediate	 (5-103	 genome	 copies/ml	 “+/-”)	 and	negative	 (<5	
genome	copies/ml	“-”).	12%	of	samples	at	P1	of	cycle	1	were	lost	to	bacterial	or	
fungal	 contamination	 (C).	 Sample	 selection	 criteria	 for	 subsequent	passage	 are	
indicated	by	arrow	colour:	“-”	grey;	“+/-”	green;	“C”	blue;	black	-	all.	Additionally	
11	negative	samples	of	 cycle	1	P1	were	randomly	selected	 for	 further	passage.	
Cycle	2	consisted	of	2	passages	and	the	outcome	was	characterized	as	for	cycle	1,	
but	 only	 as	 positive	 (>103	 genome	 copies/ml	 “+”)	 or	 negative	 (<103	 genome	
copies/ml	“-”).	As	for	cycle	1,	sample	selection	criteria	for	subsequent	passage	is	
indicated	 by	 arrow	 colour.	 Adjusted	 anti-microbial	 concentrations	 ensured	 no	
contamination	was	seen	after	P1	of	cycle	1.	All	samples	that	were	contaminated	
or	that	failed	to	grow	after	P3	during	cycle	1	or	P2	during	cycle	2	were	discarded	
(X).	 The	 overall	 outcome	 of	 all	 the	 samples	 processed	 during	 both	 cycles	 in	
shown	in	Summary.		(n	=	number	of	samples)	
		
P2 (n = 52)






P2 (n = 11)
P3 (n = 40)
P2 (n = 189)
P3 (n = 5)
Cycle 1
X
"+"  >103 
"+/-"  > 5 and < 103 
"-"  < 5  
"C" fungal or bacterial contamination
Cycle 1
"-"  < 103 
Cycle 2
X*
* 11 randomly selected "-" samples
Legend - increase in genome copies/ml
Total = 395
10.89%  "+" P1
8.61%  "+" P2











successfully	 grown	 and	 none	were	 found	 not	 to	 be	 co-infected	with	 any	 other	
respiratory	 viruses.	 3	 diverse	 strains	were	 selected	 to	 undergo	whole	 genome	
sequencing	(WGS)	and	2	(outbreak	strain	8	and	background	strain	D)	were	used	






were	 identified	 as	 suitable	 for	 amplification	 of	 the	 entire	 genome	 of	 HPIV3	 as	
described	in	Materials	and	Methods.	 	 In	the	majority	of	cases	it	was	possible	to	
generate	overlapping	amplicons	 in	such	a	way	 that	all	 sequenced	regions	were	
covered	 outside	 of	 primer	 binding	 sites,	 however	 further	 optimization	 was	
required	for	four	primer	pairs.	The	details	of	the	original	primer	sets	as	well	as	
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Amplicon Primer F Primer R Region (bp) 
1 KK-XF KK-XR1 1-190
2 KK-XF KK-XR2 1-520
3 KK-1F KK-1R 166-2127
4 KK-NR1F KK-NR1R 1569-2646
5 KK-NR2F KK-NR2R 2610-4212
6 KK-3F KK-3R 3860-5659
7 KK-4F KK-4R 5527-7587
8 KK-5F KK-5R 7500-9398
9 KK-6F KK-6R 9046-10956
10 KK-7F KK-7R 10929-12433
11 KK-8F KK-8R 12111-14064
12 KK-9F KK-9R 13164-15067
13 KK-10F PIV-5R 13975-15462
Original primers pairs
Amplicon Primer F Primer R Region (bp)
4a KK-NR1F NR1Ra 1569-2256
4b KK-NR1F NR1Rb 1569-2356
5a NR2Fa KK-NR2R 2046-4212
5b NR2Fb KK-NR2R 2148-4212
9a KK-6F 6Ra 9046-11184
9b KK-6F 6Rb 9046-10832
10a 7Fa KK-7R 10757-12433
10b 7Fb KK-7R 10728-12433
Trialled primers pairs
4	 4a	 4b	 5	 5a	 5b	 9	 9a	 9b	 10	 10a	 10b	














Figure	 3-13	 Primer	 optimization.	 13	 primer	 sets	 identified	 in	 the	
pilot	study	(A)	were	used	for	the	amplification	of	the	laboratory	strain	





Their	 respective	 locations	 are	 shown	 in	 panel	 C	 in	 green.	 	 The	 new	
primer	 pairs	 (C)	 and	 their	 original	 counterparts	 were	 then	 used	 to	
amplify	 the	 relevant	part	 of	 the	MK9	 laboratory	 strain	 genome	using	
the	 protocol	 described	 in	 Materials	 and	 Methods.	 The	 gel	 with	 the	





Two	 clinical	 isolates:	 99	 and	 153	 were	 then	 amplified	 using	 the	 primer	 sets	
shown	 in	 Figure	 3-13A	with	 optimized	primer	 pairs	 5b	 and	9a	 (Figure	 3-13B)	
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Figure	 3-14	Whole	 genome	 amplification	 of	 two	 clinical	 isolates	
using	the	optimised	primer	set.	Clinical	isolates	99	(panel	A)	and	153	
(panel	B)	were	amplified	using	primer	pairs	detailed	 in	Figure	 3-13A	
with	 primer	 sets	 5	 and	 9	 replaced	with	 5b	 and	 9a	Figure	 3-13C.	 No	
amplicon	for	primer	set	1	was	observed	for	either	strain	(not	shown	in	
figure	 for	 ease	 of	 visualization).	 As	 this	 region	 was	 also	 covered	 by	






clinical	 samples,	 the	 results	 were	 inconsistent	 and	 never	 yielded	 the	 full	
amplicon	 set	 required	 for	 whole	 genome	 sequencing.	 Additionally	 as	 well	












and	Methods)	 was	 validated	 as	 follows.	 The	 laboratory	 strain	MK9	 and	 strain	
153	were	 first	 sequenced	by	 Sanger	 sequencing,	 as	 described	 in	Materials	 and	
Methods,	as	well	as	the	previously	published	de	novo	Ebola	pipeline	using	QUASR	
for	 quality	 control	 and	 Spades	 3.5	 for	 assembly	 (Arias	 et	 al.,	 2016)	 and	 the	
optimized	 NGS	 protocol,	 described	 followed	 by	 the	 bioinformatics	 pipeline	
Original 
amplicon number
New  amplicon 
number Primer F Primer R Region (bp)
2 1 KK-XF KK-XR2 1-520
3 2 KK-1F KK-1R 166-2127
4 3 KK-NR1F KK-NR1R 1569-2646
5a 4 NR2Fa KK-NR2R 2046-4212
6 5 KK-3F KK-3R 3860-5659
7 6 KK-4F KK-4R 5527-7587
8 7 KK-5F KK-5R 7500-9398
9a 8 KK-6F 6Ra 9046-11184
10 9 KK-7F KK-7R 10929-12433
11 10 KK-8F KK-8R 12111-14064
12 11 KK-9F KK-9R 13164-15067
13 12 KK-10F PIV-5R 13975-15462
Final optimised set of primers
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established	 here.	 In	 each	 case	 the	 final	 sequences	 were	 identical	 to	 those	












Figure	 3-15	 Depth	 of	 coverage	 achieved	 for	 laboratory	 strain	 (A),	 strain	
153	 (B),	 FastQC	 (Andrews,	 2018)	 statistics	 for	 both	 sequences	 (D)	 and	
average	depth	of	coverage	for	all	sequences	(C).	Consistent	coverage	of	above	
1000	 was	 achieved	 over	 the	 full	 length	 of	 the	 genome	 of	 both	 sequences	
excluding	 the	 very	 5′	and	 3′	prime	 ends.	 This	 is	 consistent	 with	 the	 average	
depth	of	 coverage	achieved	 for	all	 sequences	 (black)	shown	 in	 (D)	with	95%CI	
(red).	 The	 length	 of	 the	 final	 sequence	 was	 15409	 base	 pairs,	 as	 the	 forward	
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Mean depth of coverage of all strains (n=23)C
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With	 a	 robust	 amplification	 protocol	 and	 sequencing	 pipeline	 established,	 23	
clinical	 strains	of	diverse	provenance,	 that	were	originally	grown	at	passage	1,	








history;	ALL	=	 acute	 lymphocytic	 leukaemia;	VUD	=	volunteer	unrelated	donor	
(transplant);	CF	=	cystic	fibrosis;	PE	=	pulmonary	embolism.	
The	majority	 of	 the	 samples	 (17/23)	were	 taken	 from	 inpatients,	 reflecting	 an	
unavoidable	sampling	bias	towards	cases	requiring	admission	and	potential	co-
morbidities.	 	 Although	 the	 majority	 of	 the	 cases	 originated	 from	 Cambridge	
Lab	ID Date 
collected
Source Sex Age Originating	hospital
In/out	
patient PMH
14 Nov-14 URT	swab F 1	year Basildon	 in unknown
16 May-14 URT	swab M 50	years CUH in post	allograft
21 Jun-14 URT	swab F 54	years no	data unknown unknown
30 Jul-14 URT	swab M 60	years CUH out post	VUD
53 Apr-14 URT	swab F 58	years CUH in asthma
60 Jun-11 URT	swab F 56	years CUH in unknown	
65 Jun-11 URT	swab F 54	years CUH in unknown
82 Jul-11 URT	swab M 2	months Harlow	 in unknown
112 Jun-12 URT	swab M 84	years CUH out on	alemtuzumab
113 Jul-12 URT	swab M 42	years CUH in unknown
121 Nov-12 URT	swab F 61	years CUH in post	allograft
122 Dec-12 NPA M 9	months Hinchingbrooke in unknown
128 Feb-13 NPA F 9	months CUH in unknown
129 Feb-13 TA F 4	years Frimley	Park	 in/ICU unknown
153 Apr-13 NPA F 12	years Frimley	Park in ALL	relapse
180 May-13 NPA F 3	months CUH out CF
362 Mar-15 URT	swab F 80	years Nursing	home out unknown	
371 Apr-15 URT	swab F 89	years Nursing	home out unknown	
390 Feb-14 URT	swab F 1	year CUH in unknown	
395 Apr-15 URT	swab M 70	years	 CUH in unknown	
8 Jul-17 URT	swab M 1	year CUH in ALL
D Jun-17 URT	swab F 20	years CUH in 1°	immunodeficiency
I Jun-17 URT	swab F 28	years CUH in PE
Sample Patient
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University	 Hospitals	 (16/23),	 the	 rest	were	 from	 a	more	 diverse	 geographical	
distribution	 reflecting	 the	 area	 covered	by	PHE	 laboratory	Addenbrooke’s	 (see	
Materials	 and	Methods).	 Relevant	 past	medical	 history	 (PMH)	 is	 shown	where	
available	 (10/23)	 and	 in	 most	 cases	 includes	 patients	 with	 haematological	
oncology	 conditions	 such	 as	 relapsed	 acute	 lymphocytic	 leukaemia	 (ALL),	
immunosuppressive	 chemotherapy	 treatment	 (alemtuzumab)	 and	 post	 bone	
marrow	 transplant	 including	 allograft	 and	 volunteer	 unrelated	 donor	 (VUD).		
This	reflects	the	immunosuppressed	population	where	HPIV3	is	known	to	have	
the	highest	 impact	 (Nichols,	2001;	 Shah	et	al.,	 2016).	 	Two	chronic	 respiratory	
conditions	 have	 also	 been	 identified:	 cystic	 fibrosis	 (CF)	 and	 asthma.		
Parainfluenza	 viruses	 have	 known	 to	 contribute	 to	 infective	 exacerbations	 of	






as	 laboratory	 strain	MK9	were	 sequenced.	A	maximum	 likelihood	phylogenetic	
tree	was	constructed	using	all	the	clinical	sequences	as	well	as	laboratory	strains	
MK9	 sequenced	 here	 and	 strain	 JS	 (accession	 number	 Z11575).	 Strain	 JS	 is	 a	
well-known	 laboratory	 reference	 strain	 that	 has	 been	 used	 extensively	 for	
vaccine	 research	 for	 HPIV3	 (see	 Introduction).	 An	 attempt	 to	 include	 the	
Washington	 strain	 (accession	 number	 47885)	was	 also	made.	 However	 it	 was	
found	 to	 be	 identical	 to	 strain	MK9	 and	 therefore	was	 not	 included	 in	 further	
analysis.	Figure	3-16	shows	the	genotypic	diversity	exhibited	by	clinical	strains.	
It	 shows	 that	 laboratory	 adapted	 strains	 form	 a	 separate	 and	 clearly	 distinct	
cluster	from	the	clinical	strains.			
This	is	consistent	with	that	has	previously	been	described	in	literature	(Palmer	
et	al.,	2012;	Palermo	et	al.,	2016).	However	 there	 is	 currently	 little	data	on	 the	
specific	 mutations	 or	 regions	 of	 the	 genome	 that	 may	 be	 involved	 in	 culture	
adaptation.	Most	of	the	research	to	date	has	concentrated	on	HN	and	F	parts	of	
genome	 as	 it	 has	 been	 observed	 that	 clinically	 adapted	 strains	 have	 fusogenic	
	 86	
phenotypes	(Henrickson,	2003;	Moscona,	2005;	Lingemann	et	al.,	2015).	In	order	
to	 clarify	 this,	 an	 analysis	 of	 the	 differences	 between	 sequences	 of	 the	 clinical	
strains	 and	 the	 consensus	 sequence	 of	 both	 JS	 and	 MK9	 was	 conducted.	 The	
results	 are	 shown	 in	 Figure	 3-17.	 	 Although	 clear	 peaks	 around	 the	 F	 coding	




MK9	 and	 JS	 of	 HPIV3	 by	 Maximum	 Likelihood	 method.	 The	 evolutionary	
history	 was	 inferred	 by	 using	 the	 Maximum	 Likelihood	 method	 based	 on	 the	
General	 Time	 Reversible	model	 +	 G	 +	 I	 (see	Materials	 and	Methods)	 (Nei	 and	
Kumar,	2000)	and	1000	bootstrap	repetitions.	The	 tree	 is	drawn	 to	scale,	with	
branch	 lengths	measured	 in	 the	 number	 of	 substitutions	 per	 site.	 The	 analysis	
involved	 25	 nucleotide	 sequences.	 Codon	 positions	 included	 were	
1st+2nd+3rd+Noncoding.	Branches	are	coloured	by	their	bootstrap	values	as	per	
































Figure	 3-17	 Differences	 between	 clinical	 HPIV3	 strains	 and	 laboratory	
adapted	 JS	 and	 MK9	 reference	 strains	 The	 differences	 between	 23	 clinical	
strains	as	detailed	in	Table	3-2	and	the	consensus	of	laboratory	adapted	strains	
JS	and	MK9	are	shown.	 In	panel	A	 the	 location	of	 the	variants	along	 the	HPIV3	
genome	 (x	 axis)	 is	 shown	 against	 the	 percentage	 of	 the	 strains	 that	 contain	 a	
variant	at	 this	 location	 (y	axis).	Panel	B	shows	 the	histogram	of	 the	number	of	
variants	 (x	 axis)	 that	 are	 shared	 by	 a	 specific	 number	 of	 strains	 (y	 axis).	 	 The	
relative	locations	of	variants	seen	in	all	the	23	strains	(165	variants)	is	shown	in	
panel	C	as	a	histogram	illustrating	the	relative	frequency	(x	axis)	at	which	these	
strains	occur	at	 a	 specific	 locations	along	 the	HPIV3	genome	 (y	axis)	 (width	of	
bin	 =	 300bp).	 Genome	 differences	 were	 analysed	 using	 UGENE.	 All	 other	
calculations	and	analyses	were	carried	out	in	GraphPad	6.	
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As	 discussed	 previously	 (see	 Introduction)	 there	 is	 evidence	 that	 connects	
variants	in	the	F	and	HN	part	of	the	HPIV3	genome	to	the	fusogenicity	of	strains	
and	hence	 to	plaque	phenotype	 in	 immortalised	 cell	 culture.	Therefore,	 having	
established	 the	 genotypic	 diversity	 of	 clinical	 strains	 as	 well	 as	 their	
considerable	 differences	 from	 the	 laboratory	 adapted	 strains	 MK9	 and	 JS,	 an	





Clinical	 strains	were	 observed	 to	 exhibit	 considerable	 diversity	 in	 plaque	 size,	





Figure	 3-18	 Diverse	 plaque	 phenotypes	 of	 clinical	 strains	 and	 reference	
strain	 MK9	 Clinical	 strains	 and	 strain	 MK9	 were	 inoculated,	 incubated	 and	








It	 could	 be	 logically	 hypothesized	 that	 strains	 exhibiting	 smaller	 plaque	
phenotypes	 would	 be	 genetically	 less	 similar	 to	 strain	 MK9	 than	 strains	






small,	 medium	 and	 large	 plaque	 phenotype	 according	 to	 plaque	 area	 (Figure	
3-18).	Consequently,	in	order	to	identify	any	significant	regions	related	to	plaque	
size	 phenotype,	 the	 sequences	 of	 these	 were	 grouped	 together	 and	 then	 each	
group	was	compared	to	 the	sequence	of	strain	MK9	that	has	a	markedly	 larger	
plaque	size	than	any	of	the	clinical	strains.		
The	 differences	 between	 each	 group	 and	 the	 reference	 strain	 were	 then	
extracted	 using	 UGENE	 (Okonechnikov,	 Golosova	 and	 Fursov,	 2012)	 and	 the	
relative	 frequency	 of	 variants	 that	 were	 seen	 in	 all	 the	 strains	 in	 a	 particular	
group	were	 plotted	 along	 the	 distance	 along	 the	HPIV3	 genome	 (Figure	 3-19).		
Similarly	 to	 Figure	 3-17,	 a	 peak	 in	 variability	 was	 observed	 at	 the	 intergenic	
region	between	M	and	F	coding	regions	for	all	plaque	phenotypes.	However,	as	







plaque	 phenotypes.	 The	 clinical	 strains	 of	 HPIV3	 were	 divided	 into	 three	
groups	according	to	plaque	phenotype	as	shown	in	Figure	3-18.	The	sequences	
of	 each	 group	 were	 aligned	 with	 strain	 MK9	 as	 reference	 and	 differences	
extracted	 using	 UGENE.	 Only	 variants	 that	 were	 present	 in	 all	 strains	 were	
selected.	The	relative	frequencies	(%)	at	which	variants	were	observed	along	the	
HPIV3	genome	are	shown	in	panel	A	(small	phenotype:	strains	8,	D,	128,	112,	14	
and	 16);	 B	 (medium	phenotype:	 strains	 180,	 362,	 153,	 129,	 113)	 and	 C	 (large	
phenotype:	strains	82	and	65).	X-axes	of	all	panels	are	aligned	to	the	schematic	
representation	 of	 the	 HPIV3	 genome.	 	 Bin	 widths	 are	 300bp.	 A	 red	 arrow	
indicates	a	location	at	the	end	of	F	part	of	the	genome	(bin	centred	on	6400bp)	
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However	 one	 must	 keep	 in	 mind	 that	 the	 numbers	 involved	 in	 the	 current	
project	 are	 small	 and	 strains	within	 the	 larger	 plaque	 phenotype	 (65	 and	 82)	
group	are	phylogenetically	closely	related.	Additionally	this	observation	may	be	
confounded	 by	 the	 fact	 that	 laboratory	 strain	 MK9	 is	 significantly	 culture	




phenotypic	 and	 genotypic	 characteristics	 with	 adaptation	 to	 immortalised	 cell	
culture	(Henrickson,	2003;	Palmer	et	al.,	2012;	Palermo	et	al.,	2016).	This	can	be	
a	confounding	factor	when	studying	phenotype	and	potentially	drug	sensitivity,	
as	 previously	 mentioned.	 More	 importantly,	 in	 the	 context	 of	 this	 project,	 the	
viral	 stock	 generated	 contained	 samples	 that	 were	 grown	 after	 1,2	 and	 3	
passages	 in	 tissue	 culture	 (Figure	 3-12)	 as	 whole	 genome	 sequences	 from	
original	clinical	samples	could	not	be	obtained.	Therefore	an	attempt	was	made	
to	examine	culture	adaptation	of	6	strains	grown	at	passage	1	in	PLC/PRF5	cells.	
The	 goal	 was	 to	 assess	 how	 plaque	 phenotype	 was	 affected	 by	 culture	
adaptation,	 as	 well	 as	 to	 determine	 whether	 samples	 grown	 at	 later	 passages	
could	be	used	for	further	work	on	clinical	strains.	To	this	end,	6	clinical	strains	
and	 the	 laboratory	 strain	MK9	were	 repeatedly	 passaged	 up	 to	 passage	 10	 as	
described	in	Materials	and	Methods.		
The	change	in	plaque	phenotype	with	passage	is	illustrated	in	Figure	3-20.	Panel	
A	 of	 Figure	 3-20	 clearly	 shows	 a	marked	 increase	 in	 plaque	 size	 with	 culture	
adaptation	in	all	clinical	strains.	A	number	of	new	smaller	plaque	variants,	were	
observed	 in	 strain	 MK9	 with	 passage.	 	 The	 distributions	 of	 plaque	 areas	 at	
passages	 1,	 5	 and	 10	 are	 illustrated	 in	 Figure	 3-20B.	 	 There	 is	 a	 clear	 shift	
towards	larger	plaque	variants	exhibited	by	all	clinical	strains,	although	smaller	
plaque	variants	still	appear	to	be	present.		
This	 is	reflected	 in	the	genome	analysis.	 	When	consensus	sequences	of	clinical	
strains	and	strain	MK9	at	passage	1,	5	and	10	were	compared,	they	were	found	
to	be	near	 identical.	All	differences	observed	were	a	 shift	 from	non-ambiguous	
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bases	 to	 ambiguous	 bases	 or	 vice	 versa,	meaning	 that	 no	 100%	 change	 in	 any	
variant	 was	 detected.	 This	 is	 reflected	 by	 the	 presence	 of	 diverse	 plaque	
phenotypes,	 as	 shown	 in	 Figure	 3-20B.	 	 The	 locations	 of	 variants	 and	 their	
frequency	 distribution	 along	 the	HPIV3	 genome	 are	 shown	 in	 Figure	 3-21.	 	 At	
passage	5,	a	peak	at	the	junction	between	and	M	and	F	genome	(bin	centered	on	
5200bp),	 showed	 the	 greatest	 increase	 (Figure	 3-21B).	 This	 is	 potentially	
consistent	with	 the	 abrogation	 of	 the	 aberrant	 read	 through	 between	M	 and	F	
parts	of	the	genome,	causing	increased	plaque	area	phenotype	(Lingemann	et	al.,	
2015)	 (see	 Introduction).	Unlike	analyses	above	 (Figure	3-17	and	Figure	3-19)	







Figure	 3-20	 Clinical	 strains	 develop	 a	 larger	 plaque	 phenotype	 with	
increased	 passage	 in	 immortalised	 cell	 culture.	 Clarified	 supernatant	 was	
collected	at	passage	1,	4	and	10	(P1,	P5	and	P10).	Cell	monolayers	were	prepared	




an	 increased	phenotype	with	 increasing	passage.	Panel	B	 illustrates	 the	plaque	
area	measured	in	mm2	with	the	median	+/-	interquartile	range	indicated	in	red.	


















Strain 1 5 10
MK9 3.94	+/-	0.09 1.23	+/-	0.08 1.22	+/-	0.11
180 0.56	+/-	0.02 1.57	+/-	0.07 1.49	+/-	0.07
153 0.84	+/-	0.03 0.84	+/-	0.06 1.10	+/-	0.08
129 0.91	+/-	0.04 1.11	+/-	0.06 1.19	+/-	0.11
128 0.07	+/-	0.01 0.20	+/-	0.02 0.73	+/-	0.05
113 0.92	+/-	0.05 0.94	+/-	0.06 1.44	+/-	0.10




Figure	 3-21	 Variants	 observed	 in	 HPIV3	 clinical	 strains	 and	 reference	
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observed	 in	 MK9	 fall	 within	 F	 or	 HN	 parts	 of	 the	 genome,	 although	 smaller	
plaque	phenotypes	are	seen	in	tissue	culture.	This	is	further	evidence	that	parts	





at	 position	 108	 has	 been	 associated	 with	 a	 smaller	 plaque	 phenotype	 and	 its	
replacement	by	lysine	(K)	to	culture	adaptation	in	a	previous	study	(Palermo	et	
al.,	 2016).	 	 This	 site	was	 considered	 to	 be	 of	 particular	 importance	 for	 plaque	
phenotype	as	it	is	located	within	the	cleavage	site	between	F1	and	F2	subunits	of	
the	 F	 protein	 (red	 arrow	 in	 Figure	 3-21).	 	 This	 is	 partially	 consistent	 with	
observations	in	this	project,	as	all	clinical	strains	with	smaller	plaque	phenotypes	
(Figure	3-18)	apart	from	strain	16	and	112	contain	an	E	variant	at	this	location.	
Strain	16	has	a	K,	whereas	 strain	112	has	an	arginine	 (R)	at	 location	108.	The	
latter	is	particularly	significant,	as	strain	112	has	been	seen	to	retain	this	variant	
at	least	until	passage	10,	but	nonetheless	has	demonstrated	a	significant	increase	
in	 plaque	 size	with	 passage	 (Figure	 3-20).	 It	 is	 also	 important	 to	 note	 that	 by	
passage	10,	 there	 is	an	 increase	 in	 frequency	 in	variants	within	 the	region	that	
encompasses	 the	 cleavage	 site	 between	 the	 F1	 and	 F2	 subunits	 (red	 arrow	 in	
Figure	 3-21),	 emphasizing	 that	 this	 region	 may	 be	 important	 for	 culture	
adaptation.	
Another	 significant	 variant	 correlated	 with	 culture	 adaptation	 has	 been	
attributed	 to	position	556	of	 the	HN	protein	of	HPIV3	 (Palermo	et	al.,	2016).	A	
change	from	an	asparagine	(N)	to	aspartic	acid	(D)	at	that	site	has	been	linked	to	
a	 decrease	 in	 neuraminidase	 activity	 and	 consequent	 increase	 in	 plaque	 size	
(Palermo	et	al.,	2016).		It	is	however	important	to	note	that	strain	JS	has	an	N	at	




they	 exhibit	 a	 reduction	 of	 the	 N	 variant	 by	 55%	 and	 71%	 respectively	 by	




(as	 it	 was	 previously	 cultured	 in	 BSC-1	 cells,	 https://www.phe-
culturecollections.org.uk)	and	would	be	shared	by	other	strains	adapting	to	the	
same	cell	line.	In	this	context,	a	notable	variant	was	observed	at	position	255	in	






genome	 have	 been	 identified	 above,	 it	 is	 beyond	 the	 scope	 of	 this	 project	 to	
determine	 the	 exact	 significance	 or	 impact	 made	 by	 each	 variant	 observed.		
Overall	 it	 can	 be	 concluded	 that	 there	 is	 a	 definite	 increase	 in	 variants	 with	
larger	plaque	phenotypes	exhibited	by	all	clinical	strains	with	increasing	culture	
adaptation.	 Additionally,	 adaption	 to	 this	 particular	 cell	 line	 was	 also	
demonstrated	 by	 reference	 strain	 MK9.	 A	 number	 of	 specific	 variants	 were	







clinical	 disease	 severity	 with	 plaque	 morphology	 in	 vitro.	 A	 distinct	 smaller	




than	 their	 larger	 plaque	 counterparts.	 In	 respiratory	 viruses,	 plaque	
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morphologies	 were	 linked	 to	 different	 strains	 of	 rhinoviruses	 (Jacobs	 et	 al.,	
2013)	 and	 different	 strains	 of	 RSV,	with	 the	more	 virulent	 strain	 A	 producing	
larger	plaques	 (Kim	et	al.,	 2015).	 	 It	would	 therefore	be	 logical	 to	 assume	 that	
there	may	be	a	correlation	between	HPIV3	phenotype	in	vitro	and	in	vivo.		To	this	
end,	the	diversity	of	HPIV3	clinical	strains	in	vitro	had	to	be	established.		
So	 far,	 most	 studies	 on	 HPIV3	 have	 been	 carried	 out	 on	 laboratory	 adapted	
strains.	 	 The	 small	 number	of	 studies	 that	 have	 looked	 at	 behaviour	 of	 clinical	
strains	of	HPIV3	have	concentrated	on	differences	between	a	limited	number	of	
closely	related	clinical	strains	and	a	reference	laboratory	adapted	strain	in	vitro	
and	 to	 an	 extent	 in	 vivo	 (Moscona,	 2005;	 Palmer	 et	 al.,	 2012,	 2014).	
Unfortunately,	differences	between	clinical	strains	themselves	have	hitherto	not	
been	explored.	Therefore	the	first	goal	of	 this	project	was	to	create	a	 library	of	
highly	 diverse	 clinical	 samples	 of	 HPIV3.	 To	 this	 end	 HPIV3	 positive	 clinical	
samples	 of	 diverse	 provenance	 were	 collected	 from	 the	 PHE	 laboratory,	
Cambridge.	The	number	of	cases	of	HPIV3	diagnosed	by	the	laboratory	over	time	
was	 consistent	 with	 published	 seasonal	 variation	 (Zhao	 et	 al.,	 2017).	 Samples	
collected	 contained	 a	 significant	 proportion	 of	 paediatric	 cases,	 which	 was	 in	
agreement	with	 previous	 assessments	 of	 HPIV3	 epidemiology	 in	 the	 literature	
(Henrickson,	2003;	Mao	et	al.,	2012;	F.	Wang	et	al.,	2015)	 (Figure	3-1).	Clinical	
samples	 selected	 for	 further	 study	 were	 also	 found	 to	 contain	 a	 significant	
proportion	 of	 immunocompromised	 cases,	 which	 also	 reflects	 the	 impact	 of	








studies	with	RSV	that	samples	 from	both	upper	and	 lower	airways	 in	the	same	
patient	yielded	the	same	RSV	strain	(Kim	et	al.,	2015).	This	means	that,	although	
the	 possibility	 that	 divergent	 HPIV3	 strains	 could	 be	 found	 exclusively	 in	 the	









severe	presentations	of	HPIV3.	 	This	 sampling	 issue,	however,	 is	not	unique	 to	
this	 project	 (Mao	 et	al.,	 2012;	 Košutić-Gulija	 et	al.,	 2017).	 In	 other	 respiratory	
studies,	 specifically	 those	 focusing	 on	 the	 pathogenesis	 of	 respiratory	 viruses,	
this	drawback	has	previously	been	addressed	by	blindly	sampling	patients	who	
were	hospitalised	for	reasons	other	than	respiratory	presentations,	for	instance	
day	 surgery	 cases	 (Gern	 et	 al.,	 2002).	 This	 approach,	 however	 would	 have	




Having	 obtained	 a	 representative	 cross-section	 of	 clinical	 samples,	 robust	
protocols	for	virus	growth	and	detection	were	established.	First	and	foremost	a	
quick	 and	efficient	 technique	 for	measuring	viral	 copy	number	was	developed.	
Molecular	 techniques	 for	 HPIV	 detection	 in	 diagnostics	 and	 research	 are	
currently	widely	used	 (Jalal	et	al.	2007;	Almajhdi	2015)	and	 the	assay	adapted	
for	my	project	 forms	part	 of	 a	 diagnostic	 respiratory	panel	 that	 has	 been	 fully	
accredited	 (https://www.gov.uk/government/organisations/public-health-
england).	 The	 primers	 and	 probe	 used	 were	 aligned	 to	 a	 part	 of	 the	 HPIV3	
nucleocapsid	 gene,	 which	 is	 highly	 conserved	 among	 HPIV3	 (Vainionpää	 and	
Hyypiä,	1994).		
Although	 a	 PCR-based	 assay	 would	 facilitate	 a	 rapid	 evaluation	 of	 viral	 copy	
number,	the	study	of	phenotype	in	vitro	required	an	infectivity	based	assay.	The	
majority	 of	 studies	 (Hawthorne	&	Albrecht	 1981;	Bailly	 et	 al.	 2016),	 that	 have	




non-cytopathic	 viruses	 such	 as	 HPIV1	 (Fukushima	 et	 al.,	 2011)	 using	 solid	
overlays	 coupled	with	 immunofocal	 staining	 techniques,	were	 adapted	 for	 this	
project.			For	HPIV3	immunofocal	staining	protocols,	primary	antibodies	directed	
against	 the	 HN	 subunit	 of	 HPIV3	 (Bailly	 et	 al.,	 2016)	 are	 most	 often	 used	 in	
literature.	However	the	HPIV3	HN	protein	is	known	to	be	highly	variable	among	
HPIV3	 clinical	 strains	 (Almajhdi,	 Alshaman	 and	Amer,	 2012;	 Goya,	Mistchenko	
and	Viegas,	2016;	Košutić-Gulija	et	al.,	2017).		Therefore	for	the	purposes	of	this	
project	 an	 antibody	 against	 highly	 conserved	 F	 protein	 epitopes	 of	HPIV3	was	
developed	and	an	immunofocal	assay	for	the	detection	of	HPIV3	was	successfully	
established.	
The	 next	 step	was	 the	 optimization	 of	 a	 growth	 protocol	 for	 clinical	 strains	 of	
HPIV3.	 Primary	 cell	 lines	 are	 generally	 considered	 to	 be	 superior	 to	





does	 not	 allow	 efficient	 upscaling	 and	 is	 poorly	 adapted	 for	 the	 production	 of	
large	 volume	 stocks	 that	were	 required	 for	 this	 project.	Additionally	HAE	 cells	
are	 obtained	 from	a	 pool	 of	 donors	 and	 this	may	 lead	 to	 heterogenous	 results	














al.,	1996).	 	 Interferon	 inhibition	has	previously	been	achieved	by	either	adding	
interferon	inhibitors	to	the	growth	media	(Stewart,	Randall	and	Adamson,	2014)	
or	by	transducing	the	cells	with	lentiviral	vectors	expressing	BVDV	NPro	and	PIV	
5V	 (Hilton	 et	 al.,	 2006;	 Childs	 et	 al.,	 2007)	 that	 are	 known	 to	 interfere	 with	
interferon	 beta	 production.	 In	 the	 current	 study,	 the	 latter	 was	 attempted,	
however	 the	 resultant	 cell	 lines	 did	 not	 yield	 higher	 viral	 titres.	 Poly	 I:C	
stimulation	of	 the	parental	 cell	 line	and	cell	 lines	 transduced	with	BVDV	NPro,	
PIV	 5V	 and	 empty	 vector	 confirmed	 that	 there	 was	 no	 difference	 in	 the	
interferon	 response	 of	 the	 wild	 type	 and	 transduced	 cell	 lines	 (Figure	 3-9).	
Further	 literature	 review	 showed	 that	 the	 PLC/PRF5	 cell	 line	 is	 chronically	
infected	with	hepatitis	B	(Daemer	et	al.,	1980;	Koch	et	al.,	1984;	Pinto,	Bey	and	
Bernstein,	1985),	which	has	a	complex	and		multifactorial	suppressive	effect	on	
type	 1	 interferon	 (Guo,	 2013)	 although	 it	 does	 not	 produce	 infectious	 virus	




reflected	by	 the	poor	 success	 rate	 achieved	here.	 Therefore	 it	 could	be	 argued	
that	a	proportion	of	 clinical	 strains	were	missed	and	 the	cultured	strains	were	
biased	towards	those	with	the	ability	to	grow	in	 immortalised	cells.	 In	order	to	
address	this	in	the	future,	a	larger	scale	study	could	be	conducted	with	a	range	of	
clinical	 samples	 were	 inoculated	 both	 into	 single	 donor	 HAE	 cells	 and	
immortalised	 cell	 culture.	 Although	 this	 is	 unlikely	 to	 reach	 statistical	
significance	due	 to	 the	 low	growth	 success	 rates	 achieved	 in	 immortalised	 cell	
culture,	it	would	nonetheless	help	to	pinpoint	some	potential	variants,	that	could	
then	be	explored	further	with	a	reverse	genetics	system	(Beaty	et	al.,	2017).		
When	 this	 project	 started	 there	 were	 very	 few	 whole	 genome	 sequences	 of	
HPIV3	 available.	 	 Over	 the	 last	 few	 years,	 this	 number	 has	 increased,	 partially	
due	to	decreased	cost	and	greater	access	to	next	generation	sequencing	(Kothari	
et	 al.,	 2017)	 and	 a	 greater	 interest	 in	 viral	 metagenomics	 of	 respiratory	
infections	 (Madi	 et	 al.,	 2018).	 However	 the	 bulk	 of	 whole	 genome	 sequences	
available	centers	on	a	small	number	of	episodes	or	studies,	yielding	clusters	of	
highly	 similar	 or	 identical	 genomes	 (Greninger	et	al.,	 2017).	Additionally	 there	
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are	still	no	whole	genome	sequences	from	circulating	UK	strains.	As	part	of	this	
project,	 a	 robust	 amplicon-based	 sequencing	 pipeline	 was	 established	 and	 23	
whole	genome	sequences	of	UK	clinical	strains	of	different	provenance	and	date	
of	 collection,	 as	well	 as	 that	 of	 the	 laboratory	 strain	MK9	were	 generated.	 The	
clinical	stains	were	sourced	from	a	diverse	range	of	patients	and	were	all	distinct	
from	both	culture	adapted	strains	MK9	and	JS	(Stokes	et	al.,	1992)	.		
Having	 established	 that	 clinical	 strains	 were	 significantly	 distinct	 from	 the	
laboratory	strain	MK9,	an	attempt	was	made	to	correlate	this	to	their	phenotype	
in	 vitro.	 Clinical	 strains	were	 found	 to	 exhibit	 a	 diverse	 range	 of	 plaque	 sizes,	
which	were	all	significantly	smaller	than	the	one	demonstrated	by	strain	MK9.	A	
correlation	 between	 plaque	 phenotype	 in	 vitro	 and	 pathogenesis	 in	 vivo	 has	
previously	 been	 demonstrated	 in	 small	 animal	 studies	 for	 RSV	 (Stokes	 et	 al.,	
2011)	 and	 rhinovirus	 (Jacobs	 et	 al.,	 2013).	 It	 is	 of	 note	 that	 strains	 that	 were	
grown	 in	HAE	cells	 (8	and	D)	had	 the	smallest	plaque	phenotype	 in	PLC/PRF5	
cells.	 This	 reflects	 that	 the	 selection	 of	 clinical	 strains	 in	 this	 project	 was	
inevitably	 biased	 towards	 strains	 that	 were	 able	 to	 grow	 in	 immortalised	 cell	
culture.	 To	 address	 this,	 a	 limited	 number	 of	 strains	 grown	 in	HAE	 cells	were	
included	for	comparison	where	possible.		
First,	 clinical	 strains	 were	 divided	 into	 three	 groups	 according	 to	 plaque	
phenotype,	 and	 genomes	 of	 each	 group	 were	 compared	 to	 the	 genomes	 of	
laboratory	 adapted	 strains	 as	 reference.	 Subsequently,	 6	 clinical	 strains	 with	
diverse	 plaque	 phenotypes	 as	 well	 as	 laboratory	 strain	 MK9	 were	 serially	





culture	 adapted	 strains	 was	 recorded.	 However	 this	 result	 could	 have	 been	
confounded	by	small	sample	size	(only	two	clinical	strains),	as	well	as	by	the	fact	
that	strains	65	and	82	were	phylogenetically	very	similar.		
All	 clinical	 strains	 exhibited	 larger	 plaque	 phenotypes	 with	 increased	 culture	
adaptation,	whereas	 strain	MK9	developed	 smaller	 sized	 variants,	which	 likely	
reflected	adaptation	 to	 the	PLC/PRF5	cell	 line.	The	 intergenic	M	–F	region	was	
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of	 the	 HPIV3	 genome	 as	 part	 of	 the	 viral	 subversion	 of	 the	 immune	 system	
(Lingemann	 et	 al.,	 2015).	 This	 leads	 to	 a	 decrease	 in	 the	 amount	 of	 F	 protein	
produced	and	subsequently	a	less	immunogenic	and	less	fusogenic	phenotype	in	
vivo	(Lingemann	et	al.,	2015).	 	Changes	in	this	part	of	the	HPIV3	genome	would	
therefore	be	potentially	 consistent	with	HPIV3	 adaptation	 to	 immortalised	 cell	
culture,	 however	 validation	 of	 this	 would	 require	 confirmation	 using	 reverse	
genetics.	 Changes	 in	 two	 specific	 variants	 previously	 identified	 in	 literature	
(Palmer	et	al.,	2012),	namely	E108K	 in	 the	F	protein,	which	has	been	 linked	 to	
larger	 plaque	 phenotype	 and	 N556D	 in	 the	 HN	 protein,	 linked	 to	 a	 deficient	
neuraminidase,	were	also	observed,	although	not	 in	all	 strains.	 	A	new	variant,	




strains	 have	 frequently	 been	 correlated	with	 culture	 adaptation	 and	 therefore	
with	a	decreased	suitability	 for	replication	 in	 the	natural	host	 (Moscona,	2005;	
Palmer	 et	 al.,	 2012,	 2014).	 However	 little	 attention	 has	 been	 given	 to	 the	
potential	that	the	larger	plaque	phenotype	could	be	a	naturally	occurring	variant,	
as	has	been	observed	 in	other	viruses	 (Mao	and	Rosenthal,	 2003;	 Jacobs	et	al.,	
2013;	 Kim	 et	al.,	 2015).	 Unfortunately	 because	 of	 this	 connection,	most	 of	 the	
data	 on	 plaque	 size	 is	 inevitably	 correlated	 with	 data	 obtained	 from	 culture	
adaptation	 studies.	 In	 the	 future,	 an	 HPIV3	 reverse	 genetics	 system	 (Pfaller,	
Cattaneo	and	Schnell,	2015;	Beaty	et	al.,	2017)	would	help	to	elucidate	the	exact	
effects	 of	 these	 variants,	 although	 a	 greater	 numbers	 of	 clinical	 strains	 are	
required	to	establish	whether	other	variants,	specifically	from	other	parts	of	the	
genome	are	involved.	
Overall,	 in	 this	 chapter,	 I	 have	 demonstrated	 the	 optimization	 of	 the	 protocols	





diverse,	 as	 well	 as	 significantly	 different	 from	 the	 culture-adapted	 reference	
strain	MK9.	 	 Serial	 passage	of	 a	number	of	 clinical	 strains	 in	 immortalised	 cell	
culture	 has	 helped	 to	 identify	 potentially	 important	 variants	 linked	 to	 tissue	
culture	 adaptation.	 Most	 importantly	 the	 above	 has	 shown	 that	 clinical	 strain	
stocks	 grown	 for	 this	 project	 are	 suitable	 for	 further	work	 on	 phenotypic	 and	
phylogenetic	diversity	of	HPIV3	 in	a	wider	context	and	potential	 correlation	 to	












Previously,	 there	 have	 been	 attempts	 to	 study	 the	 virulence	 of	 HPIV3	 in	
immortalised	 cell	 lines,	 where	 culture	 adapted	 strains	 typically	 become	 more	









More	 recently,	 primary	 cell	 lines	 such	 as	 human	 airway	 epithelial	 (HAE)	 cells	
have	 become	 more	 common	 in	 the	 study	 of	 respiratory	 viruses	 (Zhang	 et	 al.,	
2005).	 These	 readily	 support	 HPIV3	 replication	 in	 a	 natural	 environment,	
including	viral	propagation	in	an	environment	with	beating	cilia	and	directional	
apical	 budding	 of	 new	 virus	 from	 cilia	 shafts	 (Zhang	 et	al.,	 2005,	 2011).	 	 This	
system	has	also	allowed	 the	study	of	 the	 innate	 immune	responses	 induced	by	
HPIV	infection	(Schaap-Nutt	et	al.,	2012;	Lewandowska-Polak	et	al.,	2015).		Both	
in	vitro	 (Zhang	et	al.,	2005;	Schaap-Nutt	et	al.,	2012;	Lewandowska-Polak	et	al.,	
2015)	and	 in	vivo	 studies	 (Gern	et	al.,	2002;	Ottolini	et	al.,	2002;	Feghaly	et	al.,	
2012),	 have	 demonstrated	 increases	 in	 pro-inflammatory	 chemokines	 such	 as	
	 106	




whether	 the	behaviour	 of	HPIV3	 clinical	 strains	 in	 a	model	 of	 the	natural	 host	
(HAE	 cells)	 could	 be	 correlated	with	 genotypic	 and	 phenotypic	 characteristics.	
As	 previously	 described,	 most	 studies	 have	 used	 well	 established	 and	
significantly	culture	adapted	strains	to	study	HPIV3,	although	it	has	been	shown	
that	 these	 have	 distinct	 phenotypes	 and	 genotypes	 (Palmer	 et	 al.,	 2014).	
Therefore,	 in	order	 to	 look	at	potential	diversity	 in	naturally	occurring	 strains,	
well-characterised	stocks	of	clinical	HPIV3	strains	were	required	for	this	project.	
To	this	end,	stocks	of	diverse	clinical	strains	were	grown	in	PLC/PRF5	cells	and	a	
small	 number	 of	 clinical	 samples	 were	 also	 propagated	 in	 HAE	 cells.	
Subsequently	a	number	of	these	were	sequenced	and	characterized	according	to	
their	 phenotype	 in	 immortalised	 cell	 culture,	 as	 discussed	 in	 the	 Chapter	 1.	
Growth	 kinetics	 and	 cytokine	 responses	 triggered	 by	 five	 clinical	 strains	 with	
diverse	 plaque	 phenotypes	 and	 specific	 fusion	 protein	 variants,	 as	 well	 as	
reference	strain	MK9,	were	then	evaluated	in	HAE	cells.	 	Although	the	numbers	
involved	were	small,	 it	was	nonetheless	possible	 to	demonstrate	 that	 there	are	






In	 the	 previous	 chapter,	 I	 have	 described	 the	 growth	 of	 viral	 stocks	 of	 clinical	
strains	of	HPIV3,	their	characterization	by	plaque	phenotype	in	PLC/PRF5	cells,	
as	well	 as	 their	 phylogenetic	 relationship.	 The	 purpose	 of	 this	 chapter	was	 to	









culture	adaptation	 (Palermo	et	al.,	 2016).	 It	was	additionally	argued	 that	 the	E	
variant	at	108	in	the	F	protein	was	specific	to	clinical	strains	grown	in	HAE	cells	
(Palermo	 et	 al.,	 2016).	 To	 this	 end,	 strains	 grown	 both	 in	 PLC/PRF5	 cells	 (K	
variant	at	108	in	F)	as	well	as	HAE	cells	(E	variant	at	108	in	F)	were	chosen	for	
analysis	 in	 HAE	 cells	 (Figure	 4-1B).	 Additionally,	 the	 strains	 were	 paired	
phylogenetically,	 as	 shown	 in	 Figure	 4-1A,	meaning	 that	 strains	with	 different	
plaque	 phenotypes	 and	 F	 108	 variants	 were	 nonetheless	 closely	 related	 to	
reduce	 other	 potential	 confounding	 factors	 in	 their	 behaviour.	 All	 the	 clinical	





















































8 HAE small E N
D HAE small E N
16 PLC/PRF5 small K N
153 PLC/PRF5 medium K N
65 PLC/PRF5 large K N




In	 order	 to	 investigate	 the	 relative	 growth	 rates	 of	 the	 clinical	 strains	 and	 the	
laboratory	reference	strain	MK9	in	primary	cells,	five	diverse	clinical	strains	and	
the	 laboratory	 reference	 were	 grown	 in	 HAE	 cells.	 All	 strains	 were	 plaque	





for	 growth	 in	 primary	 cells.	 Additionally	 some	 differences	 were	 observed	 in	
clinical	strain	titres	at	72	hours,	with	the	smaller	plaque	phenotype	strains	8	and	
D	 reaching	 a	 roughly	 1-2	 log10	 smaller	 titres	 compared	 to	 the	 larger	 plaque	
phenotypes.		Rate	of	growth	was	calculated	by	taking	the	first	derivative	at	each	
timepoint	 (Figure	 4-2B).	 A	 slower	 rate	 for	 the	 laboratory	 strain,	 as	well	 as	 for	
strains	153	and	8	were	observed.	Due	to	potential	differences	in	neuraminidase	
function	between	 clinical	 strains	 and	 the	 laboratory	 strains	 that	would	 lead	 to	
enhanced	 cell-associated	 virus	 in	 the	 latter,	 viral	 titres	were	 also	 calculated	 in	
freeze	 thawed	 cells	 at	 72	 hours	 and	 this,	 together	with	 final	 viral	 titres	 at	 72	
hours	 is	shown	in	Figure	4-2C.	 	Due	to	 financial	constraints	only	one	biological	
replicate	 could	 be	 obtained	 for	 the	 viral	 load	 in	 cells.	 	 As	 expected,	 the	 cell	
associated	viral	titre	for	strain	MK9	was	observed	to	be	significantly	higher	than	
that	obtained	by	quantifying	 released	virus	only.	This	was	not	 the	 case	 for	 the	
clinical	 strains,	where	 a	 good	 positive	 correlation	was	 found	 between	 the	 two	
respective	 titres	 (R2	 =	 0.8,	 data	 not	 shown).	 	 Consistent	 with	 previous	 data	









viral	 titre	 increase	 at	 each	 time	 point	 (first	 derivative)	 in	 GraphPad	 Prism	
version	 6.	 Virus	 yields	 at	 72	 hours	 (3	 biological	 repeats	 +/-	 SEM)	 (A)	 are	
compared	to	yields	 in	the	cells	(one	biological	repeat)	at	72	hours	 in	panel	(C).		
For	all	clinical	strains	the	titre	in	the	supernatant	exceeds	that	found	in	the	cells,	
apart	 from	 the	 laboratory	 strain	 MK9	 where	 the	 converse	 is	 true.	 Similarly,	
strain	MK9	 shows	 a	 significant	 growth	 defect	 compared	 to	 the	 clinical	 strains,	
both	in	absolute	titres	(A)	and	growth	rate	(B).	




















































































As	 discussed	 above,	 the	 pathogenesis	 of	 HPIV3	 is	 likely	 to	 be	 reliant	 on	 an	
interplay	between	host	and	viral	factors.	Having	established	the	relative	growth	
kinetics	of	selected	clinical	strains	and	strain	MK9	in	HAE	cells,	 I	examined	the	
innate	 immune	response	triggered	 following	 infection.	To	this	end	the	 levels	of	
select	cytokines	and	chemokines	 induced	during	 the	 infection	 timecourse	were	
measured.	 A	 full	 list	 of	 the	 cytokines/chemokines	 tested	 can	 be	 found	 in	
Materials	and	Methods.	A	measurable	 response,	 that	was	significantly	different	
from	 the	negative	control	wells	was	detected	 for	RANTES,	 IP-10,	MIP1α	and	β,	
IL-1α	 and	 IL-8.	 The	 results	 are	 summarized	 in	 Figure	 4-3	 and	 Figure	 4-4.	 The	
values	recorded	for	IL-8,	were	out	of	operating	range	throughout	the	entire	time	
course	 apart	 from	 the	 final	 time	 point	 (72	 hours)	 where	 the	 samples	 were	
diluted	1:10.	Four	wells:	2	infected	by	strain	16,	1	by	strain	8	and	1	by	strain	D	
were	deemed	to	be	contaminated	and	therefore	were	not	evaluated	for	cytokine	
induction.	 Therefore	 cytokine	 induction	 by	 strain	 16	 is	 not	 shown	 and	 values	
obtained	 for	 strains	 8	 and	 D	 represent	 biological	 duplicates	 only.	 	 Induced	
cytokine	 levels	are	shown	 in	Figure	4-3A.	Strains	8	and	D	were	observed	to	be	
more	effective	in	inducing	RANTES,	which	has	been	heavily	implicated	in	asthma	
exacerbation	 linked	 to	 HPIV3	 infection	 (Lewandowska-Polak	 et	 al.,	 2015;	
Chihara	et	al.,	 2018).	 Strain	MK9,	 on	 the	other	hand	was	observed	 to	have	 the	
least	effect	immunologically,	potentially	due	to	the	lower	viral	load	at	72	hours.	
This	 was	 an	 unexpected	 result,	 as	 previously	 published	 data	 suggests	 that	
fusogenic	strains,	although	slow	growing	in	the	natural	host	had	the	capacity	to	
cause	 more	 immune	 mediated	 damage	 than	 their	 less	 fusogenic	 counterparts	









Figure	 4-3	 Infections	 with	 clinical	 strains	 and	 the	 culture	 adapted	
laboratory	strain	shows	diversity	of	chemokine	and	cytokine	responses	in	
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Figure	 4-4	 Infection	 with	 clinical	 strains	 and	 the	 culture	 adapted	 strain	
MK9	 shows	 a	 significant	 increase	 in	 IL-8	 levels.	 Absolute	 (pg/ml)	 (A)	 and	
corrected	 for	 viral	 load	 (pg/106pfu)	 levels	 of	 IL-8	 induced	by	4	 clinical	 strains	
and	 the	 laboratory	 strain	MK9	measured	 at	 72	hours.	 Each	 column	 represents	
the	mean	of	3	biological	repeats	+/-	SEM	for	strains	65,	153	and	MK9	and	a	mean	
of	 2	 biological	 repeats	 +/-	 SEM	 for	 strains	 8,	 D	 and	 negative	 control.	 All	 the	


















cells.	 	 Therefore	 this	 model	 was	 used	 to	 investigate	 the	 correlation	 between	












A. IL8 levels detected at 72 hours













B. IL8 levels at 72 hours 




of	 HPIV3	 and	 reference	 strain	 MK9	 with	 their	 growth	 kinetics	 and	 cytokine	
response	in	HAE	cells.	Strains	were	chosen	according	to	their	plaque	phenotype,	
as	well	 as	particular	 variants	 at	 amino	acid	positions	108	 in	 the	F	protein	 and	
556	 in	 the	HN	protein	(Figure	4-1).	These	were	also	paired	phylogenetically	as	
much	as	possible	(Figure	4-1A)	so	as	to	reduce	any	other	potential	confounding	
factors,	 although	 due	 to	 small	 numbers	 of	 samples	 these	 could	 not	 be	 entirely	
excluded.	 The	 F	 proteins	 of	 clinical	 strains	with	 an	 E	 at	 position	 108	 in	 the	 F	
protein	have	been	previously	observed	to	have	a	fusion	protein	cleavage	defect,	
leading	 to	 very	 small	 plaque	 sizes	 or	 failure	 to	 grow	 in	 immortalised	 cell	 lines	
(Palermo	et	al.,	2016).	This	 is	supported	by	data	discussed	in	Chapter	1,	where	
small	 plaque	 size	 was	 correlated	 with	 this	 variant	 that	 was	 lost	 with	 culture	
adaptation.	 Additionally,	 it	 was	 previously	 observed	 that	 strains	 with	 a	 D	 at	
amino	acid	556	of	the	HN	protein	had	a	5-fold	decrease	in	their	neuraminidase	
activity	 compared	 to	 those	 that	 had	 an	N	 at	 that	 position	 (Palmer	et	al.,	 2012;	
Palermo	 et	 al.,	 2016)	 .	 This	 was	 linked	 to	 culture	 adaptation	 (Palermo	 et	 al.,	
2016)	and	was	in	agreement	with	data	discussed	in	the	previous	chapter,	where	
strain	MK9	was	found	to	have	a	D	variant	and	two	clinical	strains	were	observed	
to	 acquire	 it	 during	 culture	 adaptation.	 It	 was,	 however,	 found	 that	 strain	 JS,	
another	well-known	significantly	culture	adapted	HPIV3	strain,	 contained	an	N	
variant,	 indicating	 that,	 although	 potentially	 linked	 to	 culture	 adaptation,	 a	 D	





strains	 would	 be	 impaired	 in	 the	 natural	 host	 (Moscona,	 2005;	 Palmer	 et	 al.,	
2012).	 	 This	 difference	 was	 less	 pronounced	 when	 cell-associated	 virus	 was	
measured	 (Figure	 4-2B)	 and	 is	 consistent	 with	 a	 reduced	 neuraminidase	
function	 of	 strain	 MK9,	 linked	 with	 the	 D	 variant	 at	 location	 556	 of	 the	 HN	
protein.	 A	 previous	 study	 has	 shown	 that	 HAE	 grown	 clinical	 strains	 with	 E	
variants	at	amino	acid	108	in	the	F	protein	grew	well	in	HAE	cells,	and	although	
some	differences	 in	 the	 rate	 of	 growth	were	 seen,	 similar	 viral	 loads	 by	 day	 3	
	 115	
post	 infection	 were	 observed	 in	 all	 the	 strains	 (Palermo	 et	 al.,	 2016).	 This	 is	
consistent	with	the	viral	titres	observed	in	the	current	study	for	strains	8	and	D		
(107-108	 PFU/ml).	 It	 is	 important	 to	 note	 that	 four	 clinical	 strains	 used	 in	 the	
(Palermo	et	al.,	2016)	study	were	all	closely	related,	suggesting	that	potentially	
only	one	phenotype	was	studied.	However,	in	the	current	study,	all	strains	with	a	
K	variant	 at	108	 in	 the	F	protein	were	observed	 to	have	yielded	a	higher	viral	
titre	(108-109	PFU/ml)	at	72	hours	(Figure	4-2).	This	suggests	that	this	variant	is	
not	detrimental	 to	virus	growth	kinetics	 in	 the	HAE	model.	Additionally	 it	was	
observed	that	clinical	strains	8	and	153	exhibited	a	markedly	slower	growth	rate	
compared	 to	 other	 clinical	 strains	 (Figure	 4-2B).	 This	 was	 particularly	
noteworthy,	 as	 these	 strains	 were	 not	 closely	 phylogenetically	 related	 (Figure	
4-1A)	and	contained	different	108	F	variants.		
The	 total	 number	 of	 clinical	 strains	 grown	 in	 HAE	 cells	 in	 the	 (Palermo	 et	al.,	
2016),	 study	 was	 8,	 here	 it	 was	 3.	 Although	 all	 these	 strains	 were	 found	 to	
contain	an	E	variant,	overall	the	sample	is	too	small	to	speculate	that	this	variant	
is	 overwhelmingly	 dominant	 in	 the	 natural	 host.	 Equally,	 as	 growth	 in	






Although	 growth	 kinetics	 of	 viral	 strains	 provide	 a	measure	 of	 viral	 fitness,	 in	
clinical	practice,	it	is	often	the	immune	response	provoked	by	a	particular	virus	
that	 contributes	 to	 the	 severity	 of	 the	 disease.	 This	 has	 been	 particularly	well	
studied	 in	 RSV,	 another	 paramyxovirus,	 where	 the	 severity	 of	 the	 disease	 has	
been	 linked	 to	 levels	 of	 particular	 chemokines	 (Gern	 et	 al.,	 2002;	 Habibi	 and	
Openshaw,	2012).	The	inflammatory	response	caused	by	HPIV3	has	received	less	
attention,	 although	 it	 has	 been	 studied	 in	 the	 cotton	 rat	model	 (Ottolini	 et	al.,	
2002),	ex	vivo	 in	primary	cells	(Schaap-Nutt	et	al.,	2012;	Lewandowska-Polak	et	
al.,	2015)	and	in	a	clinical	setting	(Feghaly	et	al.,	2012).		In	small	animal	models,	
infection	with	HPIV3	has	 been	 correlated	 to	 laryngotracheal	 inflammation	 and	








STAT1	and	 inhibits	 its	phosphorylation	thereby	 inhibiting	 interferon	signalling,	
as	 well	 as	 down-regulating	 viral	 RNA	 synthesis,	 and	 reducing	 the	 innate	
response,	 which	 may	 explain	 the	 lack	 of	 measurable	 interferon	 induction	
detected	here	(Caignard	et	al.,	2009).		
In	 a	 clinical	 study,	 where	 inflammatory	 chemokines	 in	 nasal	 washes	 from	
children	 infected	 with	 parainfluenza	 were	 analysed,	 IL-6,	 IL8,	 MIP1α	 and	 β,	
RANTES	 and	 MIG	 (not	 measured	 in	 this	 study)	 were	 identified	 as	 specific	 to	
infection	 with	 parainfluenza	 viruses,	 with	 IP10	 and	 IL1α	 showing	 less	
statistically	 significant	 increases	 over	 levels	 recorded	 in	 uninfected	 controls	
(Feghaly	et	al.,	2012).	Consistent	with	results	previously	described	in	 literature	
(Schaap-Nutt	 et	 al.,	 2012;	 Schomacker	 et	 al.,	 2012;	 Lewandowska-Polak	 et	 al.,	
2015),	I	have	been	able	to	obtain	measurable	increases	in	RANTES,	MIP1α	and	β,	
IP10,	IL1α	and	IL8	(Figure	4-3	and	Figure	4-4).	IL6	levels	were	found	to	be	high	
both	 in	 the	 infected	 and	 non-infected	 cells,	 this	was	 potentially	 due	 to	 culture	
handling,	as	previously	described	in	 literature	(Schaap-Nutt	et	al.,	2012).	Strain	
MK9,	 although	 yielding	 the	 lowest	 viral	 load	 (Figure	 4-2)	 was	 seen	 to	 be	
moderately	 inflammogenic	 when	 compared	 to	 clinical	 strains	 grown	 in	
PLC/PRF5	 cells	 (Figure	4-3	 and	Figure	4-4).	 This	 is	 consistent	with	previously	
reported	data	(Moscona,	2005),	that	indicates	that	strains	with	greater	fusogenic	
properties	 due	 to	 changes	 in	 their	 HN	 protein	 have	 the	 potential	 to	 trigger	 a	
greater	innate	immune	response.	In	this	context,	unexpectedly,	strains	8	and	D,	
which	 exhibited	 the	 smallest	 plaque	 phenotype	 in	 immortalised	 cell	 culture,	






release	 than	strains	with	a	K	variant	at	F	108	 (strains	65,	153).	 	Although	 it	 is	
suggested	 that	 E	 variants	 are	 disadvantaged	 in	 immortalised	 cell	 culture	
(Palermo	et	al.,	2016),	the	data	obtained	here	implies	that	the	converse	may	not	
necessarily	be	true	for	K	variants	in	the	HAE	model.		
In	 clinical	 studies,	 HPIV3	 infection	 has	 been	 distinguished	 from	 other	 types	 of	
HPIV	 by	 significantly	 increased	 levels	 of	 IL8,	 and	 less	 significant	 increases	 of	
IL1α	and	IP10	(Feghaly	et	al.,	2012;	Schaap-Nutt	et	al.,	2012),	with	IL8	and	IP10	
correlated	to	clinical	severity	(Gern	et	al.,	2002;	Feghaly	et	al.,	2012).	This	 is	 in	
agreement	with	 the	 results	 obtained	 here	 (Figure	 4-3	 and	 Figure	 4-4).	 In	 this	
study	 no	 significant	 difference	 in	 IL8	 or	 IP10	 levels	 were	 recorded	 between	
strains	when	uncorrected	for	viral	 load	(Figure	4-3A),	however	strains	8	and	D	
were	 shown	 to	 induce	 higher	 cytokine	 levels	 per	 PFU,	 than	 the	 other	 strains	
tested.	This	has	potential	implications	for	the	severity	of	disease	caused	by	these	
strains.	 For	 instance,	 RANTES	 secretion	 (Figure	 4-3A),	 which	 is	 implicated	 in	
asthma	exacerbation	caused	by	respiratory	viral	infections	(Chihara	et	al.,	2018),	
was	 increased	 in	 smaller	 plaque	 phenotype	 strains	 8	 and	 D,	 even	 without	
correction	for	viral	load	(Figure	4-3B)	compared	to	strains	65,	153	and	MK9.	The	
above	may	have	 implications	 for	more	 targeted	clinical	 treatment	as	cotton	rat	





of	growth	kinetics	and	cytokine	release.	Within	 the	 limits	of	 the	data	obtained,	
one	 cannot	 deduce	 a	 specific	 mechanism	 responsible	 for	 these	 differences.	 It	
could	be	argued	 that	 strains	8	and	D	produced	smaller	viral	 loads	due	 to	 their	
more	 inflammogenic	 nature,	 which	 could	 potentially	 be	 linked	 to	 their	 more	
efficient	replication	in	HAE	cells,	as	suggested	in	the	paper	discussed	(Palermo	et	
al.,	 2016).	 However,	 it	 could	 equally	 be	 argued	 that	 slower	 growing	 strains	
would	be	 less	adept	at	producing	sufficient	 immunomodulatory	proteins	 in	 the	
required	 time	 frame	 and	 thus	 trigger	 a	 greater	 innate	 immune	 response	

















data	 for	 closely	 related	 strains	 with	 K	 variants	 is	 available.	 Additionally	 the	
number	of	strains	involved	is	very	small,	and	although	an	attempt	was	made	to	
exclude	 confounding	 factors	 by	 phylogenetically	 matching	 the	 strains,	 other	
differences,	that	have	been	unaccounted	for	cannot	be	excluded.	Nonetheless,	the	




otherwise	 similar	 hosts.	 However,	 as	 discussed	 previously,	 there	 is	 currently	
little	 data	 on	 circulating	 strains	 within	 the	 UK	 and	 little	 consensus	 on	 the	
phylogenetic	 characterization	 thereof.	 Although,	 in	 this	 chapter,	 a	 variant	 that	
was	 not	 linked	 to	 phylogenetic	 classification	 was	 heavily	 implicated	 in	 the	
phenotype	displayed	by	HPIV3	clinical	strains	in	HAE	cells,	it	was	also	discussed	
that	 other	 variants,	 hereto	 unclassified	 cannot	 be	 excluded.	 In	 this	 context,	 a	









studies	 have	 quoted	 figures	 ranging	 from	27%	 to	 75%	mortality	 due	 to	 lower	
respiratory	tract	infection	(LRTI)	attributed	to	HPIV3	(Seo	et	al.,	2014).		This	is	in	
contrast	to	the	paucity	of	data	available	on	the	impact	of	HPIV3	in	the	paediatric	
population,	 where	 data	 is	 frequently	 conflicting	 both	 in	 terms	 of	 risk	 factors	
(Ustun	 et	 al.,	 2012;	 Torres	 et	 al.,	 2016;	 Santolaya	 et	 al.,	 2017)	 and	 outcome		
(Bowden,	 MD,	 1997;	 Christensen,	 Nielsen	 and	 Hasle,	 2005;	 Söderman	 et	 al.,	






First	 and	 foremost,	 in	 order	 to	 establish	 the	 diversity	 of	 circulating	HPIV3	UK	
strains,	 the	 genetic	 analysis	 of	 full	 genome	 sequences	of	 twenty	 circulating	UK	
strains	between	 the	years	2011-2015	was	carried	out.	This	data,	 together	with	
other	 full	 genome	 sequences	 available	 in	 the	 Genbank,	 was	 used	 to	 conduct	 a	
phylogenetic	analysis	of	UK	circulating	strains	of	HPIV3.	Previously,	phylogenetic	
analysis	of	HN	gene	sequences	has	been	used	to	characterize	emerging	strains	as	
well	 as	 tracing	 outbreaks	 (Piralla	 et	 al.,	 2009;	 Almajhdi,	 Alshaman	 and	 Amer,	
2012;	Mao	et	al.,	2012;	Goya,	Mistchenko	and	Viegas,	2016;	Košutić-Gulija	et	al.,	
2017).	 The	 F	 gene	has	 been	 shown	 to	 be	 equally	 valid	 for	HPIV3	phylogenetic	
classification	 (Košutić-Gulija	 et	 al.,	 2017).	 Additionally	 a	 small	 region	 directly	
preceding	and	overlapping	with	the	start	of	the	F	gene	has	been	historically	used	
to	 trace	outbreaks	 (Zambon	et	al.,	 1998;	 Jalal	et	al.,	 2007).	For	 the	purposes	of	
this	 project,	 a	 short	 hypervariable	 region	 in	 the	HPIV3	 genome	was	 identified	
and	 evaluated	 as	 a	 potential	 target	 for	 outbreak	 tracing	 by	 comparing	
	 120	
phylogenetic	 classification	 obtained	 using	 full	 genome	 sequences	 and	 those	
obtained	 using	 this	 hypervariable	 region.	 A	 nested	 PCR	 protocol	 for	 the	
amplification	of	this	region	was	established	and	using	this	method,	the	cluster	of	
HPIV3	cases	was	identified	as	a	point	source	outbreak.			
Subsequently	 molecular	 data	 obtained	 was	 combined	 with	 epidemiological	
information	 extracted	 from	 hospital	 records	 using	 Structured	 Query	 Language	
(SQL)	 (Weinberg	 et	 al.,	 2010),	 as	 well	 as	 a	 clear	 visualization	 tool	 based	 on	
Konstanz	 Information	Miner	 (KNIME)	version	3.3.2	 (Berthold	et	al.,	2008).	The	





A	 cluster	 of	 HPIV3	 cases	 was	 identified	 on	 a	 paediatric	 oncology	 ward	 in	 the	
summer	 of	 2017.	 In	 order	 to	 determine	 whether	 the	 activity	 observed	
represented	 a	 deviation	 from	 the	 norm,	 seasonal	 trends	 of	 HPIV3	 in	 the	
surrounding	geographical	area	as	well	as	on	the	ward	in	question	were	analysed.			
First,	 epidemiological	 trends	 were	 compared	 between	 the	 number	 of	 positive	
samples	 for	 the	 6	 adjoining	 geographical	 areas	 covered	 by	 the	 laboratory	 and	
those	 for	 the	 hospital	 alone	 for	 years	 2014-2017	 and	 the	 paediatric	 oncology	
unit	for	the	same	dates	up	to	and	including	August	2017.	Once	the	outbreak	was	
identified,	 samples	 from	 the	 15	 outbreak	 cases	 and	 15	 non-outbreak	
parainfluenza	cases	were	collected	for	further	analysis.	
The	 number	 of	 positive	 cases	 identified	 by	 the	 PHE	 laboratory	 at	 the	 index	
teaching	hospital	 between	 the	 years	2014-2017	 is	 summarized	 in	Figure	5-1A.	
Expected	seasonal	fluctuations	in	HPIV3	prevalence,	with	peaks	in	late	string	and	
summer	were	observed.	No	unusual	activity	pointing	to	a	potential	outbreak	was	
identified.	 This	 was	 confirmed	 when	 the	 number	 of	 total	 HPIV3	 cases	 in	 the	
index	 teaching	 hospital	 was	 compared	 to	 the	 number	 of	 cases	 within	 the	 full	



























A. Total number of HPIV3 paediatric and adult cases diagnosed by PHE 















C. HPIV3 cases on the paediatric oncology ward between 01/11 and 08/17












B. HPIV3 cases within the index teaching hospital, compared to total number of 
cases diagnosed (panel A) between 01/11 and 08/17






any	 other	 organisms	 isolated	 and	 potential	 impact	 of	 the	 infection	 are	
summarized	in	Table	5-1.	
	
Table	 5-1	 Clinical	 details	 of	 patients	 involved	 in	 outbreak.	 	 This	 table	
summarises	 the	 clinical	 details,	 including	 the	 underlying	 diagnosis	 as	 well	 as	
other	 microorganisms	 isolated	 for	 patients	 1-9	 and	 11-15.	 Patient	 10	 had	 a	
genetically	different	strain	of	HPIV3	and	was	therefore	not	included	in	the	final	
analysis.	There	was	only	one	fatality	(patient	6),	that	was	unrelated	to	infection	
with	 HPIV3.	 Negative	 numbers	 of	 days	 indicate	 that	 the	 patient	 became	
symptomatic	 before	 the	 admission	when	 they	were	 diagnosed	 for	HPIV3.	 This	




due	 to	 their	 underlying	 condition	 or	 treatment,	 only	 one	was	 post	 transplant.	
The	most	common	underlying	diagnosis		(6/15)	was	acute	lymphocytic	leukemia	
(ALL)	 and	 other	 blood	 cancers	 such	 as	 Non	 Hodgkin’s	 lymphoma,	 anaplastic	
large	cell	lymphoma	(ALCL)	and	acute	myeloid	leukemia	(AML)	accounting	for	3	
more	 cases.	 There	 were	 four	 cases	 of	 CNS	 malignancy,	 one	 of	 a	 non-
haematological	malignancy	and	one	post	transplant.	The	most	common	cause	of	
admission	(8/14)	was	febrile	neutropenia,	which	is	defined	as	pyrexia	with	a	low	




























1 CNS	tumour febrile	neutropenia 1 -2 3 N Y rhinovirus
2 CNS	tumour febrile	neutropenia 2 0 2 Y Y adenovirus
3 CNS	tumour febrile	neutropenia 4 0 4 N Y rhinovirus
4 AML new	diagnosis 15 13 2 Y N
5 ALL elective 0 N Y Gram	+ve	cocci*
6 ALL febrile	neutropenia 33 N N
7 ALCL febrile	neutropenia 1 0 1 Y Y rhinovirus
8 ALL elective 1 0 1 N N
9 ALL relapse 18 11 7 Y N
10 post-transplant post-	transplant 253 N N
11 ALL febrile	neutropenia 2 Y Y rhinovirus
12 non-malignant	haematology	disorder elective 0 N N
13 Non	Hodgkin's	lymphoma elective 0 -3 3 Y Y
14 CNS	tumour febrile	neutropenia 4 Y Y rhinovirus




and	 one	 new	 diagnosis.	 	 The	 most	 common	 additional	 organism	 isolated	 was	
rhinovirus	 and	 this	 reflects	 the	 common	 occurrence	 of	 this	 virus	 within	 the	
paediatric	patient	cohort.		
5.2.3 Phylogenetic	analysis	of	the	full	genome	sequence		
In	 order	 to	 confirm	 whether	 this	 cluster	 of	 cases	 represented	 a	 point	 source	
outbreak	 and	 to	 determine	 the	 best	 method	 for	 molecular	 analysis,	 the	
epidemiology	and	evolution	of	HPIV3,	in	the	context	of	strains	circulating	within	















the	 number	 of	 substitutions	 per	 site.	 The	 analysis	 involved	 56	 nucleotide	
sequences.	 Evolutionary	 analyses	 were	 conducted	 in	 MEGA7.	 Clusters,	
subclusters	and	strains	were	identified	using	Automatic	Barcode	Gap	Discovery	






of	 the	 full	 genome	 sequences	was	 used	 to	 define	 anything	 separated	 by	more	
than	a	genetic	distance	of	0.043	as	a	cluster	and	0.02	as	a	sub	cluster.	Using	this	




























































































5-2.	 It	 is	 of	 note	 that	 apart	 from	 strain	 1b(ii)	 that	 currently	 only	 contains	 one	
sequenced	strain	from	the	USA	(2017)	no	temporal	or	geographical	correlation	
between	 strains	 was	 observed.	 The	 rate	 of	 substitution/site/year	 has	 been	
calculated	 to	 be	 4.2	 x10-4	 subs/site/year	 using	 an	 uncorrelated	 relaxed	 clock	
(Drummond	 et	 al.,	 2006),	 General	 Time	 Reversible	 model	 (GTR)	 with	 gamma	
distributed	 rate	 and	 invariant	 sites	 (GTR	 +	 I	 +	 G)	 (Tavaré,	 1986;	 Yang,	 1994;	
Ferreira	 and	 Suchard,	 2008)	 and	 an	 MCMC	 length	 of	 600	 million,	 using	
BEASTv1.8.4	as	described	in	Materials	and	Methods.	This	is	consistent	with	rates	






Full	 genome	 sequencing,	 particularly	 in	 the	 context	 of	 diagnositic	 laboratories	
can	 be	 expensive	 and	 time	 consuming.	 In	 the	 current	 project,	 as	 previously	
discussed,	 whole	 genome	 amplification	 directly	 from	 clinical	 sample	 was	
unsuccessful	and	growth	in	immortalised	cell	culture	yielded	a	very	low	success	
rate	(approximately	10%	at	passage	1,	Figure	3-12).		To	this	end	a	smaller	region	




Figure	 5-3	 Relative	 site	 by	 site	 evolutionary	 rate	 of	 the	 HPIV3	 genome.		
Mean	(relative)	evolutionary	rate	are	shown	for	each	site	next	to	the	site	number	
with	a	window	of	200.	These	rates	are	scaled	such	that	the	average	evolutonary	
rate	across	all	 sites	 is	1.	This	means	 that	 sites	 showing	a	 rate	<	1	are	evolving	
slower	than	average,	and	those	with	a	rate	>	1	are	evolving	faster	than	average.	
These	relative	rates	were	estimated	under	the	GTR	+	I	+	G	model.	The	analysis	




The	 site	by	 site	 relative	 evolutionary	 rate	was	 calculated	using	 the	GTR	+	 I=	G	
model	 (Tavaré,	 1986;	 Yang,	 1994;	 Ferreira	 and	 Suchard,	 2008)	 of	 substitution	







The	 suitability	 of	 the	 hypervariable	 region	 for	 phylogenetic	 analysis	 was	 then	
evaluated	 by	 constructing	 a	 phylogenetic	 tree	 and	 comparing	 it	 to	 the	 one	
obtained	by	using	full	genome	sequences	(Figure	5-2).	 	The	BEAST	(Drummond	
et	al.,	2012)	evolutionary	tree	for	the	hypervariable	region	can	be	seen	in	Figure	
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5-4.	 The	 rate	 of	 substitution	 for	 this	 region	 was	 calculated	 to	 be	 1x10-3	







Table	 5-2	 Subdivisions	 identified	 by	 ABGD	 analysis	 of	 whole	 genome	
sequences	of	HPIV3	and	hypervariable	region	of	HPIV3.	The	corresponding	
subdivisions	 into	 clusters,	 subclusters	 and	 strains,	 identified	 by	 Automatic	
Barcode	Gap	Discovery	 (ABGD)	 for	whole	genome	sequences	 (Figure	 5-2)	and	
the	 hypervariable	 region	 of	 HPIV3	 (Figure	 5-4)	 are	 summarized.	 These	 are	
coloured	according	to	the	scheme	used	in	(Figure	5-2	and	Figure	5-4)	for	ease	
of	visualization.		














Figure	 5-4	 Molecular	 phylogenetic	 analysis	 of	 the	 HPIV3	 hypervariable	
region	 using	 Bayesian	 Phylogenetics	 with	 BEAST.	The	 evolutionary	history	
was	inferred	by	using	Bayesian	Phylogenetics	based	on	the	TRN	+I	model	using	
BEAST	 v1.8.4.	 The	 tree	 with	 the	 highest	 log	 likelihood	 (-2020.47)	 using	 path	
sampling	 and	 stepping	 stone	 analysis	 is	 shown.	 A	 strict	 clock	 and	 a	 constant	
coalescent	prior	were	used.	The	MCMC	length	was	10,000,000.		Convergence	was	
assessed	with	Tracer	and	the	maximum	clade	credibility	tree	was	generated	with	
Tree	 Annotator.	 Dates	 of	 strain	 emergence	 (in	 years)	 are	 shown	 in	 the	 figure	
legend	All	branches	are	colour	coded	by	the	posterior	probability	as	per	colour	
legend	 in	 the	 figure.	 	 Automatic	 Barcode	 Gap	 Discovery	 was	 used	 to	 analyse	
genetic	 distances	 and	 0.1	 (cluster)	 and	 0.04	 (subcluster)	 were	 defined.		
Subclusters	 A-E	 are	 shown	 next	 to	 their	 respective	 branches.	 All	 strains	 and	
cluster	and	subcluster	labels	are	coloured	identically	to	the	phylogenetic	analysis	






























































Figure 6 Molecular Phylogenetic analysis of HPIV3 hypervariable 












the	 full	 genome	 (Figure	5-2)	 and	hypervariable	 (Figure	5-4)	 analysis	methods.	
Strain	180	has	moved	from	strain	1b	in	Figure	5-2	to	subcluster	A	in	Figure	5-4	
(see	 Table	 5-2	 for	 corresponding	 subdivisions)	 and	 strain	 KF530247.1	
(USA2006)	was	noted	 to	have	moved	 from	cluster	2	 to	cluster	1.	 	 It	was	 found	
that	strain	180	contained	3.7%	ambiguous	bases	within	its	hypervariable	region	
(0.9%	R;	 2.6%	 Y;	 0.1%	W).	 This	 falls	 just	 below	 the	 definition	 of	 a	 subcluster	














et	 al.,	 2007).	 This	 approach	 would	 place	 the	 primer	 sites	 within	 the	
hypervariable	region	 itself	(defined	here	as	position	4703	to	5160,	Figure	5-3),	
potentially	limiting	amplification	success	rate.		In	the	current	analysis,	the	region	
identified	 was	 flanked	 by	 two	 regions	 of	 reduced	 variability,	 creating	 ideal	




Table	 5-3	 Nested	 primer	 sets	 used	 for	 amplification	 of	 the	 HPIV3	
hypervariable	 region.	 Sequences,	 relative	 positions	 and	 product	 sizes	 of	 two	




The	 amplicons	 were	 subsequently	 sequenced	 by	 Sanger	 sequencing	 and	 the	
contigs	 were	 assembled	 to	 a	 reference	 genome	 using	 Sequencher	 5.4	 from	
Genecodes	(https://www.genecodes.com).	 	For	HPIV3,	a	consensus	sequence	of	
the	 hypervariable	 region	 was	 extracted	 using	 alignments	 with	 the	 Muscle	
algorithm	 with	 UGENE	 (Okonechnikov,	 Golosova	 and	 Fursov,	 2012).	 It	 was	
subsequently	 trimmed	 by	 50bp	 and	 52bp	 at	 the	 3 ′ 	and	 5 ′ 	prime	 ends	
respectively.	 The	 resulting	 fragment	 had	 good	 quality	 coverage	 in	 both	
directions	 and	 was	 therefore	 deemed	 to	 be	 suitable	 for	 further	 phylogenetic	
analysis.		For	rhinovirus,	the	alignments	were	done	to	the	consensus	sequence	of	
published	 rhinovirus	 sequences	KX610685;	KY131965;	KY645964;	MF422576;	
MF422577;	 MF422578;	 MF422580;	 MF422581,	 as	 described	 previously	 (W.	
Wang	et	al.,	2015).		The	consensus	was	extracted	as	described	above.	
5.2.8 Phylogenetic	analysis	of	the	outbreak		
In	 order	 to	 identify	 whether	 the	 cases	 on	 the	 paediatric	 oncology	 ward	
represented	 a	 point	 source	 outbreak	 or	 were	 merely	 a	 reflection	 of	 the	
circulating	 community	 strains	 at	 that	point	 in	 time,	 30	 cases	were	 selected	 for	
molecular	analysis,	where	15	constituted	the	suspected	outbreak	(Table	5-1)	and	
15	 were	 control	 cases	 unrelated	 to	 the	 outbreak.	 The	 pertinent	 clinical	
information	 for	 all	 cases	 is	 summarized	 in	 Figure	 5-5A	 and	 B.	 	 All	 patients	
involved	in	the	outbreak	were	coded	1-15.	These	were	all	paediatric	patients	on	





















(range	 7	 months	 –	 92	 years),	 geographical	 location	 and	 immunosuppression	
status.	 It	 is	 of	 note	 that	 among	 the	 unrelated	 cases,	 the	 majority	 of	 patients	





Figure	 5-5	 Outbreak	 (1-15)	 and	 non-outbreak	 (A-O)	 sample	 details	 and	
molecular	 phylogenetic	 analysis	 by	Maximum	Likelihood	Method.	Panel	A	
summarises	 the	 dates	 of	 first	 HPIV3	 positive	 samples	 for	 all	 patients	 (1-15	 in	
red)	 involved	 in	 the	 outbreak.	 Demographics	 of	 patients	 not	 involved	 in	 the	
outbreak	 (A-O	 in	 blue)	 are	 shown	 in	 panel	 B,	 those	 marked	 with	 an	 asterix	
originated	 in	 the	 wider	 geographical	 area	 rather	 than	 at	 the	 index	 teaching	
hospital.	Panel	C	shows	the	molecular	phylogenetic	analysis	of	all	samples.	The	
evolutionary	history	was	inferred	using	the	Maximum	Likelihood	method	based	
on	 the	 Tamura-Nei	 +	 I	 model	 with	 1000	 bootstrap	 repetitions.	 Branches	 are	
colour	coded	by	their	respective	bootstrap	values	as	per	the	colour	legend.	The	
tree	 is	 drawn	 to	 scale,	 with	 branch	 lengths	 measured	 in	 the	 number	 of	
substitutions	per	site	with	the	legend	shown.	There	were	a	total	of	351	positions	
in	the	final	dataset.	Evolutionary	analyses	were	conducted	in	MEGA	version	7.		
A. Sample dates of patients involved in outbreak
Figure 3 Outbreak  (1-15) and non-outbreak (A-O) sample details and molecular 
phylogenetic analysis by Maximum Likelihood Method.
B. Sample dates and demographics of patients  not 
involved in outbreak




















A 67 Y 18-May
B 48 N 26-May
C* 7	months unknown 24-Jun
D 21 N 26-Jun
E 74 Y 28-Jun
F 69 N 01-Jul
G 30 Y 05-Jul
H 35 Y 06-Jul
I 38 Y 08-Jul
J 92 Y 12-Jul
K* 1 unknown 13-Jul
L 70 N 14-Jul
M 53 Y 19-Jul
N 69 Y 31-Jul








































invariant	 sites	 (Tamura	 and	 Nei,	 1993)	 (Figure	 5-5C)	 using	 MEGA	 version	 7	
(Kumar,	 Stecher	 and	 Tamura,	 2016),	 as	 detailed	 in	 Materials	 and	 Methods.	
Phylogenetic	 analysis	 indicated	 that	 12/15	 outbreak	 strains	 were	 genetically	




rather	 than	 being	 unique	 to	 this	 outbreak.	 	 Outbreak	 sample	 10	 was	 seen	 to	
cluster	separately	from	other	cases	involved	in	the	outbreak.	This	was	consistent	
with	the	clinical	history	of	patient	10,	who	had	been	an	inpatient	for	a	number	of	
months	prior	 to	 this	 incident	and	has	had	no	points	of	 contact	with	any	of	 the	
other	 cases	 (Table	 5-1).	 Other	 non-related	 strains	 were	 shown	 to	 form	 two	
separate	 clusters,	 one	 being	 closely	 related	 to	 the	 outbreak	 strains	
(approximately	 98%	 conformity	with	 the	 outbreak	 strain)	 and	 the	 other	more	
distinct	(approximately	87%	conformity	with	the	outbreak	strain).			
As	 rhinovirus	 was	 identified	 as	 a	 common	 secondary	 pathogen	 (6/15	 cases),	
genotyping	of	rhinovirus	was	attempted	using	an	established	protocol	(W.	Wang	
et	al.,	2015).	To	 this	end	 the	VP4/VP2	part	of	 the	rhinovirus	genome	sequence	
was	amplified	and	aligned	successfully	for	patients	7,11	and	3.	All	strains	of	the	
virus	 were	 found	 to	 be	 different	 and	 therefore	 no	 evidence	 of	 dual	 infection	
transmission	was	found	in	these	cases.	
5.2.9 Phylogenetic	analysis	in	the	context	of	other	strains	of	HPIV3		
Having	 confirmed	 a	 point-source	 outbreak,	 the	 sequences	 obtained	 were	
analyzed	 in	 the	 context	 of	 other	 historically	 circulating	 strains	 to	 establish	
whether	 the	 outbreak	 was	 caused	 by	 a	 newly	 emerging	 strain.	 To	 this	 end	 a	
Bayesian	 phylogenetic	 tree	 including	 the	 hypervariable	 region	 from	 the	 30	
strains	 identified	 above,	 as	 well	 as	 the	 56	 strains	 used	 for	 primer	 design,	 as	
detailed	in	Materials	and	Methods,	was	constructed	using	BEAST	v1.8.4	(Figure	
5-6).	 This	 analysis	 confirmed	 a	 point	 source	 outbreak	 and	 served	 to	 illustrate	






10)	 and	 demonstrate	 the	 diversity	 of	 HPIV3	 strains	 circulating	within	 a	 given	
time	 period	 (Figure	 5-6).	 Additionally	 outbreak	 strain	 8	 and	 two	 background	
strains	(I	and	D)	were	grown	in	HAE	cells	as	described	in	Materials	and	Methods	
and	 full	 sequences	 of	 these	 were	 obtained.	 These	 were	 then	 added	 to	 the	








(A-O	 in	 blue)	 strains	 in	 the	 context	 of	 historically	 circulating	 strains	 of	
HPIV3.	 The	 evolutionary	 history	 was	 inferred	 using	 Bayesian	 Phylogenetics	
based	on	 the	Tamura-Nei	+	 I	model	using	BEAST	v1.8.4	with	a	 strict	 clock	and	
constant	 coalescent	prior.	The	MCMC	 length	was	10,000,000.	Convergence	was	
assessed	 with	 Tracer	 (effective	 sample	 size	 >200).	 Inferred	 dates	 of	 strain	
emergence	(in	years)	are	shown	in	the	figure	legend.	All	branches	are	coloured	
by	 their	 posterior	 probability	 as	 per	 the	 colour	 legend.	 Clusters	 were	 defined	
with	Automatic	Barcode	Gap	Discovery.	Cluster	2,	subclusters	B	and	D	and	a	part	
of	cluster	A	have	been	collapsed	for	ease	of	visualization.	All	outbreak	strains	(1-































































Figure 4 Molecular analysis of outbreak (1-15 red) and non-outbreak (A-O blue) 













Figure	 5-7	 Molecular	 analysis	 of	 outbreak	 strain	 8	 and	 two	 background	
strains	 (I	 and	D)	 in	 the	 context	of	other	 full	 genome	sequences	of	HPIV3.	
The	evolutionary	history	was	inferred	by	using	the	Maximum	Likelihood	method	
based	on	 the	GTR	+	 I	+	G	model	and	1000	bootstrap	repetitions.	The	 tree	with	
the	highest	log	likelihood	(-43462.08)	is	shown.	The	tree	is	drawn	to	scale,	with	
branch	 lengths	measured	 in	 the	 number	 of	 substitutions	 per	 site.	 The	 analysis	
involved	 59	 nucleotide	 sequences.	 Evolutionary	 analyses	 were	 conducted	 in	
MEGA	version	7.	Cluster	2,	and	strains	1a(ii)	and	1b(i)	have	been	collapsed	 for	
ease	of	visualization.	Clinical	strains	8,	I	and	D	are	shown	in	orange;	subdivisions	
into	 strains	 and	 clusters	 are	 coloured	 according	 to	 the	 scheme	used	 in	Figure	

















































After	 identifying	 the	 cluster	 as	 a	 point	 source	 outbreak	 the	 potential	
transmission	 routes	 between	 patients	were	 investigated.	 First	 an	 attempt	was	
made	to	identify	the	overlap	of	patients	in	space	and	time,	to	this	end	a	timeline	
was	 constructed	 based	 on	 admission	 dates,	 symptom	 onset	 and	 first	 positive	
sample	date	for	the	patients	involved	(Figure	5-8A).		This	clearly	demonstrated	a	
significant	 temporal	overlap	between	patients	 involved	 in	 the	outbreak	as	well	
as	 potential	 delays	 between	 symptom	 onset	 and	 a	 sample	 being	 taken,	 where	
available	(8/15	cases).		The	number	of	cumulative	new	cases	at	the	end	of	each	
week	 is	 shown	 in	 Figure	 5-8B,	 together	with	 the	 date	when	 the	 outbreak	was	
suspected.	It	is	clear	that	the	outbreak	was	declared	as	the	number	of	cases	was	




Figure	 5-8	 Timeline	 of	 patients'	 admissions	 to	 the	 hospital	 including	 the	
date	(A)	and	cumulative	number	of	new	cases	of	HPIV3	at	the	end	of	each	
week	(B)	during	May-August	2017.	Panel	A	shows	the	movements	in	and	out	
of	 hospital	 of	 15	 patients	 (coded	 1-15	 on	 the	 y	 axis)	 involved	 in	 the	 outbreak	
during	 the	 period	 encompassing	 a	 week	 before	 the	 first	 confirmed	 positive	

















































































Timeline of HPIV3 oubreak showing patient admissions (black) with date of symptom 











































































duration	 of	 the	 outbreak	 (Piralla	 et	 al.,	 2009))	 and	 phylogenetic	 plausibility.	
Based	 on	 molecular	 data,	 Patient	 10	 was	 identified	 as	 not	 being	 part	 of	 the	
outbreak.	 	 Patients	 11	 and	 12,	 that	 had	 a	 strain	 that	 differed	 by	 one	 identical	
nucleotide	from	the	main	outbreak	strain,	remained	as	part	of	the	outbreak.	This	
was	because	the	possibility	of	an	original	 infection	by	the	main	outbreak	strain	
or	 the	 acquisition	 of	 their	 unique	 strain	 from	 another	 patient	 could	 not	 be	





Figure	 5-9	 Inferred	 infection	 transmission	 routes	 between	 patients.	
Transmission	 routes	 between	 patients	were	 analysed	with	 SQL	 and	 visualized	
using	 KNIME	 3.3.2.	 Patient	 location,	 as	 well	 as	 symptom	 onset	 date	 where	
available	 (A)	 and	 first	 positive	 HPIV3	 sample	 date	 (B)	 were	 used.	 All	
phylogenetically	 implausible	 connections	 have	 been	 removed.	 The	 connectors	
between	patients	are	colour	coded	according	to	patient	location	as	shown	in	the	
legend	 and	 the	 direction	 of	 the	 arrow	 conforms	 to	 the	 direction	 of	 infection	
spread.	The	map	of	 the	unit	with	 locations	 shaded	 in	 corresponding	 colours	 is	
shown	in	panel	C	(bays	were	numbers	arbitrarily	1-10).	
	
Transmission routes between patients
Figure 6
A. Symptom onset date B.First confirmed positive sample date
Paediatric oncology ward bay 10
Paediatric oncology ward bay 2
Paediatric oncology ward bay 3
Paediatric oncology ward bay 1
Paediatric day unit (PDU)
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and	 confirmed	 HPIV3	 positive	 sample	 is	 summarized	 in	 Figure	 5-9.	 	 KNIME	
analysis	by	symptom	onset	date	(Figure	5-9A)	has	identified	12	phylogenetically	
plausible	 transmission	events,	 linking	10/14	patients	 involved	 in	 the	outbreak,	
and	 identifying	 a	 potential	 source	 of	 infection	 in	 6/14	 cases.	 Analysis	 by	 first	
positive	 sample	 date	 (Figure	 5-9B)	 identified	 15	 phylogenetically	 plausible	
transmission	events,	linking	10/14	patients	and	identifying	a	potential	source	of	
infection	 in	 7/14	 patients.	 It	 is	 interesting	 to	 note	 that	 although	 these	 highly	
complex	patients	were	periodically	admitted	onto	a	number	of	different	wards,	
the	 paediatric	 oncology	 unit	 (ward	 and	 day	 unit)	 were	 the	 main	 hotspots	 for	





Outbreaks	 of	 respiratory	 viral	 infections	 are	 common	 causes	 of	ward	 closures	
causing	disruption	as	well	as	increased	cost	to	the	National	Health	Service	(NHS)	
(Elliot,	 Cross	 and	 Fleming,	 2008).	 These	 are	 statistically	 more	 common	 on	
paediatric	 wards	 (Chow	 and	 Mermel,	 2017).	 This	 is	 due	 to	 a	 combination	 of	
factors:	 first	 and	 foremost	 children	 are	 at	 increased	 risk	 of	 infection	 due	 to	
immature	 immune	 systems	 (Maddux	and	Douglas,	2015;	 Simon,	Hollander	and	
McMichael,	2015).	Additionally,	many	unique	transmission	routes	including	toys,	
eyes,	 aerosolisation	 of	 droplets	 and	 increased	 socializing	 that	 is	 normally	
encouraged	on	children’s	wards	should	be	taken	into	account	(Koutlakis-Barron	
and	 Hayden,	 2016).	 HPIV3	 has	 in	 turn	 been	 described	 as	 both	 a	 prevalent	
(Torres	 et	 al.,	 2016)	 and	 a	 rare	 (Meidani	 and	 Mirmohammad	 Sadeghi,	 2018)	
cause	 of	 nosocomial	 respiratory	 infection	 outbreaks	 on	 paediatric	 wards	 with	
additional	 conflicting	 evidence	 as	 to	 the	 potential	 impact	 in	 the	
immunocompromised	 paediatric	 cohort	 (Ustun	 et	 al.,	 2012;	 Santolaya	 et	 al.,	
2017).	In	this	chapter,	I	discuss	one	such	outbreak	that	took	place	in	the	summer	
of	2017.	As	with	most	outbreaks	in	literature,	this	was	identified	retrospectively	
(Liao	et	al.,	 2017).	One	 could	 argue	 that	 increased	vigilance	would	 allow	 these	
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outbreaks	 to	 be	 identified	 contemporaneously	 with	 potential	 timely	





to	 determine	 whether	 this	 peak	 was	 due	 to	 the	 nosocomial	 transmission	 of	 a	
single	 strain,	 sequence	 analysis	 of	 the	 respiratory	 samples	 was	 performed.	





Piralla	 et	al.,	 2009;	 Baier	 et	al.,	 2018).	 	 The	most	 common	 approach	 to	 HPIV3	
investigations	has	previously	been	the	amplification	of	 the	HN	coding	region	of	
the	genome	(Piralla	et	al.,	2009).	As	this	part	of	the	genome	is	considered	to	be	
an	 important	 antigenic	 site	 (Van	 et	 al.,	 1987),	 it	 has	 been	 surmised	 that	 this	
region	of	the	genome	would	show	the	greatest	variation.	This	is	also	consistent	
with	 previous	 phylogenetic	 analysis	 of	 HPIV3,	 that	 relied	 solely	 on	 the	 HN	
sequence	(Almajhdi,	Alshaman	and	Amer,	2012;	Shi	et	al.,	2015;	Košutić-Gulija	et	





more	 systematic	way,	 in	 this	 project,	 the	 evolutionary	 rate	 of	HPIV3	 along	 the	
entire	 length	 of	 the	 genome	was	 examined	 and	 a	 hypervariable	 region	 located	
within	 the	 intergenic	region	between	M	and	F	was	 identified.	The	suitability	of	
this	region	for	phylogenetic	analysis	was	examined	by	comparing	the	clustering	
achieved	with	whole	 genome	 sequences	 and	 that	 using	 only	 the	 hypervariable	
region.	To	 this	 end	whole	 genome	sequences	 from	 this	project	were	 combined	
with	 others	 obtained	 from	 Genbank	 and	 a	 Maximum	 Likelihood	 phylogenetic	
tree	of	 the	resulting	56	sequences	was	generated	as	described	 in	 the	Materials	
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and	Methods.	All	duplicate	and	highly	similar	sequences	as	well	as	significantly	
culture	 adapted	 strains	 were	 excluded	 leaving	 56	 unique	 sequences.		
Consequently	 only	 two	 clusters,	 as	 opposed	 to	 three	 previously	 identified	 in	
literature	 (Mao	 et	 al.,	 2012;	 Almajhdi,	 2015;	 Košutić-Gulija	 et	 al.,	 2017)	 were	
observed.	This	was	most	likely	due	to	the	exclusion	of	strains	from	the	middle	of	
last	century	that	are	known	to	be	heavily	culture	adapted	and	have	therefore	not	
been	 included	 in	 this	 analysis.	 Automatic	 Barcode	 Gap	 Discovery	 (ABGD)	 was	
used	to	separate	the	sequences	into	clusters,	subclusters	and	strains	(Puillandre	
et	al.,	2012).	This	method	has	previously	been	used	in	literature	to	classify	HPIV3	
sequences	 (Mao	 et	 al.,	 2012;	 Košutić-Gulija	 et	 al.,	 2017)	 and	 is	 generally	
considered	 to	be	one	of	 the	best	options	 for	 classification	of	 organisms,	where	
the	 correlation	 between	 genotype	 and	 phenotype	 has	 not	 been	 established	
(Kekkonen	et	al.,	2015).		It	does,	however,	rely	purely	on	sequence	similarity	and	
therefore	the	correlation	between	strain	classification	and	phenotype	in	vivo	may	
be	 poor	 (Kekkonen	 et	 al.,	 2015).	 	 More	 information	 on	 the	 clinical	 impact	 of	




The	 approach	 adapted	 in	 this	 thesis,	where	 the	 region	 of	 highest	 variability	 is	
identified	 and	 the	 phylogenetic	 classification	 is	 then	 compared	 to	 the	 results	
achieved	 with	 whole	 genome	 sequences,	 is	 significantly	 different	 from	 those	
adapted	 in	 previous	 studies	 (Jalal	 et	 al.,	 2007;	 Almajhdi,	 Alshaman	 and	 Amer,	
2012;	Goya,	Mistchenko	and	Viegas,	2016),	where	only	a	fragment	of	the	genome	




a	 potential	 recombinant	 strain,	 which	 was	 in	 agreement	 with	 the	 results	
obtained	 here.	 However	 the	 hypervariable	 region	 identified	 in	 this	 thesis	 was	
significantly	 smaller	 (457bp)	 than	 the	 HN	 (1795bp)	 and	 F	 coding	 regions	 of	
HPIV3	 (1850bp),	 which	 increases	 the	 likelihood	 of	 successful	 amplification	
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directly	 from	 sample	 as	 well	 as	 the	 efficiency	 and	 rapidity	 of	 phylogenetic	
analysis.		
However	a	number	of	drawbacks	inherent	in	this	method	should	be	considered.	
The	 region	 identified	 shows	 the	 highest	 variability	 within	 the	 HPIV3	 genome.	
The	 rate	 of	 substitution	 calculated	 for	 the	 entire	 HPIV3	 genome	 was	 4.2x10-4	
subs/site/year	and	this	is	consistent	with	other	RNA	viruses	(Jenkins	et	al.,	2002;	
Sanjuán	 et	 al.,	 2010).	 A	 faster	 substitution	 rate	 of	 1x10-3	 subs/site/year	 was	
calculated	for	the	hypervariable	region.	This	 implies	that	new	emerging	strains	
could	 be	 identified	 earlier	 when	 analyzing	 only	 the	 hypervariable	 region,	 as	
exemplified	by	outbreak	strains	11	and	12	that	differed	from	the	other	outbreak	
strains	by	a	single	mutation	(A182C).	 	Although	this	serves	as	a	more	sensitive	
system,	 it	 may	 nonetheless	 be	 less	 specific,	 as	 the	 significance	 of	 a	 single	
mutation	within	 the	hypervariable	 region	would	be	difficult	 to	 interpret	 in	 the	
context	 of	 the	 entire	 genome,	 although	 this	 does	 constitute	 a	 very	 sensitive	
system	 for	 outbreak	 tracing.	 Equally,	 as	 no	 correlation	with	 in	 vivo	 phenotype	
has	 been	 established,	 a	 mutation	 within	 that	 region	 may	 have	 profound	
consequences	for	the	behaviour	of	this	strain	in	vivo.		It	is	also	important	to	note	
that	 the	M-F	 intergenic	region	has	been	identified	as	a	significant	area	both	for	
plaque	 phenotype	 in	 vitro	 and	 culture	 adaptation,	 as	 previously	 discussed.	







and	 infection	 control	 implications	 of	 this	 can	 be	 approached	 logically	 by	
analyzing	 potential	 preventative	measures,	 early	 identification	 and	 isolation	 of	
cases	as	well	as	early	recognition	of	nosocomial	transmission	and	outbreak.	One	
could	also	argue	that	an	outbreak	that	has	been	identified	post	factum	has	failed	
on	 all	 of	 these	 accounts.	 Therefore	 each	 of	 these	 points	 should	 be	 addressed	
separately	in	the	current	context.		
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Preventative	 measures	 during	 seasonal	 peaks	 have	 previously	 been	 described	
for	viruses	such	as	RSV	(Baier	et	al.,	2018),	however	the	evidence	base	for	their	














Cases	 of	 health	 care	 workers	 contributing	 to	 nosocomial	 outbreaks	 are	 well	
documented	 (Aitken	 and	 Jeffries,	 2001;	 Goins,	 Talbot	 and	 Talbot,	 2011;	
Danzmann	et	al.,	2013;	Kim	et	al.,	2017)	and	cannot	be	excluded	by	the	current	
analysis.	 Therefore,	 in	 order	 to	 address	 this	 point,	 measures	 such	 as	 staff	
screening	 and	personal	protective	 equipment	 for	 staff	 in	 areas,	where	patients	
are	at	an	increased	risk	of	hospital	acquired	infections,	should	be	discussed	both	
with	the	clinical	and	infection	control	teams.		
Measures	 that	ensure	rapid	 identification	and	 isolation	of	potentially	 infectious	
cases	 are	 also	 well	 established,	 especially	 on	 wards	 for	 immunosuppressed	
patients	 (Beuvink,	 2018).	 However	 in	 the	 context	 of	 nosocomial	 outbreaks,	
symptom	 onset	 data	 is	 frequently	 not	 available	 and	 the	 date	 of	 first	 positive	
sample	is	used	for	all	epidemiological	modeling	(Piralla	et	al.,	2009;	Berrueco	et	
al.,	 2013).	 Although	 sufficient	 for	 outbreak	 tracing,	 this	 can	 potentially	
underestimate	the	impact	of	early	symptom	identification	and	prompt	screening	
on	 outbreak	 prevention.	 	 To	 this	 end,	 this	 data,	 together	with	 data	 on	 patient	
admission	 was	 collected	 where	 possible	 (Figure	 5-8).	 Subsequently,	
transmission	 models	 involving	 both	 dates,	 if	 available,	 were	 included	 in	 this	
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study	 (Figure	 5-9).	 	 Twelve	 transmission	 events,	 linking	 10	 patients	 were	
identified	 using	 the	 symptom	 onset	 date,	 whereas	 15	 potential	 transmission	
events	 were	 identified	 by	 the	 model	 using	 the	 positive	 sample	 date.	 It	 is	
important	to	note	that	data	on	symptom	onset	was	only	available	in	8	out	of	14	
cases	 involved	 in	 the	 outbreak	 and	 this	was	 further	 confounded	 by	 secondary	
infections	 (Table	 5-1).	 Overall	 within	 the	 limitations	 of	 the	 data	 available,	 the	
current	 analysis	 identified	 3	 potential	 transmission	 events	 and	 1	 potential	
infection	 that	 could	 have	 been	 prevented	 if	 screening	 were	 carried	 out	 when	
symptoms	were	first	identified.	One	could	argue	that	this	could	be	addressed	by	
increasing	 awareness	 and	 more	 specific	 definitions	 of	 what	 constitutes	 a	
symptomatic	 individual	 among	 health	 care	 workers.	 However	 within	 the	
constraints	of	ward	designs	and	lack	of	isolation	rooms	and	facilities,	patients	are	
frequently	prioritized	by	severity	of	symptoms.	 In	this	case,	 the	onus	 falls	back	
on	 good	 infection	 control	 practices	 and	 the	 fine	balance	between	 the	pros	 and	
cons	of	 limiting	contact	between	patients	(Koutlakis-Barron	and	Hayden,	2016;	
Baier	et	al.,	2018).		
In	 the	 case	 where	 both	 of	 the	 above	 stages	 have	 failed	 and	 a	 nosocomial	
transmission	does	occur,	the	outbreak	could	be	identified	at	an	earlier	stage	by	
ensuring	 a	 greater	 awareness	 of	 a	 rising	 number	 of	 cases	 and	 integration	 of	
information	across	different	clinical	teams.		In	the	current	study,	the	correlation	
of	 an	 increased	 number	 of	 cases	 within	 space	 and	 time	 was	 masked	 by	 the	
seasonality	 of	 HPIV3.	 Seasonal	 bias	 is	 a	 well-recognized	 confounder	 in	 public	
health	 reporting	 and	 failures	 to	 identify	 outbreaks	 have	 previously	 been	
described	 in	 viral	 diseases	 with	 a	 strong	 seasonal	 bias	 (Pelecanos,	 Ryan	 and	
Gatton,	2010;	Li	et	al.,	2012).		Usually	it	is	overcome	by	an	outbreak	surveillance	
system	 that	 takes	 into	 account	 information	 on	 the	 background	 level	 of	 virus	
activity	 (Enki	et	al.,	 2016).	There	are	a	number	of	 complex	algorithms	 that	are	
employed	for	this	purpose	for	country	wide	surveillance	(Enki	et	al.,	2016;	Liao	
et	al.,	 2017;	Wang	et	al.,	 2018).	 These	methods	 are	 usually	 not	 employed	on	 a	
smaller	scale	 in	hospitals	and	therefore	 integration	of	 information	between	the	
clinical	team,	infection	control	and	the	laboratory-based	team	is	crucial.	In	order	
to	 address	 this	 in	 the	 future,	 a	 simple	 graphical	 interface	 that	 allows	 the	
visualization	 of	 trends	 of	 cases	 due	 to	 a	 particular	 microorganism	 within	 a	
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this	virus	 (Piralla	et	al.,	 2009).	 	However,	HPIV3	was	 recognized	as	a	potential	
cause	of	an	admission	or	prolonged	stay	in	9	out	of	14	cases,	although	in	8	out	of	
9	 cases	 a	 potential	 secondary	 pathogen	 was	 also	 identified,	 emphasizing	 the	
potential	 importance	 of	 dual	 infections	 (Table	 5-1)	 Rhinovirus,	 a	 highly	
prevalent	infection	in	the	paediatric	cohort	(Söderman	et	al.,	2016)	was	a	notable	
secondary	 viral	 respiratory	 pathogen,	 isolated	 in	 six	 of	 the	 cases.	 Although	 no	
instances	 of	 dual	 infection	 transmission	 were	 identified	 in	 this	 study,	 the	
incidence	of	dual	 infection	was	broadly	 in	keeping	with	some	previous	 reports	
(Benites	et	al.,	2014).		Overall	a	much	wider	review	of	the	impact	of	HPIV3	in	the	
paediatric	population	is	required	in	order	to	determine	the	exact	clinical	impact	
of	 HPIV3	 in	 this	 setting	 (Santolaya	 et	 al.,	 2017).	 It	 is	 important	 to	 emphasize	
further	 that	 currently,	 good	 infection	 control	 policies	 are	 the	 only	 approach	 to	






















Although	a	number	of	potential	 therapeutic	 candidates	exist,	 there	 is	 currently	
no	 licensed	 therapy	 or	 vaccine.	 	 Hence	 there	 is	 a	 clear	 and	 urgent	 need	 to	
develop	 robust	 therapeutic	 models	 to	 evaluate	 potential	 candidates	 for	 the	
treatment	of	this	virus.	A	sizeable	amount	of	work	on	HPIV3	has	been	conducted	
with	 a	 view	 to	 elucidating	 potential	 therapeutic	 targets	 for	 the	 virus,	 but	 the	
majority	of	the	research	has	concentrated	on	tissue	culture	adapted	strains.		
In	this	chapter	an	infectivity	based	in	vitro	model	for	the	evaluation	of	potential	















candidate	 for	 treatment	of	haemorragic	 fever	viruses	 including	CCHF	(Crimean	
Congo	Haemorragic	Fever)	and	Lassa	fever	(Watts	et	al.,	1989;	Günther	and	Lenz,	
2004)	 however	 despite	 encouraging	 results	 in	 vitro,	 it	 has	 been	 a	 lot	 less	
successful	 in	 vivo	 (Ceylan	 et	 al.,	 2013;	 Carrillo-Bustamante	 et	 al.,	 2017).	 The	
latter,	 coupled	 with	 the	 ribavirin	 toxicity	 profile	 and	 its	 teratogenic	 effects	
(Thomas,	 Ghany	 and	 Liang,	 2012),	 which	 make	 aerosolized	 delivery	 for	
respiratory	infections	highly	complex	and	impractical,	has	meant	that	its	use	for	
treatment	 of	 HPIV3	 has	 declined.	 One	 possible	 reason	 for	 the	 lack	 of	 efficacy	
could	 be	 that	 clinical	 stains	 are	 more	 resistant	 to	 ribavirin	 and	 therefore	 a	
detailed	evaluation	of	its	inhibitory	effect	on	clinical	strains	is	necessary.		
Favipiravir	(T-705)	has	a	similar	mechanism	of	action	to	ribavirin	(Vanderlinden	
et	al.,	 2016)	 and	 functions	by	 inducing	 lethal	mutagenesis	 (Furuta	et	al.,	 2013;	
Arias,	 Thorne	 and	 Goodfellow,	 2014;	 Vanderlinden	 et	 al.,	 2016).	 	 It	 has	
demonstrated	good	inhibitory	activity	against	a	broad	range	of	viruses	including	
Paramyxoviridae	 in	 vitro	 and	 in	 small	 animal	 models,	 as	 well	 as	 laboratory-





of	 influenza,	 although	 its	 efficacy	 in	 this	 capacity	 has	 recently	 been	 called	 into	
question	 (Jefferson	 et	 al.,	 2014).	 In	 vitro	 it	 has	 shown	 to	 be	 effective	 against	
laboratory	 adapted	 strains	 of	 HPIV3,	 although	 at	 therapeutically	 unattainable	
50%	maximum	effective	 concentrations	 (EC50)	 values	 (Greengard	 et	al.,	 2000).	
However,	given	the	structural	similarities	between	the	HPIV3	HN	and	influenza	
neuraminidase	binding	pockets	(Lawrence	et	al.,	2004),	as	well	as	the	ability	of	








and	 2015	 from	 the	 PHE	 diagnostic	 laboratory,	 Addenbrooke’s	 hospital,	
Cambridge.	 Nine	 clinical	 strains	 collected	 from	 different	 years	 from	 diverse	
patient	 demographics	 and	 plaque	 phenotype	 were	 chosen	 for	 susceptibility	
testing	(Table	6-1).		
	
Table	6-1	Clinical	 strains	selected	 for	 susceptibility	 testing.	Clinical	strains	
were	collected	between	2011	and	2015,	all	originated	from	the	upper	airway	of	
patients.	Plaque	area	for	the	clinical	strains	averaged	0.82	mm2	+/-	(SEM)	with	a	
range	 between	 0.3	 mm2	 and	 1.47	 mm2,	 with	 strains	 from	 2011	 (65	 and	 82),	





















































LS	MK9 n/a n/a 3.96+/-0.45 n/a n/a n/a n/a
Sample Patient
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All	 9	 strains	were	 collected	 from	 the	upper	 respiratory	 tract	 (URT)	of	patients	
including	nasopharyngeal	 aspirates	 (NPAs),	 tracheal	 aspirates	and	 swabs.	Four	
samples	 originated	 in	 Addenbrooke’s	 hospital,	 Cambridge,	 and	 the	 remaining	
were	from	East	of	England	and	London	geographical	areas.		Seven	samples	were	
collected	 in	 an	 inpatient	 setting	with	one	 sample	 (129)	 from	an	 intensive	 care	





The	source	of	samples	also	reflects	 the	general	pattern	of	 the	clinical	 impact	of	
HPIV3,	with	the	majority	(2/9)	coming	from	an	inpatient	setting,	one	originating	
from	 ICU	 and	 two	 from	outpatient	 sources.	 The	 significant	 difference	 between	
the	 plaque	 area	 of	 clinical	 strains	 and	 strain	 MK9	 likely	 reflects	 the	 culture	
adaptation	of	the	laboratory	strain.	
The	 toxicity	 of	 all	 inhibitors	 was	 first	 examined	 in	 PLC/PRF5	 cells	 and	 no	









incubated	 at	 33°C	 for	 7	 days	 and	 assayed	 with	 CellTiter-Blue®	 Cell	 Viability	



































Figure	6-2	Laboratory	adapted	HPIV3	strain	MK9	 is	 sensitive	 to	 ribavirin	
and	 favipiravir	but	not	zanamivir,	as	measured	by	plaque	area	reduction.	
Figure	 shows	mean	 plaque	 area	 reduction	 as	 percentage	 of	 the	 plaque	 area	 of	
untreated	 control	 +/-	 SEM	 for	 ribavirin	 (B),	 favipiravir	 (C)	 and	 zanamivir	 (D).	
Experimental	design	is	shown	in	(A).	All	plaque	areas	were	measured	using	Fiji.	
Curves	were	fitted	using	GraphPad	Prism	version	6.00	with	R2>0.9.	Dashed	lines	
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6-2A),	we	would	expect	zanamivir	not	 to	show	a	significant	 inhibitory	effect	 in	
this	case.	
In	 order	 to	 determine	 the	 effect	 of	 the	 inhibitors	 on	 a	 different	 part	 of	 the	
lifecycle	 of	HPIV3,	 the	 effect	 of	 each	 inhibitor	 on	 the	 growth	kinetics	 of	HPIV3	
was	evaluated.	Ribavirin	(Figure	6-3B	and	C)	and	favipiravir	(Figure	6-3D	and	E)	
were	observed	to	be	effective	inhibitors	of	HPIV3.	Due	to	the	mutagenic	nature	of	








Figure	6-3	Growth	of	HPIV3	 laboratory	strain	MK9	 is	effectively	 inhibited	
at	24	hours	in	the	presence	of	ribavirin	and	favipiravir	but	not	zanamivir.	
Experimental	 design	 is	 shown	 in	 A.	 For	 each	 inhibitor	 concentration,	 the	
reduction	 of	 infectious	 units	 in	 the	 supernatant	 is	 shown	 as	 a	 percentage	 of	
















B. Ribavirin PFU/ml reduction 











D. Favipiravir PFU/ml reduction









F. Zanamivir PFU/ml reduction











C. Ribavirin viral copy number reduction











E. Favipiravir viral copy number reduction











G. Zanamivir viral copy number reduction
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its	 effect	 on	 the	 viral	 particle	was	 assessed	 by	 adding	 the	 inhibitor	 during	 the	
inoculation	 and	 pre-incubating	 stages	 respectively.	 Zanamivir	 was	 found	 to	
inhibit	HPIV3	at	a	high	concentration	(EC50	of	295	μM)	when	added	during	the	
inoculation	stage	(Figure	6-4).	This	is	consistent	with	previous	studies	that	have	
concentrated	on	 the	 effect	 of	 zanamivir	 during	 receptor	 binding	 (Greengard	et	
al.,	 2000).	 Pre-incubation	 of	 HPIV3	 with	 zanamivir	 has	 had	 no	 effect	 on	 the	





Figure	 6-4	 Zanamivir	 inhibits	 HPIV3	 binding	 to	 host	 cells.	 Experimental	
design	 is	 shown	 in	 A	 (binding	 inhibition)	 and	 C	 (pre-incubation).	 The	 figure	
shows	 the	 effect	 on	 laboratory	 strain	 MK9	 when	 zanamivir	 is	 present	 during	
inoculation	 (B)	 and	 when	 pre-incubated	 with	 zanamivir	 (D)	 to	 exclude	 the	
possibility	of	direct	effects	on	virus	particles.	Panel	D	(pre-incubation)	shows	no	
significant	 effect	 on	 viral	 replication.	 In	 both	 cases	 the	 figure	 shows	 the	
reduction	of	the	number	of	infectious	units	as	a	percentage	of	untreated	control	
by	plaque	titration	+/-	SEM.	All	plaques	were	counted	using	Fiji.	All	curves	were	
fitted	 using	 GraphPad	 Prism	 version	 6.00	with	 R2>0.9.	 Dashed	 lines	 represent	
95%	confidence	intervals.		



































C. Experimental timeline - pre-incubation
A. Experimental timeline - binding inhibition




































B. Results - binding inhibition
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In	order	 to	assess	 the	sensitivity	of	clinical	 isolates	 to	ribavirin,	 favipiravir	and	
zanamivir,	we	selected	2	concentrations	of	each	inhibitor.	The	EC50	and	EC90	for	
ribavirin	and	favipiravir	were	interpolated	using	the	dose	response	curves	fitted	
to	 the	 reduction	 of	 released	 infectious	 viral	 particles	 data	 for	 the	 laboratory	
strain	(Figure	6-3B	and	D).	As	no	equivalent	dose	response	curve	could	be	fitted	













the	 growth	 kinetic	 inhibition	 assay	 (Figure	 6-3),	 at	 200	 μM	 	 (lower	
concentration)	5/9	of	clinical	strains	were	more	sensitive	to	zanamivir	than	the	
laboratory	strain.	At	1	mM	(higher	concentration)	all	clinical	strains	are	shown	




Table	 6-2	 Clinical	 strain	 susceptibility	 to	 favipiravir,	 ribavirin	 and	
zanamivir.	 Average	 EC50	 and	 EC90	 values	 for	 each	 clinical	 strain	 and	 for	 the	
laboratory	 strain	 MK9	 (PHE	 cultures)	 determined	 by	 plaque	 titration	 of	
supernatant	after	24	hour	incubation	(Figure	6-5)	are	summarized.	A	summary	












RBVIC50 47.94+/-5.97 21.5+/-2.08 0	(0%) 8	(89%) 1	(11%)
RBVIC90 9.12+/-0.76 5.15+/-0.78 1	(11%) 4	(44.5%) 4	(44.5%)
FVP	IC50 47.95+/-1.37 39.77+/-3.69 1	(11%) 4	(44.5%) 4	(44.5%)
FVP	IC90 13.56+/-0.23 14.03+/-1.73 1	(11%) 3	(33%) 5	(56%)
ZNV	200μM 98.63+/-4.11 75.86+/-3.21 0	(0%) 5	(55.5%) 4	(44.5%)













figure	 shows	 the	 reduction	 of	 infectious	 units	 in	 the	 supernatant	 assessed	 by	
plaque	 titration	 as	 a	 percentage	 of	 the	 untreated	 control	 +/-	 SEM.	 	 9	 clinical	
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6.2.5 Zanamivir	inhibits	binding	of	HPIV3	clinical	strains	to	the	host	cell.	
In	 order	 to	 investigate	 further	 the	 effect	 of	 ZNV	 on	HPIV3	 during	 binding,	 the	














In	 this	 chapter	 ribavirin,	 favipiravir	and	zanamivir	were	evaluated	as	potential	
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A. Experimental timeline - binding inhibition
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side	 effect	 with	 this	 method	 of	 delivery	 is	 bronchospasm.	 	 Plasma	 levels	
achieved,	 as	 reported	 by	 the	 manufacturers	 (Virazole)	 range	 from	 0.76μM	 to	
6.8μM,	 depending	 on	 the	 length	 of	 delivery	 (2.5	 hours/day,	 n=4,	 and	 20	
hours/day	n=3,	 respectively)	 (ICN	Pharmaceuticals,	 Inc,	Costa	Mesa,	California,	
USA,	 no	 date)	 .	 This	 is	 significantly	 lower	 than	 the	 EC50	 for	 ribavirin	 reported	
here	 in	 other	 in	 vitro	 studies.	 It	 is	 likely	 that	 concentrations	 in	 respiratory	
secretions	 exceed	 these,	 although	 unfortunately	 no	 data	 on	 this	 is	 available.		
Furthermore	the	aerosolized	method	of	delivery	remains	problematic	due	to	risk	
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of	 teratogenicity,	 as	well	 as	 being	 time	 consuming.	 As	 such,	 although	 ribavirin	
remains	 an	 effective	 inhibitor	 of	 HPIV3	 in	 vitro,	 further	 optimization	 of	 drug	
design	 or	 combination	 therapy	 is	 required	 to	 yield	 a	 regimen	 capable	 of	
delivering	 therapeutically	useful	concentrations	at	 the	site	of	 infection.	Current	
results,	at	least	partially,	explain	the	lack	of	clinical	efficacy	of	ribavirin	in	vivo.	
Favipiravir	 is	 a	 nucleoside	 analogue	with	 a	 broad	 spectrum	 of	 action,	 and	 has	
been	 shown	 to	 be	 effective	 against	 other	 RNA	 viruses	 such	 as	 influenza,	 ebola	
and	 laboratory	 adapted	 parainfluenza	 strains	 in	 vitro	 (Mentré	 et	 al.,	 2015;	





et	 al.,	 2016),	 giving	 rise	 to	 abundant	 non-infectious	 particles	 at	 lower	
concentrations.	Overall	we	observed	 that	 favipiravir	 is	 an	 effective	 inhibitor	 of	
HPIV3	 both	 by	 plaque	 reduction	 and	 growth	 inhibition	 assay	 (Figure	 6-2	 and	
Figure	6-3),	with	8	out	of	9	 clinical	 strains	 tested	being	at	 least	 as	 sensitive	 to	




plasma	 concentrations	 achieved	 in	humans	 is	 available	 (Madelain	et	al.,	 2016),	
although	a	number	of	 in	vivo	studies	using	small	rodent	models	(Mendenhall	et	
al.,	 2011;	 Gowen	 et	 al.,	 2015;	 Jochmans	 et	 al.,	 2016)	 and	 well	 as	 non-human	
primates	 (Madelain	 et	 al.,	 2017)	 have	 been	 conducted.	 Recently	 released	 data	
from	 the	 JIKI	 trial	 (Efficacy	 of	 favipiravir	 against	 ebola	 trial)	 quoted	 trough	
plasma	levels	of	293	μM	on	day	2	and	165	μM	on	day	4	of	treatment	(Nguyen	et	
al.,	 2017).	 	 Additionally,	 a	 theoretical	 dose	 regimen	 derived	 from	murine	 and	
theoretical	 pharmacokinetic	 models	 provided	 by	 the	 manufacturers	 (Toyama	
Chemical)	was	used	to	estimate	that	plasma	levels	as	high	as	855	μM	on	average	
can	be	achieved,	while	remaining	within	well-tolerated	levels	in	humans	(Mentré	
et	 al.,	 2015).	 This	 exceeds	 the	 EC50	 and	 EC90	 values	 observed	 here.	 Although	









the	 sensitivity	 to	 ZNV	 in	 its	 capacity	 as	 a	 binding	 inhibitor	 of	 the	 laboratory	





protein	 (Porotto	 et	 al.,	 2007).	 The	 fusion	 and	 release	 processes,	 on	 the	 other	
hand	have	been	linked	to	binding	site	II	(Porotto	et	al.,	2007;	Palmer	et	al.,	2012).	
Moreover	 a	 specific	 mutation	 (N556D)	 at	 binding	 site	 II,	 has	 been	 linked	 to	
culture	 adaptation	 and	 has	 been	 shown	 to	 confer	 a	 5-fold	 decrease	 in	
neuraminidase	 activity	 between	 a	 wild	 type	 strain	 and	 a	 significantly	 culture	
adapted	 strain	 (Palermo	 et	 al.,	 2016).	 This	 has	 been	 linked	 to	 a	 more	 robust	
interaction	 with	 the	 cell	 receptor	 (Murrell	 et	 al.,	 2003)	 and	 a	 larger	 plaque	
phenotype	(Table	6-1)	 in	culture	adapted	strains	(Palermo	et	al.,	2016).	 It	 is	of	
note	that	the	reference	strain	MK9	contains	that	mutation	and	hence	the	reduced	




Data	 on	 the	bioavalability	 of	 zanamivir	 is	widely	 available	 in	 the	 context	 of	 its	
clinical	 use	 against	 influenza.	 	 It	 is	 found	 to	 be	 a	well-tolerated	 drug	with	 few	
side-effects	 and	 no	 drug-drug	 interactions	 reported.	 Oral	 bioavailability	 of	
zanamivir	 is	 2%,	 although	 studies	with	 permeability	 enhacers	 (Shanmugam	 et	
al.,	 2013)	 are	 aiming	 to	 improve	 this.	 	 A	 correlation	 between	 intravenous	
administration	and	concentration	 in	nasal	secretions	has	been	established	with	
approximately	 300	 μM	 achieved	 4	 hours	 after	 a	 600	mg	 infusion,	 dropping	 to	
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200	 μM	 12	 hours	 post	 drug	 administration,	 but	 no	measurements	were	 taken	
from	the	lower	respiratory	tract	(Cass,	Efthymiopoulos	and	Bye,	1999).	In	either	
case	these	values	are	significantly	below	inhibitory	EC50	and	EC90	of	zanamivir	as	
determined	 in	 the	 current	 set	 of	 experiments.	 Nonetheless	 the	 observed	
susceptibility	 of	 clinical	 strains	 to	 zanamivir	 confirms	 the	 importance	 of	
conducting	 further	 studies	 in	 this	 area	on	 clinical	 strains	with	minimal	 culture	
adaptation.			
In	 this	 chapter	 an	 in	 vitro	 infectivity	 based	 model	 for	 evaluating	 HPIV3	
susceptibility	to	potential	therapeutic	candidates	using	a	tissue	culture	adapted	
reference	 strain	 MK9	 and	 9	 diverse	 clinical	 strains	 has	 been	 presented.	 	 A	
necessary	limiting	factor	in	methodologies	that	involve	immortalised	cell	culture	
is	the	reliance	on	viruses	that	are	able	to	grow	in	this	environment.	A	markedly	
larger	 plaque	 phenotype	 is	 associated	 with	 significant	 culture	 adaptation	 as	
demonstrated	 by	 the	 laboratory	 strain	 (Palermo	 et	 al.,	 2016).	 	 Within	 these	
constraints,	and	as	all	clinical	samples	have	been	minimally	and	equally	passaged	
in	 cell	 culture,	 the	 diversity	 in	 plaque	 size	 is	 an	 indication	 of	 diversity	 of	
phenotype	 of	 the	 clinical	 samples	 used.	 	 There	 is	 good	 evidence	 that	 heavily	
laboratory	 adapted	 HPIV3	 strains	 are	 non-representative	 of	 the	 currently	





strain	 and	 clinical	 strains	 of	 HPIV3.	 	 Overall	 clinical	 strains	 were	 significantly	
more	 susceptible	 to	 zanamivir.	 Further	 work	 on	 clinical	 circulating	 strains,	





HPIV3	 is	 an	 important	 respiratory	 virus	with	 the	potential	 to	 cause	 significant	
pathology,	 particularly	 in	 immunosuppressed	 patients	 or	 those	 with	 a	 past	
respiratory	medical	history	(Herzog	et	al.,	1989;	Schomacker	et	al.,	2012;	Ustun	
et	al.,	2012;	Liu	et	al.,	2013).	Moreover,	to	date	neither	a	licensed	treatment	nor	
vaccine	 is	available.	Hence	further	research	 is	required	 into	both	the	pathology	
as	well	as	methods	of	prevention	and	treatment	of	this	virus	(Henrickson,	2003;	
Zhao	 et	al.,	 2017).	 	 Consequently	 the	 aims	 of	 the	 current	 project,	 as	 set	 out	 in	
Introduction,	 were	 to	 characterise	 the	 currently	 circulating	 clinical	 strains	 of	
HPIV3	 both	 phenotypically	 and	 phylogenetically,	 as	 well	 as	 to	 evaluate	 the	
clinical	 significance	 thereof.	 	The	 final	aim	was	 to	study	 therapeutic	candidates	
against	this	virus	using	a	panel	of	diverse	clinical	strains.		




Palermo	 et	 al.,	 2016).	 Therefore	 a	 library	 of	 diverse	 clinical	 strains	 was	
established	for	this	project.	395	clinical	samples	diagnosed	positive	for	HPIV3	by	
two	 rounds	 of	 diagnostic	 qPCR	 between	 2011-2015	were	 grown	 in	 PLC/PRF5	
cells	 using	 a	 growth	 protocol	 developed	 within	 this	 project.	 Consequently	 43	
diverse	 clinical	 strains	 lacking	 detectable	 co-infections	 with	 other	 respiratory	
viruses	 were	 grown	 successfully	 at	 first	 passage.	 In	 order	 to	 evaluate	 clinical	
strains	 that	 had	 not	 been	 exposed	 to	 immortalised	 cell	 culture	 and	within	 the	
financial	 constraints	 of	 this	 project,	 3	 clinical	 strains,	 collected	 as	 part	 of	 the	
outbreak	investigation	in	summer	2017,	were	grown	in	human	airway	epithelial	
cells.	 	 The	 limited	 stock	 obtained	 was	 used	 for	 further	 work	 on	 phenotype	
characterization	to	meet	the	first	objective	of	this	thesis.	
Phenotype	 in	 vitro	 was	 evaluated	 both	 by	 examining	 clinical	 strain	 plaque	
phenotype	 and	 the	 effect	 of	 culture	 adaptation	 on	 clinical	 stains.	 There	 is	
sufficient	 data	 from	 studies	 on	 other	 viruses	 (Blaney	 et	 al.,	 2002;	 Mao	 and	
Rosenthal,	2003;	Jia	et	al.,	2007;	Kim	et	al.,	2015)	to	suggest	that	there	may	be	a	
correlation	 between	 viral	 phenotype	 in	 vitro	 and	 virulence	 in	 vivo.	 In	 this	
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literature,	 larger	 HPIV3	 plaque	 phenotypes	 have	 been	 correlated	 with	 culture	
adaptation	and	most	of	the	focus	has	centered	on	the	HN	and	F	proteins	(Palmer	
et	al.,	2012,	2014).	This	is	in	line	with	data	obtained	in	this	project	as	all	clinical	
strains	developed	 larger	plaque	phenotypes	 following	extended	passage	 in	 cell	
culture.	However	the	majority	of	variants	were	found	to	be	located	within	the	M-
F	intergenic	region	(Lingemann	et	al.,	2015),	that	has	previously	been	linked	to	
both	 virulence	 and	 plaque	 size,	 	 rather	 that	 exclusively	 within	 the	 HN	 and	 F	
coding	 segments	 of	 the	 HPIV3	 genome.	 The	 above	 indicates	 that	 culture	
adaptation	 studies	 of	 HPIV3	 should	 be	 expanded	 to	 encompass	 the	 potential	





the	 natural	 host.	 There	 have	 been	 a	 number	 of	 small	 animal	models	 of	 HPIV3	
infection	(Mascoli	et	al.,	1976;	Murphy,	Dubovi	and	Clyde,	1981;	Ye	et	al.,	2010;	
Jochmans	et	al.,	2016)	however	a	primary	cell	line	ex	vivo	model	has	been	shown	
to	 be	 ideal	 for	 growth	 of	 this	 virus	 (Ottolini	 et	 al.,	 1996;	 Yamaya	 et	 al.,	 2002;	
Zhang	 et	 al.,	 2005).	 Therefore,	 as	 a	 close	 approximation	 of	 the	 natural	 host	
(Yamaya	 et	 al.,	 2002),	 a	 primary	 cell	 model,	 using	 HAE	 cells	 was	 used	 for	
characterization	of	this	virus	in	this	project.	In	line	with	prior	observations,	the	
laboratory	 strain	 (Palmer	 et	 al.,	 2012;	 Palermo	 et	 al.,	 2016),	 has	 a	 significant	
growth	defect	 in	a	more	natural	model,	although	surprisingly	 it	 is	not	 the	 least	
immune-stimulatory	when	viral	 load	 is	 corrected	 for.	Other	 results	obtained	at	
this	stage	were	contrary	to	what	was	expected	from	previously	published	data.	It	
could	 be	 hypothesized	 that	 strains	 with	 small	 plaque	 phenotypes,	 potentially	
correlated	with	the	least	culture	adaptation,	would	be	expected	to	grow	best	in	
an	 ex	 vivo	 model	 (Moscona,	 2005;	 Palmer	 et	 al.,	 2012;	 Palermo	 et	 al.,	 2016).	
However	 in	 the	current	project	 the	strains	with	 the	smallest	plaque	phenotype	
were	found	to	exhibit	neither	the	highest	growth	rate	nor	the	highest	viral	titres	








It	 is	 essential	 to	 remember	 that	 the	 clinical	 impact	 of	 a	 particular	 pathogen	 is	
inevitably	 a	 combination	 of	 both	 host	 and	 pathogen	 factors	 (Openshaw	 and	
Tregoning,	 2005;	 Schomacker	 et	al.,	 2012).	 In	 this	 project	 the	 response	 of	 the	




was	 particularly	 noted	 in	 two	 specific	 cytokines,	 that	 have	 previously	 been	
identified	 as	 markers	 of	 clinical	 severity	 in	 paramyxovirus	 infection:	 RANTES	
(Chihara	et	al.,	2018)	and	IL8	(Gern	et	al.,	2002).	Although	it	was	impossible,	at	
this	stage,	to	determine	whether	the	correlation	was	due	to	the	slower	growth	of	
these	 strains	 and	 hence	 to	 their	 consequent	 reduced	 inhibitory	 effect	 on	 the	
immune	system	(Caignard	et	al.,	2009;	Ding	et	al.,	2017;	Shil	et	al.,	2017)	or	vise	
versa,	it	nonetheless	served	to	demonstrate	that	there	was	a	potential	correlation	
between	 in	 vitro	 and	 in	 vivo	 phenotype	 of	 HPIV3	 with	 possible	 clinical	
implications.			
In	 this	 project,	 a	 very	 limited	 number	 of	 clinical	 strains	 have	 been	 used.	
Furthermore	a	proportion	of	them	were	minimally	passaged	in	immortalised	cell	
culture,	 and	 thus	 exposed	 to	 artificial	 selective	 pressure	 prior	 to	
experimentation.	 The	 generation	 of	 large	 volume	 of	 well-characterised	 viral	
stocks	 necessitated	 the	 growth	 and	 selection	 of	 clinical	 samples	 in	 cell	 culture	
models.	 In	 literature,	 primary	 cell	 lines,	 such	 as	 HAEs	 have	 been	 described	 as	
well	suited	for	this	purpose	(Palmer	et	al.,	2012,	2014).	However	within	practical	
and	 financial	 constraints,	 it	 would	 be	 unfeasible	 to	 use	 these	 cells	 if	 large	
quantities	of	viral	stock	were	required.	An	alternative	approach	would	be	to	use	
the	 data	 collected	 in	 this	 project	 and	 apply	 it	 in	 a	 reverse	 genetics	 model	 of	





a	 new	 amplicon-based	 protocol	 and	 bioinformatics	 pipeline	 for	whole	 genome	




virus,	 and	 with	 new	 cheaper	 sequencing	 techniques	 becoming	 more	 available	
(Jain	et	al.,	2016;	Faria	et	al.,	2017),	the	aim	in	the	future	would	be	to	develop	a	
protocol	to	obtain	whole	length	genome	sequences	directly	from	clinical	samples	
and	compare	 these	with	 the	sequences	obtained	 in	 this	project.	 It	 is	 likely	 that	
limited	 variability	 detected	 in	 the	 samples	 in	 this	 project	 is	 a	 reflection	 of	 a	
genetic	 bottleneck	 encountered	 during	 initial	 limited	 cell	 culture	 passage.		
Recent	 advances	 in	 nanopore	 sequencing	 technology	 could	 be	 used	 to	 obtain	
high	 quality	 sequences	 in	 samples	 as	 well	 as	 to	 identify	 sites	 of	 nucleoside	
analogue	 incorporation	 for	 detailed	 inhibitor	 research	 (Garalde	 et	 al.,	 2018;	
Keller	et	al.,	2018).		
As	 whole	 genome	 amplification	 is	 procedurally	 and	 financially	 difficult	 in	 a	
clinical	 setting,	 a	method	 for	 epidemiological	 and	phylogenetic	 classification	of	
HPIV3	 was	 developed.	 Unlike	 previously	 published	 methods	 (Almajhdi,	
Alshaman	and	Amer,	2012;	Goya,	Mistchenko	and	Viegas,	2016;	Košutić-Gulija	et	
al.,	2017),	 it	did	not	 rely	on	a	protein	coding	 	region	of	 the	genome	but	on	 the	
most	 variable	 one.	 It	 is	 interesting	 to	 note	 that	 the	 region	 of	 the	 genome	 thus	
identified	was	 the	 intergenic	M-F	 region	 and	 the	 phylogenetic	 analysis	 carried	
out	with	it	yielded	the	same	clustering	results	as	that	obtained	using	the	whole	
genome	 sequence.	 This	 approach	 was	 markedly	 different	 from	 previously	
published	 studies	 (Almajhdi,	Alshaman	and	Amer,	2012;	Goya,	Mistchenko	and	
Viegas,	 2016;	 Košutić-Gulija	 et	 al.,	 2017),	 	 as	 it	 directly	 compared	 the	
phylogenetic	 analysis	between	 the	 fragment	of	 the	 genome	and	whole	 genome	
data.		However	it	did	not	provide	any	insights	into	a	more	meaningful	function-
based	 classification	 of	 HPIV3,	 relying	 instead	 on	 clustering	 based	 on	 sequence	
similarity	 as	 before	 (Mao	 et	 al.,	 2012;	 Puillandre	 et	 al.,	 2012;	 Kekkonen	 et	 al.,	
2015).	 	A	more	meaningful	approach	would	require	a	greater	understanding	of	
the	 relationship	between	 genotype	 and	phenotype	 in	vivo	 potentially	 involving	
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both	 a	 greater	 library	 of	 clinical	 strains	 as	 well	 as	 a	 more	 controlled	 system	
involving	reverse	genetics.		
Nonetheless	 the	method	 developed	 in	 this	 project	 was	 successfully	 applied	 to	
identify	a	point	source	outbreak	on	a	paediatric	oncology	ward.	Infection	control	
approaches	 as	 well	 as	 outbreak	 identification	 tools	 were	 evaluated	 in	 this	
context.	 In	 addition	 to	 well	 established	 infection	 control	 procedures,	
supplementary	measures	centered	on	limiting	social	contact	and	play	areas,	that	
would	inevitably	have	a	deleterious	effect	on	the	mental	wellbeing	of	paediatric	
patients	 (Baier	 et	 al.,	 2018)	 were	 discussed.	 These	 additional	 interventions	
would	 necessitate	 a	 re-evaluation	 of	 the	 benefits	 and	 drawbacks	 of	 such	 an	
arrangement	(Koutlakis-Barron	and	Hayden,	2016;	Beuvink,	2018).	A	review	of	
literature	 available	 on	 the	morbidity	 and	mortality	 of	 HPIV3	 in	 the	 paediatric	
immunocompromised	 cohort	 has	 shown	 that	 there	 is	 no	 consensus	 on	 the	
severity	of	HPIV3	impact	in	this	patient	population	(Piralla	et	al.,	2009;	Ustun	et	
al.,	 2012;	 Torres	 et	 al.,	 2016;	 Santolaya	 et	 al.,	 2017).	 The	 scarcity	 of	 data	
available,	 combined	 with	 different	 conclusions	 presented,	 provides	 additional	
evidence	 that	 there	 may	 be	 different	 circulating	 strains	 with	 different	 clinical	
impact.	 Therefore	 any	 fundamental	 change	 to	 infection	 control	 procedures	
would	entail	a	more	systematic	re-evaluation	of	the	data	available	on	the	clinical	




HPIV3.	 The	 inhibitors	 chosen	 for	 this	 purpose	 were	 ribavirin,	 favipiravir	 and	
zanamivir.	 Previous	 research	 on	 HPIV3	 inhibitors	 has	 been	 conducted	 on	
significantly	 laboratory	 adapted	 strains	 with	 no	 data	 on	 the	 susceptibility	 of	
clinical	 strains	 available.	 Consequently	 in	 this	 project,	 an	 in	 vivo	 model	 using	
diverse	 clinical	 strains	 was	 set	 up.	 	 Ribavirin	 has	 been	 shown	 to	 be	 a	 good	
inhibitor	 of	 culture	 adapted	 strains	 of	 HPIV3	 in	 vitro	 in	 numerous	 studies	
(Leyssen	 et	 al.,	 2005)	 and	 has	 previously	 been	 used	 to	 treat	 respiratory	
infections	with	this	virus	(Chakrabarti	et	al.,	2000;	Falsey,	2012),	although	recent	
data	does	not	suggest	a	significant	impact	on	morbidity	and	mortality	in	a	clinical	





neuraminidase	 inhibitor,	 licensed	against	 influenza	(Mckimm-Breschkin,	2013).	
It	 has	 previously	 been	 evaluated	 against	 laboratory	 strains	 of	 HPIV3	 and	 has	
been	 considered	 a	 candidate	 for	 treatment	 because	 of	 the	 similarities	 in	 the	
structure	 of	 the	neuraminidase	binding	pockets	 of	 influenza	 and	parainfluenza	
(Greengard	 et	 al.,	 2000;	 Lawrence	 et	 al.,	 2004).	 Overall,	 all	 of	 these	 inhibitors	
appeared	to	be	promising	therapeutic	candidates.	Therefore,	in	this	project,	they	
were	 evaluated	 against	 9	 diverse	 clinical	 strains	 of	 HPIV3,	 as	 well	 as	 in	 the	
laboratory	 adapted	 strain.	 Additionally	 a	 review	 of	 the	 data	 available	 on	 the	
bioavalability	of	these	drugs	was	conducted	in	order	to	evaluate	their	suitability	
for	clinical	use.		
Clinical	 strains	 were	 shown	 to	 be	 at	 least	 as	 susceptible	 to	 favipiravir	 and	
ribavirin	as	the	laboratory	strain.	However	the	clinical	bioavailability	of	ribavirin	
quoted	in	the	literature	may	be	insufficient	to	reach	the	required	EC50	and	EC90	




drug	 in	 Ebola	 virus	 infection	 demonstrate	 that	 there	 is	 a	 potential	 to	 reach	
required	therapeutic	levels	in	patients	(Sissoko	et	al.,	2016;	Nguyen	et	al.,	2017).	
Coupled	with	an	excellent	toxicity	profile,	 favipiravir	should	be	considered	as	a	
potential	 therapeutic	 candidate	 for	 HPIV3	 in	 the	 future.	 It	 is	 important	 to	
remember	 that	 nucleoside	 analogues	 such	 as	 favipiravir	 have	 the	 potential	 to	




Interestingly,	 it	 was	 observed	 that	 clinical	 strains,	 on	 the	 whole,	 were	 more	






et	al.,	 2016).	 	 Unfortunately	 the	 levels	 required	 for	 clinical	 strain	 inhibition	 in	
vitro	 would	 be	 unattainable	 in	 vivo	 (Cass,	 Efthymiopoulos	 and	 Bye,	 1999)	 and	
therefore	without	further	advances	in	drug	absorbance	or	delivery,	this	drug	was	
not	considered	to	be	a	viable	option.	However	it	is	worth	noting	that	zanamivir	
was	 developed	 against	 a	 similar	 but	 not	 identical	 protein	 in	 a	 different	 virus	
(Mckimm-Breschkin,	 2013),	 as	 such	 its	 efficacy	 against	 HPIV3	 suggests	 that	
inhibitors	designed	to	target	HPIV3	HN	specifically	would	be	a	fruitful	avenue	for	
future	research	(Guillon	et	al.,	2014).		
It	 is	 important	 to	 have	 a	 robust	 model	 for	 trialing	 of	 potential	 therapeutic	
candidates	for	any	pathogen.	In	this	project	an	 in	vitro	model,	using	cell	culture	
was	described.	Other	options	would	include	an	ex	vivo	model	using	primary	cell	
lines	 or	 small	 animal	 models.	 Hamsters	 (Crookshanks-Newman	 and	 Belshe,	
1986;	Greer	et	al.,	2007;	 Jochmans	et	al.,	2016),	cotton	rats	(Porter	et	al.,	1991;	
Prince	and	Porter,	1996;	Ottolini	et	al.,	2002)	and	 ferrets	 (Mascoli	et	al.,	1976)	
have	 previously	 been	 used	 for	 this	 purpose	 for	 HPIV3.	 However,	 so	 far	 there	
have	been	no	models	based	on	HAE	cells,	although	some	work	has	been	done	on	
the	benefits	of	antibiotic	 treatment	 in	 influenza	A	(Yamaya	et	al.,	2010)	and	on	
immunomodulatory	 treatment	 of	 rhinovirus	 infections	 (Jiang	 et	 al.,	 2016).	 As	
these	 are	 considered	 a	 very	 powerful	 ex	 vivo	 model	 for	 respiratory	 viral	
replication	 (Yamaya	 et	 al.,	 2002)	 the	 next	 logical	 step	 would	 be	 to	 repeat	 the	
work	described	above	 in	this	model.	Additionally,	as	HAE	cells	provide	both	an	
apical	 and	 basolateral	 approach,	 it	 would	 provide	 the	 opportunity	 to	 look	 for	
different	methods	of	drug	delivery	and	correlate	the	basolateral	concentrations	
achieved	(systemic	delivery)	with	the	apical	ones	(topical/inhaled	delivery).	This	




Overall	 in	 this	 project,	 diverse	 UK	 circulating	 strains	 of	 HPIV3	 were	
characterized	 according	 to	 phenotype	 and	 genotype.	 We	 have	 found	 evidence	
that	 clinical	 strains	 demonstrate	 different	 plaque	 phenotypes	 in	 immortalised	
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cell	culture	and	in	an	ex	vivo	model,	both	in	terms	of	growth	kinetics	as	well	as	in	
terms	 of	 the	 immune	 response	 triggered.	 It	 was	 also	 observed	 that	 the	
phenotype	exhibited	by	the	clinical	strains	was	markedly	different	 from	that	of	
the	significantly	culture	adapted	laboratory	strain	MK9.	A	phylogenetic	analysis	
did	not	 identify	 a	 specific	UK	 strain,	 but	 confirmed	 that	many	different	 strains	
circulate	at	any	one	time	with	new	strains	emerging.		An	evolutionary	rate	site	by	
site	analysis	of	 the	HPIV3	genome	was	used	 to	 identify	a	hypervariable	region.	
This	 region	 was	 shown	 to	 be	 suitable	 for	 phylogenetic	 and	 epidemiological	
monitoring	of	this	virus.	These	results	were	then	used	to	develop	a	nested	PCR	
protocol	 that	 was	 applied	 to	 outbreak	 tracking	 on	 a	 paediatric	 oncology	 unit.		
















To	 start	 with,	 I	 would	 like	 to	 evaluate	 different	 methods	 of	 extracting	 RNA	
including	 magnetic	 bead	 extraction	 to	 maximise	 RNA	 yield	 (He	 et	 al.,	 2017),	
followed	by	3rd	generation	sequencing	strategies,	such	as	Oxford	Nanopore	(Lu,	
Giordano	 and	 Ning,	 2016).	 	 Data,	 thus	 obtained	 would	 greatly	 enhance	 the	
phylogenetic	analysis	conducted	in	this	thesis	that	relied	on	minimally	passaged	
clinical	 strains.	 This	 approach	 would	 also	 provide	 a	 different	 perspective	 on	
outbreak	tracking,	particularly	when	using	Phyloscanner	(Wymant	et	al.,	2018),	
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which	 would	 allow	 to	 infer	 transmission	 within	 and	 between	 hosts	 in	 larger	
outbreaks.			
In	the	long	run,	I	would	like	to	work	on	therapeutics	for	HPIV3,	 looking	at	new	
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A Oligo Name Sequence (5'-3') B Oligo Name Sequence (5'-3')
KK-XF ACCAAACAAGAGAAGARACTTGTYTG NR1Ra GCYTCTTCCATRATCACTGTTTCTAC
KK-XR2 TCCAGGTCACTTCCAAATATCCA NR1Rb CGATTGCTCTCTTCTGTATCCTTCC
KK-1F CAGCYGGTGGAGCTATCATT NR2Fa CACACGAATRTACAACRGAAGG
KK-1R GAGCTGCTTCTTCTCCCAGG NR2Fb TGGTCYCTRGAGGAATCYCC
KK-NR1F AAACAARGCAGTCAACCACC 6Ra AGCYTGAGGAAGAATTCTCCCATCATA
KK-NR1R TCTGTTTGCCCCTTTGTGTC 6Rb CCAGARTCAGGGTGATCCTCYAATGA
KK-NR2R TGGCATCRAACAGCATTCCT 7Fa TTGGTTACAYCCTCGTCTTGAAGGAAG
KK-3F ACCCCACATTAGAGTTGCCA 7Fb CAATCTATGTAGGTGATCCTTACTGYCCT
KK-3R TCCTGCTGCTTCACAACCTA
KK-4F GGACACAAAYAAAGCAGTGC
KK-4R AGGAGTGCTAGAGARATGACT
KK-5F ACTCAGACTTGGTACCTGACT
KK-5R TGCACTTATATTCCATCGGCC
KK-6F AYGTGCTATCRAAATTAGCCTCA
KK-7F ATAGGYGTGAGGGTGACTGC
KK-7R TGTGAGGCTTCCATCCAAGA
KK-8F GGACTTGAAACRCCTGACCCA
KK-8R GGAAGAGCCTGTCCTTGTCT
KK-9F GAAGGTAGRGATCTCATTTGGGA
KK-9R CCTGTAAGYAATCGAGTCGAT
KK-10F TYGGAATCAACAGCACTAGTTG
PIV-5R ACCAAACAAGAGAAGAACTCTGYTTGG
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Appendix	3	–	Pipeline	and	primers	for	sequencing	of	full	HPIV3	genome	
Full	pipeline	used	for	NGS	sequencing	of	full	HPIV3	genome	
	
#!	/usr/bin/perl	-w	
	
#	
#			
#	
#	command	line	switches	
#	-h																						-	prints	out	the	syntax	and	exits	
#	-s																						-	only	prints	out	the	commands	of	the	pipelines,	without	running	
them	
#	-c	<config	file>								-	configuration	file	name	
#	-i	<input	file>	
#	-r	<reference>	
#	-w	<working	directory>		-	if	not	specified	a	directory	with	name	derived	from	
the	input	file	name	will	be	used	
#	-l	<log	file>											-	if	not	specified	STDOUT	will	be	used	
#	
#	tools	used:	
#	
#	cutadapt	
#	trim_galore	
#	FastQC	
#	bowtie2	
#	samtools	
#	Picard	
#	GATK	
#	VPhaser2	
#	
#	
#	09	Dec	2016	
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use	strict;	
	
use	File::Copy;	
use	Cwd;	
	
##################################	
#	
#	declare	some	global	variables	
#	
#################################	
	
#	store	the	current	perl	working	dir	
my	$curdir	=	cwd();	
	
#	declare	variables	to	keep	the	command	line	options	
my($input,	$reference,	$working_dir,	$logfile,	$cfgfile);	
	
#	this	variable	will	control	if	the	actual	tools	are	called	or	just	the	commands	
printed	out	
use	vars	qw($simul_only);	
	
#	this	is	the	log	file	handle	variable	
use	vars	qw($logfh);	
	
##################################	
#	
#	process	the	commmand	line	switches	
#	
#################################	
	
use	Getopt::Std;	
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#	declare	the	perl	command	line	flags/options	we	want	to	allow	
my	%cfg=();	
getopts("hsc:i:r:w:l:",	\%cfg);	
	
#	prepare	usage	help	string	
my	$syntax_help	=	"$0	-c	<config	file>	-i	<input	file	stub	(no	extension)>	-r	
<reference	file	stub	(no	extension)>	-w	<work	folder>	-l	<log	file>";	
	
#	print	the	help	and	die	if	-h	switch	is	provided	
#	die	$syntax_help	if	defined	$cfg{h};	
if	(defined	$cfg{h})	{	
		print	"Usage:\n$syntax_help.\n";	
		exit;	
}	
	
#	retrieve	the	command	line	options	
$simul_only	=	1	if	defined	$cfg{s};	
($cfgfile	=	$cfg{c})	or	die	"Configuration	file	name	parameter	missing,	syntax:\n	
$syntax_help";	
($input	=	$cfg{i})	or	die	"Input	file	name	parameter	missing,	syntax:\n	
$syntax_help";	
($reference	=	$cfg{r})	or	die	"Reference	file	name	parameter	missing,	syntax:\n	
$syntax_help";	
if	(defined	$cfg{w})	{	
				$working_dir	=	$cfg{w};	
}	
else	{	
				$working_dir	=	"$curdir/${input}.wd";	
}	
$logfile	=	$cfg{l};	
	
#	Create	the	working	directory	if	it	does	not	exist	
if	(!	-e	$working_dir)	{	
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				mkdir	$working_dir	||	die	"Could	not	create	folder	$working_dir";	
}	
	
#	Prepare	the	log	file	
if	($logfile)	{	
				open(	$logfh,	">",	$logfile	);	
}	
	
	
###############################	
#	Load	configuration	from	a	povided	cfg	file	
#	
#	we	are	expecting	a	file	with	<name>=<value>	pairs,	one	in	each	line	containing	
the	following	parameters:	
#			input	=																		#	this	is	the	input	file	name	stub,	without	.1.fq,	etc	
#			reference	=														#	this	is	the	reference.fa	file	without	fa	extension	
#			working_folder	=									#	this	is	where	the	various	temporary	files	will	be	
created	
#			forward_primers_file	=			#	this	is	the	file	name	containing	a	list	of	forward	
primers,	one	per	line	
#			reverse_primers_file	=			#	this	is	the	file	name	containing	a	list	of	reverse	
primers,	one	per	line	
###############################	
	
open(	CONFIG,	"<",	$cfgfile	)	or	die	"Could	not	load	the	configuration	file	$cfgfile";	
	
my	$cfg;	
while	(<CONFIG>)	{	
				chomp;																		#	no	newline	
				s/#.*//;																#	no	comments	
				s/^\s+//;															#	no	leading	white	
				s/\s+$//;															#	no	trailing	white	
				next	unless	length;					#	anything	left?	
	 219	
				my	($var,	$value)	=	split(/\s*=\s*/,	$_,	2);	
				$cfg{$var}	=	$value;	
}		
	
close	(CONFIG);	
	
#########	
#	
#	Paths	to	various	tools	to	use	
#	
#########	
	
sub	repltilda	{	
		my	$orgname	=	shift;	
		$orgname	=~	s/~/$ENV{HOME}/;	
		return	$orgname;		
}	
	
my	$cutadapt_master_bin_dir	=	repltilda($cfg{cutadapt_master_bin_dir})	if	
defined	$cfg{cutadapt_master_bin_dir};		
my	$cutadapt_dir	=	repltilda($cfg{cutadapt_dir})		if	defined	$cfg{cutadapt_dir};		
my	$FastQC_dir		=	repltilda($cfg{FastQC_dir})		if	defined	$cfg{FastQC_dir};		
my	$trim_galore_dir	=	repltilda($cfg{trim_galore_dir})		if	defined	
$cfg{trim_galore_dir};		
my	$picard_dir	=	repltilda($cfg{picard_dir})		if	defined	$cfg{picard_dir};		
my	$gatk_dir	=	repltilda($cfg{gatk_dir})		if	defined	$cfg{gatk_dir};		
my	$vphaser2_dir	=	repltilda($cfg{vphaser2_dir})		if	defined	$cfg{vphaser2_dir};		
	
#	these	are	the	file	names	containing	lists	of	forward	and	reverse	primers	
(respectively),	one	primer	per	line	
my	$forward_primers_file	=	repltilda($cfg{forward_primers_file})	if	defined	
$cfg{forward_primers_file};		
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my	$reverse_primers_file	=	repltilda($cfg{reverse_primers_file})	if	defined	
$cfg{reverse_primers_file};		
	
	
#########	
#	
#	check	if	the	required	settings	are	there	
#	
#########	
	
die	'variable	cutadapt_master_bin_dir	not	set	in	the	config	file'	if	!	
$cutadapt_master_bin_dir;	
die	'variable	cutadapt_dir	not	set	in	the	config	file'	if	!	$cutadapt_dir;		
die	'variable	FastQC_dir	not	set	in	the	config	file'	if	!	$FastQC_dir;	
die	'variable	trim_galore_dir	not	set	in	the	config	file'	if	!	$trim_galore_dir;		
die	'variable	picard_dir	not	set	in	the	config	file'	if	!$picard_dir;	
die	'variable	gatk_dir	not	set	in	the	config	file'	if	!	$gatk_dir;		
die	'variable	vphaser2_dir	not	set	in	the	config	file'	if	!	$vphaser2_dir;		
	
#	these	are	the	file	names	containing	lists	of	forward	and	reverse	primers	
(respectively),	one	primer	per	line	
die	'variable	forward_primers_file	not	set	in	the	config	file'	if	!	
$forward_primers_file;		
die	'variable	reverse_primers_file	not	set	in	the	config	file'	if	!	
$reverse_primers_file;		
	
###############	
#	
#	define	cmd_run	function	
#	
##############	
	
sub	cmd_run	{	
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				my	$cmd_to_run	=	shift;	
				my	$title	=	shift;	
				my	$run_regardless	=	shift;					
	
				my	$logmsg	=	"\n#########	$title		######\n";	
				$logmsg	.=	"$cmd_to_run\n";	
	
				#	print	to	the	log	file	
				if	($logfh)	{	
	 		print	$logfh	$logmsg;	
				}	
	
				#	print	to	STDOUT	
				print	$logmsg;	
					
				if	((!	$simul_only)	||	($run_regardless))	{	
						$logmsg	=	`$cmd_to_run`	.	"\n";	
	
						#	print	to	the	log	file	
						if	($logfh)	{	
	 			print	$logfh	$logmsg;	
						}	
	
						#	print	to	STDOUT	
						print	$logmsg;	
				}	
}	
	
	
###############	
#	
#	define	log_msg	function	
#	
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##############	
	
sub	log_msg	{	
				my	$msg	=	shift;	
				my	$fh	=	shift;	
	
				my	$logmsg	=	"\n######	$msg\n";	
					
				#	print	to	the	log	file	
				if	($fh)	{	
	 print	$fh	$logmsg;	
				}	
	
				#	print	to	STDOUT	
				print	$logmsg;	
}	
	
	
###############	
#	
#	define	get_primers	function	
#	
#	procedure	takes	the	primers	file	name	and	the	switch	to	use	with	them	and	
produces	one	string	of	primers	ready	to	be	used	in	a	cmd	
#	
##############	
sub	get_primers	{	
				my	$primers_file	=	shift;	
				my	$prefix	=	shift;	
				my	$primers	=	'';	
	
				open(	PRMFILE,	"<",	"$primers_file"	)	or	die	"Cannot	open	primers	file	
$primers_file:	"	.	$!;	
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				while	(<PRMFILE>)	{	
	 chomp;																		#	no	newline	
	 s/#.*//;																#	no	comments	
								s/^\s+//;															#	no	leading	white	
	 s/\s+$//;															#	no	trailing	white	
								next	unless	length;					#	anything	left?	
								$primers	.=	"	-$prefix	$_";	
				}		
				return	$primers;	
}	
	
	
########################	
#	
#			Start	the	pipepline	
#	
########################	
	
my	$cmd;	
	
	
###	
#	STEP	0:	read	the	forward	and	reverse	primers	list	
###	
	
log_msg("Reading	primers	from	$forward_primers_file	and	
$reverse_primers_file");	
my	$forward_primers	=	get_primers("$forward_primers_file",'a');	
my	$reverse_primers	=	get_primers("$reverse_primers_file",'G');	
	
###	
#	STEP	1:	go	to	trip	galore	folder	for	initial	calculations	
###		
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chdir	$trim_galore_dir	or	die	$!	.	":		trim_galore_dir	=	$trim_galore_dir";	
cmd_run("pwd","change	directory	to	$trim_galore_dir",1);	
	
###	
#	STEP	2:	export	paths	
###	
	
#	these	should	not	be	neeed	
#	$ENV{PATH}	=	"/usr/local/bin:$ENV{PATH}";	
#	$ENV{PATH}	=	"/usr/bin:$ENV{PATH}";	
	
#$ENV{PATH}	=	"$cutadapt_master_bin_dir:$ENV{PATH}";	
#$ENV{PATH}	=	"$cutadapt_dir:$ENV{PATH}";	
#$ENV{PATH}	=	"$FastQC_dir:$ENV{PATH}";	
	
log_msg(	"PATH="	.$ENV{PATH}	);	
	
	
###	
#	STEP	3:		remove	NEXTERA	adapters	
#	produces	2	files:	output.1.fq,	output.2.fq	
###	
$cmd	=	"cutadapt	-a	CTGTCTCTTATA	-G	TATAAGAGACAG	-o	output.1.fq	-p		
output.2.fq	${input}.1.fq	${input}.2.fq";	
cmd_run($cmd,"remove	NEXTERA	adapters");	
	
###	
#	STEP	4		remove	amplicon	primers	
#	produces	2	files:		output.1f.fq,	output.2f.fq	
###	
	
#	run	the	removal	tool	
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$cmd	=	"cutadapt	$forward_primers	$reverse_primers	-o	output.1f.fq	-p		
output.2f.fq	output.1.fq	output.2.fq";	
cmd_run($cmd,"Remove	amplicon	primers	");	
	
	
###	
#	STEP	5			run	final	check	fastQC	
#	
#	output	of	this	is	output.1f_val_1.fq		output.2f_val_2.fq	
##	
$cmd	=	"./trim_galore	--paired	--trim1	output.1f.fq	output.2f.fq";	
cmd_run($cmd,"run	final	check	fastQC	");	
	
#	move		output.1f_val_1.fq		output.2f_val_2.fq	to	$working_dir	
log_msg("move		output.1f_val_1.fq	output.2f_val_2.fq	to	$working_dir");	
if	(!	$simul_only)	{	
		move(	"output.1f_val_1.fq",	"$working_dir/output.1f_val_1.fq")	or	die	$!;	
		move(	"output.2f_val_2.fq",	"$working_dir/output.2f_val_2.fq")	or	die	$!;	
}	
	
#	cd	~/$working_dir	
chdir	$working_dir;	
cmd_run("pwd","change	directory	to	$working_dir",1);	
	
##	
#	STEP	8	build	sequence	index	using	Bowtie	
##	
$cmd	=	"bowtie2-build	${reference}.fa	$reference";	
cmd_run($cmd,"build	sequence	index	using	Bowtie		");	
	
##	
#	STEP	9	index	reference	sequence	(samtools)	
#	
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#	This	will	create	${reference}.fa.fai	
##	
$cmd	=	"samtools	faidx	${reference}.fa";		
cmd_run($cmd,"index	reference	sequence	(samtools)		");	
	
##	
#	Step	10	create	sequence	dictionary	(picard)	
##	
	
#	copy	reference.fa	and	reference.fa.bai	to	~/picard	
log_msg("copy	${reference}.fa	and	${reference}.fa.fai	to	$picard_dir");	
if	(!	$simul_only)	{	
		copy(	"${reference}.fa",		$picard_dir	)	or	die	$!;	
		copy(	"${reference}.fa.fai",		$picard_dir	)	or	die	$!;	
}	
	
#cd	~/picard	
chdir	$picard_dir;	
cmd_run("pwd","change	directory	to	$picard_dir",1);	
	
$cmd	=	"java	-jar	picard.jar	CreateSequenceDictionary	R=	${reference}.fa	
O=${reference}.dict";	
cmd_run($cmd,"create	sequence	dictionary	(picard)	");	
	
	
##	
#	align	using	bowtie2	
#	
#	will	create	alignedoutput.sam	
#	
##	
	
#	cd	~/$working_dir	
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chdir	$working_dir;	
cmd_run("pwd","change	directory	to	$working_dir",1);	
	
$cmd	=	"bowtie2	-x	$reference	-1	output.1f_val_1.fq	-2	output.2f_val_2.fq	-S	
alignedoutput.sam";	
cmd_run($cmd,"align	using	bowtie2	");	
	
##	
#	step	14	convert	alignment	from	sam	to	bam	
#	
#	will	create	alignedoutput.bam	
#	
##	
	
$cmd	=	"samtools	view	-bSo	alignedoutput.bam	alignedoutput.sam";	
cmd_run($cmd,"convert	alignment	from	sam	to	bam	");	
	
##	
#	step	15	sort	bam	file	
#	
#	will	create	${input}.sorted.bam	
##	
	
$cmd	=	"samtools	sort	-o	${input}.sorted.bam	alignedoutput.bam";	
cmd_run($cmd,"sort	bam	file		");	
	
##	
#	step	16	index	bamfile	
#	
#	will	create	${input}.sorted.bam.bai	
##	
	
$cmd	=	"samtools	index		${input}.sorted.bam";	
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cmd_run($cmd,"index	bamfile	");	
	
##	
#	step	17	mark	duplicates	in	picard	
#	
#	will	create	output.dups.bam	and	output.dups.txt	
##	
	
#	copy	the	files	needed	
log_msg(	"copy		${input}.sorted.bam	and	${input}.sorted.bam.bai	to	
$picard_dir");	
if	(!	$simul_only)	{	
		copy(		"${input}.sorted.bam",	$picard_dir	)	or	die	$!;	
		copy(		"${input}.sorted.bam.bai",	$picard_dir)		or	die	$!;	
}	
	
#	Change	to	the	right	directory	
chdir	$picard_dir;	
cmd_run("pwd","change	directory	to	$picard_dir",1);	
	
#	Run	the	command	
$cmd	=	"java	-jar	picard.jar	MarkDuplicates	I=${input}.sorted.bam	
O=output.dups.bam	METRICS_FILE=output.dups.txt	REMOVE_DUPLICATES=true	
VALIDATION_STRINGENCY=LENIENT";	
cmd_run($cmd,"mark	duplicates	in	picard	");	
	
	
##	
#	removed	addorreplace	groups	and	fixmate	with	PICARD	
#	see	full	annapipeline	for	full	flow	
##	
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$cmd	=	"samtools	sort	-o	output.dups.sorted.bam	output.dups.bam";	
cmd_run($cmd,"sort	file	");	
	
##	
#	step	23	index	file		
#	
#	this	will	produce	output.dups.sorted.bam.bai	
##	
	
$cmd	=	"samtools	index	output.dups.sorted.bam";	
cmd_run($cmd,"index	the	file		");	
	
##	
#	removed	realign	for	indels,	as	conflict	with	VPhaser2	
#	
#		
##	
	
	
	
	
#	copy	the	output	files	to	~/VPhaser-2-02112013	and	to	the	working	directory	
log_msg(	"Copy	output.dups.sorted.bam	and	output.dups.sorted.bam.bai	to	
$vphaser2_dir	and	$working_dir");	
if	(!	$simul_only)	{	
		copy(	"output.dups.sorted.bam",	$vphaser2_dir)	or	die	$!;	
		copy(	"output.dups.sorted.bam.bai",	$vphaser2_dir)	or	die	$!;	
		copy(	"output.dups.sorted.bam",	$working_dir)	or	die	$!;	
		copy(	"output.dups.sorted.bam.bai",	$working_dir)	or	die	$!;	
}			
	
#	change	to	the	vphaser	directory	
chdir	$vphaser2_dir;	
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cmd_run("pwd","change	directory	to	$vphaser2_dir",1);	
	
#	create	folder	$input	in	~/	VPhaser-2-02112013		
log_msg(	"Creating	output	folder	$vphaser2_dir/$input"	);	
mkdir	"$input"	||	die	"Could	not	create	folder	$vphaser2_dir/$input";	
	
#	launch	VPhaser	
$cmd	=	"OMP_NUM_THREADS=8		bin/variant_caller	-i	output.dups.sorted.bam		-
o	${input}";	
cmd_run($cmd,"run	VPhaser	");	
	
#	cleanup	-	important	as	it	messes	up	next	runs	
log_msg(	"Deleting	temorary	files	output.dups.sorted.bam,	
output.dups.sorted.bam.bai	and	output.dups.sorted.bam.bti	from	
$vphaser2_dir");	
if	(!	$simul_only)	{	
		unlink("$vphaser2_dir/output.dups.sorted.bam");	
		unlink("$vphaser2_dir/output.dups.sorted.bam.bai");	
		unlink("$vphaser2_dir/output.dups.sorted.bam.bti");	
}	
	
##	
#		Closing	tasks	
##	
	
#	Print	finish	message	
log_msg(	"All	Done.	Phew!"	);	
	
#	close	the	log	file	
if	($logfh)	{	
				close	$logfh;	
}	
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Forward	primers	list	
ACCAAACAAGAGAAGAAACTTGTCTG	
ACCAAACAAGAGAAGAGACTTGTCTG	
ACCAAACAAGAGAAGAGACTTGTTTG	
CAGCCGGTGGAGCTATCATT	
CAGCTGGTGGAGCTATCATT	
AAACAAAGCAGTCAACCACC	
ACCCCACATTAGAGTTGCCA	
GGACACAAACAAAGCAGTGC	
GGACACAAATAAAGCAGTGC	
ACTCAGACTTGGTACCTGACT	
ACGTGCTATCAAAATTAGCCTCA	
ACGTGCTATCGAAATTAGCCTCA	
ATGTGCTATCAAAATTAGCCTCA	
ATGTGCTATCGAAATTAGCCTCA	
ATAGGCGTGAGGGTGACTGC	
ATAGGTGTGAGGGTGACTGC	
GGACTTGAAACACCTGACCCA	
GGACTTGAAACGCCTGACCCA	
GAAGGTAGAGATCTCATTTGGGA	
GAAGGTAGGGATCTCATTTGGGA	
TCGGAATCAACAGCACTAGTTG	
TTGGAATCAACAGCACTAGTTG	
ACCAAACAAGAGAAGAAACTTGTTTG	
AAACAAGGCAGTCAACCACC	
TGGTCCCTAGAGGAATCCCC	
TGGTCCCTAGAGGAATCTCC	
TGGTCCCTGGAGGAATCCCC	
TGGTCCCTGGAGGAATCTCC	
TGGTCTCTGGAGGAATCTCC	
TGGTCTCTGGAGGAATCCCC	
TGGTCTCTAGAGGAATCCCC	
TGGTCTCTAGAGGAATCTCC	
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Reverse	primers	list	
	TGGATATTTGGAAGTGACCTGGA		
CCTGGGAGAAGAAGCAGCTC	
GACACAAAGGGGCAAACAGA	
AGGAATGCTGTTTGATGCCA	
AGGAATGCTGTTCGATGCCA	
TAGGTTGTGAAGCAGCAGGA	
AGTCATCTCTCTAGCACTCCT	
GGCCGATGGAATATAAGTGCA	
TATGATGGGAGAATTCTTCCTCAGGCT	
TATGATGGGAGAATTCTTCCTCAAGCT	
TCTTGGATGGAAGCCTCACA	
AGACAAGGACAGGCTCTTCC	
ATCGACTCGATTGCTTACAGG	
ATCGACTCGATTACTTACAGG	
CCAAGCAGAGTTCTTCTCTTGTTTGGT	
CCAAACAGAGTTCTTCTCTTGTTTGGT	
GGACACAAATAAAGCAGTGC	
	
	
	
